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APOBEC2 is a member of the AID/APOBEC cytidine deaminase family of proteins.
Unlike most of AID/APOBEC, however, APOBEC2’s function remains elusive. Previous
research has implicated APOBEC2 in diverse organisms and cellular processes such as
muscle biology (in Mus musculus), regeneration (in Danio rerio), and development (in
Xenopus laevis). APOBEC2 has also been implicated in cancer. However the enzymatic
activity, substrate or physiological target(s) of APOBEC2 are unknown. For this thesis, I
have combined Next Generation Sequencing (NGS) techniques with state-of-the-art
molecular biology to determine the physiological targets of APOBEC2. Using a cell
culture muscle differentiation system, and RNA sequencing (RNA-Seq) by polyA
capture, I demonstrated that unlike the AID/APOBEC family member APOBEC1,
APOBEC2 is not an RNA editor. Using the same system combined with enhanced
Reduced Representation Bisulfite Sequencing (eRRBS) analyses I showed that, unlike
the AID/APOBEC family member AID, APOBEC2 does not act as a 5-methyl-C
deaminase. Finally, using a combination of biochemical, Chromatin Immunoprecipitation
Sequencing (ChiP-Seq) and polyA RNA-Seq analyses I show that APOBEC2 is a
(negative) regulator of gene expression (at least in muscle cells) and binds chromatin

directly to inhibit transcription of genes involved in muscle cell differentiation. While the
precise mechanism behind this activity is still a matter of investigation, this role of
APOBEC2 in inhibiting genes involved in cell cycle exit, might have implications for its
role in in cancer.
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CHAPTER 1. Introduction

1.1 Beyond the central dogma of Molecular Biology
DNA was determined to be the chemical basis of heredity and life processes through the work
by Avery et al. in 1944 (Avery et al., 1944) and subsequently confirmed in 1952 by

Hershey and Chase (Hershey and Chase, 1952). The collective efforts of many scientists
such as Miescher (Miescher, 1871), Avery et al. (Avery et al., 1944), Chargaff et al.
(Chargaff et al., 1951), Wilkins et al. (Wilkins et al., 1953), Franklin and Gosling
(Franklin and Gosling, 1953) and many others behind the scenes (Judson, 1996; Maddox,
2003) produced many pieces of the puzzle that lead Watson and Crick to successfully put
them together into the discovery of the double helical structure of the DNA in 1953
(Watson and Crick, 1953). These important scientific advances combined with
knowledge about mRNAs and protein synthesis lead Crick to propose the theory of the
“Central Dogma of Molecular Biology” in 1958 (Crick, 1958) and later in 1970 (Crick,
1970). The general concept was that information flows from DNA to RNA to protein,
which determines the cellular and organismal phenotype.
The “Central Dogma of Molecular Biology” is a significant biological idea that
led biologists to an informatics perspective on living organisms. Life itself is coded
(DNA>RNA>Protein) and the code is heritable. To this day the central dogma informs
our understanding of the role of heredity in deciphering biological functions, disease, and
the process of evolutionary change. Nonetheless as it is the case for most breakthroughs
as they open the door to many discoveries, they also provide many unanswered questions.
For example some of these questions are: if genomic information is the basis of
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biological function how can we explain the pronounced diversity among genomically
identical cells in a multicellular organism? Given that identical twins have the same
genetic make up how can we explain that they do not behave as “clones” of each other?
Given the limited amount of genomic DNA, how can we explain our ability to make such
a diverse number of antibodies responding to a vast number of foreign pathogens? Today,
about 60 years after the conception of the “Central Dogma of Molecular Biology”, the
picture has gotten more complicated, and we have discovered many mechanisms that lead
to biological diversity such as epigenetics, regulatory noncoding RNAs, alternative
splicing,

RNA

modifications

(epitranscriptomics),

protein

post-translational

modifications and DNA/ RNA editing (Figure1.1). Therefore the central dogma of
molecular biology has ‘evolved’. Below I will give an overview of polynucleotide
cytidine deamination as an example of how biological diversity that is not encoded in the
genome can be generated.
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Figure 1.1 The expansion of the central dogma of molecular biology
In red are shown processes of genetic information flow that were known as of 1958 based
on the “Central Dogma of Molecular biology”. Current known types of processing in
DNA, RNA in higher eukaryotes that cannot be deduced from what is coded in the
genome (in gray), including DNA/RNA editing (in blue)

1.2 Polynucleotide Cytidine Deaminases: The AID/APOBEC family of enzymes
Biological information is encoded in DNA and RNA. Normally organisms tend to avoid
mutations during DNA replication and transcription through DNA repair mechanisms.
This allows the information encoded in DNA to be faithfully inherited to the next
generation of cells and organisms. Problems in controlling mutations could lead to severe
consequences as DNA and RNA are decoded. The AID (activation induced
deaminase)/APOBEC (apolipoprotein B mRNA editing catalytic polypeptide-like) family
of proteins was a surprising discovery that uncovered an unexpected level of gene
expression control. They induce mutations on single stranded (ss) DNA or RNA by
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catalyzing the removal of the amino group from a cytidine base in the context of
polynucleotides, resulting in specific gene products being expressed or restricted (through
mutations). Their enzymatic activity results in a cytidine (C) to uridine (U) transition
(Figure 1.2). Functional studies have demonstrated how they are cleverly used by the cell
to induce nucleic acid changes in polynucleotides in a targeted way and with a specific
biological goal, but they can also be considered a threat to the stability of the genome or
transcriptome when not properly regulated. The members of the family are very closely
related to one another based on homology and conservation of the enzymatic domains,
but they have different tissue-specific expression, substrates, and biological functions.

Figure 1.2 Deamination of (deoxy)cytidine by AID/APOBEC

1.2.1 The startling discovery of the AID/APOBEC family
The story of the AID/APOBEC family of enzymes began in 1987 with the discovery that
the transcript of apolipoprotein B (apoB) mRNA contained a C to U base modification
that was not coded in the corresponding genomic DNA (Chen et al., 1987; Powell et al.,
1987). This posttranscriptional modification of the apoB mRNA at nucleotide position
6666 changes the genomically encoded glutamine codon (CAA) into a translational stop
codon (UAA) that leads to an early translation termination. The editing of apoB mRNA
4

explained the formation of the truncated isoform. Hence two proteins apoB-100 (the full
length form) and apoB-48 (the short form) can be generated from the same primary
transcript.
ApoB is a structural component of lipoproteins and is important for carrying lipid
and cholesterol in circulation from the digestive tract and liver to the rest of the tissues.
At the time ApoB was known to be a protein related to the risk for atherosclerosis
(Breslow, 1988). The potential that the editing of apoB mRNA could be related to
atherogenic disease lead to a lot of interest. The cDNA encoding a protein that is essential
for the deamination of C6666 was discovered in 1993 (Teng et al., 1993) and was named
in 1995 as apolipoprotein B editing catalytic subunit 1 (APOBEC1), with number 1
indicating the possibility that other related genes may exist (Davidson et al., 1995).
Indeed that was the case, many other members of the APOBEC family of enzymes have
been discovered since then.

1.2.2 The common evolutionary origin of the AID/APOBEC family
In humans the AID/APOBEC family of enzymes includes 11 members of primary and
alternatively spliced variants: Activation-induced deaminase (AID), APOBEC2,
APOBEC3 (A-D, F–H), and APOBEC4 proteins. AID/APOBEC are apart of large
superfamily of zinc-dependent deaminases that act on free cytidine, cytosine or
deoxycytidine triphosphate (dCTP) and are involved in the metabolism of purines and
pyrimidines, as well as deaminases that act on adenosine in the context of RNAs. Based
on phylogenetic analysis, gene organization and catalytic domain the AID/APOBEC
family probably originated from the Tad (tRNA adenosine deaminase)/ADAT2

5

(adenosine deaminase, tRNA- Specific 2), which edit adenosine to inosine at the
anticodon of various tRNAs (Conticello, 2008, 2012). The AID/APOBEC family
originated alongside the appearance of the vertebrate lineage, where deaminases are
suggested to have split into two primary branches in the common ancestor of jawed and
jawless vertebrates: APOBEC4-like and the AID-like branch (Figure 1.3). The
APOBEC4-like branch thus arose independently of AID and is thought to be a result of a
retrotransposition event due to the absence of introns in the deaminase-like region of
APOBEC4 (Iyer et al., 2011), (Conticello, 2008). The other APOBECs are suggested to
have originated from ancestral AID-like genes in jawless fish (PmCDA1 and PmCDA2,
P.marinus cytosine deaminase). The AID-like branch further diversified giving rise to
AID itself and APOBEC2, the most ancient members of the family (in bony and
cartilaginous fish) about 500 million years ago. APOBEC2 was suggested to have arisen
as a result of a retrotranspositional event given its different gene structure from that of
other members, where APOBEC2 has an N-terminal exon with no similarity to any other
known protein and the absence of introns in the deaminase-like region (Conticello et al.,
2007a). APOBEC2 has been under purifying selection through evolution suggesting
functional importance. The duplication of the AID locus about 300-400 years ago lead to
the evolution of APOBEC1 in mammals. APOBEC3s arose in placental from duplication
of AID after the divergence of the placentals from the marsupials about 170 million years
ago, being under strong positive selection which lead to its rapid expansion in primates
which have seven APOBEC3s (Conticello et al., 2007a).
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Figure 1.3 The evolutionary path of the AID/APOBEC
The plot indicates the phylogenetic relations among the various AID/APOBECs (and
their common ancestral tRNA editor enzymes) plotted against the time of their
emergence. The enzymes are shown beside the known function with the physiologic
targets listed beneath. The branches of the zinc-dependent deaminases are colored based
on type of deamination: A>I deamination (blue); C>U deamination (red). Branches of
unknown catalytic activity are indicated by the name of the protein group prefixed by a
question mark. APOBEC1 RNA editing is marked with an asterisk to indicate that
APOBEC1 acts on DNA as well, but this activity has not yet been linked to a
physiological role. Figure adapted from Conticello, 2012
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1.2.3 AID/APOBECs are similar by structure homology
Insights about the structure of many of the members of AID/APOBEC have been gained
using NMR spectroscopy and/or X-ray crystallography of full length, truncated or
mutated versions of the proteins. All AID/APOBECs share the same sequential
arrangement of secondary structural features (α-helices and β-sheets) forming a cytidine
deaminase CDA domain (Figure 1.4a). It is thought that the differences in length,
composition, location of these secondary structural features and the loops connecting
them may determine the variability in the biological functions, substrate selection,
localization, oligomerization and regulation of deamination activity. Moreover the
catalytic function and substrate binding of the AID/APOBECs could be regulated through
the binding of other protein co-factors, other RNAs, cis/trans regulatory DNA elements
or oligomerization (Salter et al., 2016).
All APOBECs have at least one CDA domain, which contains a highly conserved
zinc-dependent deaminase (ZDD) sequence motif (H-X-E-X[24-36]--P-C-X[2-4]-C, where X=
any amino acid) responsible for catalyzing the deamination reaction. This motif forms the
catalytic pocket where a Zn2+ metal ion is coordinated by 3 amino acids (two cysteines
(C) and one histidine (H)) and is bound to a water molecule that gets activated resulting
in a zinc hydroxide group (ZnOH-). The mechanism of deamination is thought to be the
same

as

the

one

for

bacterial

cytidine

deaminase

(Betts

et

al.,

1994).

Cytidine/deoxycytidine binds within the catalytic pocket and gets deaminated through a
nucleophilic attack on carbon 4 of cytidine (C-4) by ZnOH-. The conserved glutamate
(E) acts a proton (H+) donor to the leaving amino group (NH2) of the
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cytidine/deoxycytidine. Overall the loss of ammonia (NH3) leads to a net conversion of
cytosine to uracil (Figure 1.4b).

Figure 1.4 Diagram of the AID/APOBEC cytidine deaminase (CDA) fold
a) An example of the conserved CDA fold. Cartoon representation of the solution NMR
structure of APOBEC2 (Δ40) (PDB 2RPZ). The structures are colored based on the
secondary structure. The Zinc ion is shown as a sphere in purple
b) The proposed mechanism of cytidine deamination. Image from Harris and Liddament,
2004

1.2.4 AID/APOBECs are very diverse in their biological function and physiological
substrates
Even though all of the AID/APOBECs have at least one conserved ZDD motif and
common CDA fold, they are very diverse in terms of the tissue specific expression and
biological functions that they perform. Here I summarize some of the physiological
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substrates and biological roles of the AID/APOBEC members: AID, APOBEC1 and
APOBEC3 family.
Role in RNA editing
RNA editing is defined as alteration of an RNA sequence through nucleotide
insertion, deletion or modification mechanisms that leads to variations in sequence
compared to what is encoded in the genome (Wedekind et al., 2003).
APOBEC1, as already mentioned above is an RNA editing enzyme that edits
mRNAs through base modification. It was the first of the AID/APOBEC proteins shown
to have a biological role, enzymatic activity, and physiological substrate. APOBEC1 was
shown to catalyze a C to U change in the apoB mRNA, creating a premature stop codon
and leading to the generation of a shorter transcript in the small intestine, a novel mRNA
important for lipid metabolism (Teng et al., 1993). Thus here, APOBEC1 operates by
creating mRNAs with differential function from a single locus. Transcriptome wide
analyses in mice have also identified several APOBEC1-dependent editing sites mainly
in the 3’ untranslated regions (3’UTR) of various genes in small intestine and/or liver
(Blanc et al., 2014; Rosenberg et al., 2011). A portion of these edited sites alter mRNA
levels and protein translation efficiency (Blanc et al., 2014) in the specific tissues but the
function of most of the sites is not known. Additional studies using transcriptome
analysis in mice have shown that there are several transcripts that are edited by
APOBEC1 (mainly 3’UTRs) beyond the liver or small intestine, in macrophages of the
immune system (Harjanto et al., 2016; Rayon-Estrada et al., 2017) and also in microglia
of the central nervous system (CNS) (Cole et al., 2017). Some of these edited sites
correlate with gene expression changes through the modulation of translation (but not
10

mRNA stability). Lack of APOBEC1 mediated editing in macrophages has functional
consequences in phagocytosis and migration (Rayon-Estrada et al., 2017); while lack of
editing in microglia of the CNS leads to overall microglia functional dysregulation,
which lead to behavioral and motor deficiencies (Cole et al., 2017). Two co-factors have
been shown to be important in APOBEC1 directed editing: A1 complementation factor
(ACF or A1CF) was shown to direct APOBEC1 to an 11nt mooring sequence (Mehta et
al., 2000) and RNA binding motif protein 47(RBM47) (Fossat et al., 2014). The ancestral
function of APOBEC1 involves editing of the genomic DNA, since when expressed in E.
coli it results in mutations in genomic DNA and in ex vivo assays it restricts
retroelements (Harris et al., 2002; Ikeda et al., 2011; Severi et al., 2011). It is not known
whether under physiological conditions, APOBEC1 can also act on DNA in mammals.
Role in DNA editing
AID/APOBEC can also alter a DNA sequence by enzymatically deaminating
deoxytcytidine, converting it to deoxyuridine (here termed as DNA editing). There are
two members that can mediate DNA editing physiologically: AID and APOBEC3
proteins.
AID is highly expressed in activated B cells and is essential in adaptive immunity
by mediating antibody affinity maturation and diversification (Muramatsu et al., 2000).
The initial hypothesis was that AID acts on RNA, given its sequence similarity with
APOBEC1, which was the only AID/APOBEC member characterized at the time
(Muramatsu et al., 1999). Further research (reviewed in (Delker et al., 2009; Di Noia and
Neuberger, 2007)), showed that AID edits the genomic immunoglobulin (Ig) loci and
triggers class-switch recombination (CSR), somatic hypermutation (SHM) and
11

sometimes gene conversion (GCV). These processes that are important for Ig gene
diversification, where during CSR, AID leads to double-strand breaks and genomic
recombination, while during SHM, AID leads to point mutations. AID can target genes
beyond the Ig loci in B cells when overexpressed (Robbiani et al., 2008), but it is
unknown whether there is any other physiological targets in B cells. Additionally AID
has been shown to inhibit retrotransposition through DNA deamination-independent
mechanisms (MacDuff et al., 2009) and also targets viruses (Liang et al., 2013), but it is
unknown whether these are physiological roles.
APOBEC3 proteins are known for their role in innate immunity through the
hypermutation and restriction of a wide range of viruses and retroelements reviewed in
(Harris and Liddament, 2004). The arms race between APOBEC3 and the viruses that it
targets has led to the expansion of APOBEC3 from single copy in mouse to seven
paralogs in primates (A-D, F-H) (Conticello, 2008). The importance of APOBEC3 in
viral defense was realized with the identification of APOBEC3G as the protein involved
in the restriction of HIV that is antagonized by the HIV protein Vif (Sheehy et al., 2002).
This is done through hypermutation (through APOBEC3G DNA editing) of the nascent
viral DNA genome during reverse transcription (Harris et al., 2003; Lecossier et al.,
2003; Mangeat et al., 2003; Zhang et al., 2003). Since this discovery APOBEC3G, all the
paralogs have been shown to be important in innate defense mechanism against diverse
viruses, endogenous transposable elements and foreign DNA reviewed in (Harris and
Dudley, 2015; Knisbacher et al., 2016).
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Role in epigenetics
Besides the very well characterized roles in RNA editing and DNA editing
AID/APOBEC family of enzymes have also been linked to epigenetic changes through
active DNA demethylation (5mC removal). 5mC modification of gene elements is widely
shown to correlate with gene expression changes and is crucial in mammalian
development (Smith and Meissner, 2013). This modification is maintained during cell
division through DNA methyl transferase (Dnmt) enzymes. There are two mechanisms
proposed for DNA demethylation: passive and active. Passive demethylation refers to the
dilution of DNA methylation during cell division in the absence of maintenance
methylation, while active methylation involves removal of methylation marks through an
active process in the absence of cell division. There are multiple studies supportive of a
potential role of AID in active DNA demethylation, yet the genetic evidence for a such a
claim has been challenged (reviewed in (Bochtler et al., 2017; Ramiro and Barreto,
2015)). Nonetheless there is strong evidence that AID might be important in affecting
methylation status of target genes in B cells during activation in the mouse (Dominguez
and Shaknovich, 2014). It is unlikely that AID has any genome wide effects in active
DNA methylation during development as it has been previously proposed (Bhutani et al.,
2010). However it is remains possible that AID is important in gene specific methylation,
but the mechanisms of how this happens are unknown.
The physiological functions of APOBEC4, which is expressed in testes (Rogozin
et al., 2005) is still unknown and APOBEC4 does not deaminate DNA in mutation assays
in E. coli and yeast (Lada et al., 2011). There is some recent evidence that it might act to
enhance transcription of host promoters and endogenous LTR promoters (Marino et al.,
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2016). Whether this is a physiological relevant role and dependent on ZDD motif remain
to be elucidated.
Role in cancer
The ability of AID/APOBEC family of enzymes to induce RNA/DNA editing is a
double-edged sword. While these enzymes are important in many biological functions as
mentioned above, if not properly expressed, they can be mutagenic and lead to cancer
progression. Mouse models where AID/APOBEC(s) are overexpressed exhibit cancer
development in various tissues (Swanton et al., 2015). An important example is how the
increase of the levels of AID correlates with c-Myc oncogenic translocation in B cell
tumors (Robbiani et al., 2008; Takizawa et al., 2008). Interestingly, the severity of
lymphomas recently has been linked to the epigenetic role of AID in B cells (Teater et al.,
2018). Analysis of human cancer genome data has revealed that APOBEC signatures are
evident in many tumor genomes (Roberts et al., 2013), in the form of strand-coordinated
C-to-T hypermutation and there are direct links of the misregulation of APOBEC3A and
APOBEC3B(Henderson and Fenton, 2015). APOBEC1 RNA editing activity has been
linked to oncogenesis due to the hyperediting of a novel APOBEC1 target mRNA (Nat1),
encoding a translational repressor in mouse models (Hersberger et al., 2003; Yamanaka et
al., 1997). It also has been linked to peripheral nerve sheath tumors in humans due to
abnormal editing of the tumor suppressor neurofibromatosis type 1 RNA (NF1)
(Mukhopadhyay et al., 2002). Moreover lack of APOBEC1 has been shown to decrease
the progression of intestinal tumors, suggesting a potential role of APOBEC1 RNA
editing in cancer progression (Blanc et al., 2007). It is possible that the misregulated
expression of APOBEC1 can also affect the DNA editing of the genome given
14

APOBEC1’s known role in mutagenesis when overexpressed in E.coli (Harris et al.,
2002).

In the last 30 years since the discovery of AID/APOBEC(s), cytidine deamination
has emerged to be a prevailing driver of biological diversity in mammals. These proteins
lead to changes not encoded in the genome through a range of processes: acting as RNA
editors to create novel mRNAs and sequence changes in 3’UTRs of mRNA that affect
translation stability; acting as DNA editors to create novel genes, and to restrict viruses
and retrotransposons; and changing the DNA 5mC modification levels which leads to
transcript abundance differences. Their ability to edit transposable elements and genomic
DNA can lead to increase in beneficial/protective mutations, on one hand, and cancer on
the other.

1.3 APOBEC2, the ‘orphan’ deaminase
APOBEC2 was discovered to be a member of the AID/APOBEC family based on
sequence similarity (Anant et al., 2001; Liao et al., 1999). It is evolutionary wellconserved through the vertebrate lineages (similar to AID) and even in bony fish (where
two copies of APOBEC2 are present, thus alleviating the purifying selection), both
paralogues show little sequence divergence. Through evolution, the amino acid sequence
of APOBEC2 is constrained potentially by the need to preserve its function (as opposed
to APOBEC3 who has been under positive selection and whose rate of sequence
evolution has diverged due to the arms race with the target sequence) (Conticello et al.,
2005, 2007b). The structure of APOBEC2 has been elucidated and even though there are
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disparities on whether APOBEC2 is a rod-shaped tetramer (Prochnow et al., 2007) or a
monomer in solution (Krzysiak et al., 2012), the presence of a CDA fold characteristic of
the cytidine deaminases is well supported (Figure 1.4a). A number of phenotypes have
been reported in the absence of APOBEC2 suggesting that APOBEC2 has a biological
function, however there has been no demonstration of its predicted cytidine deaminase
enzymatic activity or potential physiological substrates. APOBEC2 is deemed an orphan
deaminase because it shows no catalytic activity and binding toward single stranded
DNA or RNA. This gap in knowledge of the specific substrate or enzymatic activity
could explain why APOBEC2 is one of the least studied AID/APOBEC(s) (Figure 1.5).
In the sections below I will review the current knowledge in the field about APOBEC2’s
biological role and activity on polynuclotides at the time when I started this project.

Number of publications

150

AID

100

Apobec3

50

0
1991

Apobec1
Apobec2
Apobec4
2001

2011

2017

Figure 1.5 The number of pubmed publications on AID/APOBEC, 1991-2017
APOBEC2 and APOBEC4 are the least studied of the AID/APOBECs, mainly due to the
lack of specific substrate or enzymatic activity linked to either protein.
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1.3.1 No study has demonstrated enzymatic activity for APOBEC2
Traditionally two types of assays have been used to demonstrate that AID/APOBEC
proteins are enzymatically active on DNA(Coker et al., 2006):
(A) The mutation assay tests if cytidine deaminases can act as DNA mutators when
expressed in unnatural hosts. It involves overexpressing the protein of interest in
unicellular organisms such as Escherichia coli (E. coli) plated in media containing a
lethal drug that targets an essential protein. If the AID/APOBEC protein induces
mutations that restore the function of the host’s essential protein by changing the binding
affinity of the drug, the cells survive. The number of drug resistant mutant cell colonies
serves as a measure of the mutator activity of the enzyme. Cytosine deamination
produces uracil, which is mostly removed via the uracil DNA glycosylase (UDG/ung)dependent base excision repair pathway. Therefore assaying DNA deaminase activity in
E.coli in the absence of ung increases the number of C-to-T mutations observed in the
assay supporting the deaminase action on cytidine in DNA. Studies using this method has
shown that APOBEC2 does not exhibit a mutator effect when expressed in E. coli (Harris
et al., 2002) or in yeast (Lada et al., 2011). Absence of the mutation activity might mean
that either (1) the cytidine deaminase does not act on the DNA used as a substrate, (2) the
host environment is not ideal for appropriate folding of the cytidine deaminase, (3)
cofactors or other proteins that might be necessary for the activity of the enzyme are
lacking, (4) the proper substrate sequence specificity is not found in the reporter system,
(5) the protein is not enzymatically active, and (6) a combination of some or all of the
above.
(B) The biochemical DNA deamination assay tests if cytidine deaminases could induce
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mutations in a synthetic single stranded DNA oligonucleotide that contains a
deoxycytidine (or modified deoxycytidine). It involves incubating the artificial
oligonucleotide substrate with the cytidine deaminase purified from E. coli (or other
source) and then allowing the template to bind to its complimentary strand. The product
is then treated with DNA glycosylases that will cleave the glycosidic bond if they find
mismatches, yielding an abasic site. Cleavage of the abasic sites under alkaline conditions
allows for specific detection of product after separation on a denaturing gel. The extent of
deamination is a measure of the amount of the cleaved product. Previous studies showed
no detectable cytidine deaminase activity for APOBEC2 (purified from E.coli) on
cytidine, 5-methylcytidine (5mC) or 5-hydroxymethylcytidine (5hmC) using DNA
oligonucleotides (Mikl et al., 2005; Nabel et al., 2012). Absence of the deamination
activity could mean that: (1) APOBEC2 has not cytidine deaminase activity (2)
APOBEC2 does not target DNA, (3) other cofactors are lacking, (4) sequence context
used to test deamination is not appropriate, and (4) a combination of the above.
Other investigations into the biochemical properties of the protein (Sato et al.,
2010) do not provide support for the idea that APOBEC2 acts on RNA. They suggest that
mouse APOBEC2 present in muscle is unlikely to be associated with RNA because when
treated with RNAse A its molecular weight in a Western blot analysis does not shift.
Given that they do not use a crosslinking method, the results from this experiment are
questionable since potential RNAs bound to APOBEC2 might have been degraded or lost
during the handing of the extracts. They also show that APOBEC2 is not able to bind
AU-rich or apoB-100 transcript after UV-crosslinking, unlike APOBEC1. The latter
could be due to inappropriate target tested.
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All the experiments published looking for APOBEC2 activity use protein purified
from E. coli or test its activity in a host cell that does not normally express APOBEC2.
These unnatural environments might be lacking important required cofactors or
physiological substrates. Additionally, such assays are non-stoichiometric and may not be
representative of what happens physiologically even when they show activity. For
example, the DNA mutator assay shows that APOBEC1 is capable of mutating DNA
(Lada et al., 2011), yet no study so far has been able to show that this happens naturally
in tissues where APOBEC1 is expressed at physiological levels.
In conclusion, published work on APOBEC2 indicates that the lack of a substrate
for APOBEC2 makes it difficult to prove its enzymatic activity and elucidate its potential
contributions in biology. Since APOBEC2 is a functional protein in many organisms, the
identification of its specific physiological function is most likely to be achieved from the
identification of its substrate. Thus, identifying the potential nucleic acid substrate(s) in
cells or tissues that normally express APOBEC2 before recapitulating the activity of
APOBEC2 biochemically might be instrumental in determining its enzymatic activity.

1.3.2 Many studies demonstrate that APOBEC2 has a biological function
APOBEC2 is widely expressed in cardiac and skeletal muscle in humans and mice (Liao
et al., 1999) and is conserved in all jawed vertebrates including bony fish and mammals
(Conticello, 2008). In mice APOBEC2 is more highly expressed in slow-twitch fibers. In
APOBEC2 null mice, there is a shift from fast to slow fibers, a development of mild
myopathy with age, a reduction in the total body mass correlating with a decrease in
muscle mass (Sato et al., 2010). Furthermore APOBEC2 is predicted to be a novel
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regulator of skeletal muscle growth during postnatal muscle development (Yang et al.,
2015), and it is upregulated in aging skeletal muscle providing evidence for a role in
sarcopenia (degenerative loss of skeletal muscle mass during aging) (Piec et al., 2005).
Moreover APOBEC2 expression increases with denervation of mouse soleus and
extensor digitorum longus muscle (Sato et al., 2010), suggesting that the protein might be
important for postnatal adaptation following injury or during muscle homeostasis.
Induction of neonatal mouse myoblast and C2C12 myoblast cell line to differentiate in
culture results in an increase in the expression of APOBEC2, suggesting a role in muscle
differentiation (Sato et al., 2010; Vonica et al., 2011).
APOBEC2 has also been implicated in DNA demethylation. The best evidence
for a possible function of APOBEC2 in DNA demethylation comes from zebrafish. The
zebrafish Apobec2 genes (Apobec2a and Apobec2b) together with AID were shown to be
required for the demethylation of a DNA fragment injected into the single cell embryo of
the zebrafish, which is in turn accompanied by hypomethylation of the zebrafish genome
(Rai et al., 2008). The Apobec2a/2b genes are also crucial for optic nerve regeneration in
zebrafish, which is achieved through the return of the neurons and glia to a stem cell state
(Powell et al., 2012). Given that DNA demethylation is important during reprogramming
and that regeneration in zebrafish is dependent on Apobec2a/2b, these data suggest that
APOBEC2 might be important in DNA demethylation in zebrafish. Subsequent studies
from the same group showed that APOBEC2 had little impact on site-specific DNA
demethylation during the process of retina regeneration suggesting that its role still
remains to be determined (Powell et al., 2013).
APOBEC2 has also been shown to be important during development. In zebrafish
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APOBEC2 has been implicated with muscle development potentially through a
mechanism that involves binding to Unc45b, a chaperone protein. Knockdown of
APOBEC2a/b in zebrafish leads to a dystrophic phenotype in skeletal musculature and
impairs heart function (Etard et al., 2010). A study in Xenopus demonstrated that
APOBEC2 is regulated by transforming growth factor β (TGF-β) signaling and that its
activity is crucial for the determination of left-right axis specification during early
embryogenesis (Vonica et al., 2011). Additionally APOBEC2 was shown to inhibit the
TGF-β pathway, upstream of Smad2 transcriptional response. The inhibitory role or leftright phenotype was not observed when mutations were introduced in the conserved
amino acids of the enzymatic domain required for the activity of other well-characterized
cytidine deaminases, strongly suggesting that in Xenopus APOBEC2 has cytidine
deaminase activity. Further evidence shows that the inhibitory role in the TGF-β pathway
is conserved in mouse APOBEC2. Vonica et al. shows that APOBEC2 mediates
inhibition of TGF-β signaling and that this might be necessary for proper differentiation
of the myoblast cell line C2C12.
Changes in expression levels of APOBEC2 have also been linked to cancer
development. Transgenic mice constitutively expressing APOBEC2 in all tissues develop
liver and lung cancers by 1.5 years of age. These tumors correlate with mutations in the
mRNAs (but not DNA) of two tumor suppressors genes, Pten and Tp53 (Okuyama et al.,
2012). In this study only specific tumor related genes were sequenced, thus there is a
possibility that APOBEC2 could target more genes in the transcriptome/genome.
Moreover Apobec2 loss of function deletions are discovered as candidate cervical cancer
driver events (Bierkens et al., 2013).
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Overall the above-mentioned studies provide evidence that APOBEC2 has
biological role(s) in diverse species. However there is no agreement on how APOBEC2
achieves these effects. It has been hypothesized that APOBEC2 may be involved in RNA
editing (Liao et al., 1999; Okuyama et al., 2012), DNA demethylation (Guo et al., 2011;
Powell et al., 2012; Rai et al., 2008), or that it has lost its deaminase activity altogether
and may act by a different mechanism (Etard et al., 2010; Sato et al., 2010; Vonica et al.,
2011). Determining what the direct physiological targets are, whether APOBEC2’s
biological function is mediated through deamination, whether it deaminates cytidines and
whether this activity is conserved remains to be determined.

Studies spanning different model organisms confirm that APOBEC2 is important
in skeletal muscle biology and development. In the following sections of this chapter I
will be briefly describing myogenesis, the process of creating muscle, which is the model
I will use for my experimental work in the chapters that follow.

1.4 Myogenesis, the process of cell differentiation to generate muscle
The process of cell differentiation entails the transition of a stem cell (a cell capable of
giving rise to many cell types, thus high in differentiation potential/“stemness”) to a more
specialized cell through the activation and maintenance of specific gene expression
program(s) characteristic for that specific cell type. During development cell
differentiation is important for cell fate (or lineage) specification allowing the pluripotent
embryo to give rise to the diverse somatic cell types of a multicellular complex organism.
In the adult, cell differentiation of multipotent adult stem cell (or progenitors) occurs
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when new specialized cells need to be replenished during homeostasis maintenance,
growth, or tissue regeneration. In response to specific environmental or developmental
cues the cellular identity is directed through transcription factor(s) (TF) binding to DNA
that establish specific gene expression patterns and is reinforced through mitotically
inheritable chromatin states, which determine TF accessibility to DNA (Atlasi and
Stunnenberg, 2017).
Skeletal muscles representing the largest tissue mass important for movement and
metabolism (Braun and Gautel, 2011). The adult skeletal muscle is mainly composed of
terminally differentiated, contractile (due to the sarcomere), multinucleated and
postmitotic myofibers, and a small pool of quiescent muscle stem cells, known as satellite
cells that can be ‘activated’ to form myoblasts (undifferentiated committed cells that can
specialize to form muscle cell). This process of generating muscle during differentiationmyogenesis- occurs early during development (embryonic and - stages), and postnatally
to allow muscle growth, tissue homeostasis and muscle regeneration upon injury
(Bentzinger et al., 2012).
During developmental myogenesis, mesoderm-derived structures generate the
first muscle fibers (primary fibers). In subsequent waves, additional fibers (secondary
fibers) are generated along the initial fibers, which serve as scaffolds. Initially myogenic
progenitors increase in numbers through proliferation, but later on decrease as the
number of myonuclei (nuclei of myofibers) reaches a steady state. Once the muscle has
matured, they enter quiescence and reside as satellite cells. Fully formed skeletal muscle
in adults relies on satellite cells, which can self-renew and replenish muscle with new
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terminally differentiated myofibers during cell turnover or regeneration (Dumont et al.,
2015).
1.5 Master regulators controlling differentiation of muscle cells
Muscle cell lineage progression is associated with hierarchical and coordinated
expression of various TF(s) that lead to cell specific gene expression (Figure 1.6)
(Bentzinger et al., 2012). Higher up in the hierarchy are sine oculis homeobox
transcription factors 1/4 (Six1/4) and paired-homeobox transcription factors 3/7 (Pax3/7),
which are master regulators of early lineage specification in the embryo. In the postnatal
organism, Pax3 and Pax7 mark the presence of satellite cells located underneath the basal
lamina of adult myofibers. Pax3 is mainly involved in the regulation of embryonic
functions and maintenance of an undifferentiated phenotype, while Pax7 appears to
regulate proliferation and inhibition of differentiation, through binding to genes involved
in the maintenance of adult satellite cell phenotype (Soleimani et al., 2012).
Myogenic formation in different scenarios (e.g. embryonically or postnatally in
the adult) is defined by the expression of the myogenic regulatory factors (MRFs), a
group of basic helix–loop–helix (bHLH) transcription factors that include myogenic
factor 5(Myf5), myoblast determination protein (MyoD), muscle-specific regulatory
factor 4 (Mrf4 also known as Myf6) and Myogenin (Myog). MRFs bind to E-protein
family of bHLH proteins forming heterodimers and bind to E-box consensus sequence
(CANNTG) present in the regulatory regions of muscle-specific genes (Berkes and
Tapscott, 2005). MRFs act at multiple points in the muscle lineage to coordinately
establish the skeletal muscle phenotype through regulation of proliferation, irreversible
cell cycle withdrawal of myoblasts, and fusion of myoblasts into myotubes. Moreover
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regulation of other muscle specific genes facilitates the differentiation and assembly of
the sarcomere, the contractile units of the muscle mostly made up of actin and myosin
filaments and arranged in highly ordered arrangement (Hernández-Hernández et al.,
2017). Mouse genetic models demonstrate that MyoD and Myf5 function in
determination of myogenic cells, Myog and MyoD function on terminal differentiation
and Mrf4 has a role in both determination and differentiation. The Myf5-/-MyoD-/- mice
show postnatal lethality, due to a complete absence of skeletal myoblasts or myofibers
(Rudnicki et al., 1993), suggesting they are important in specifying the myogenic lineage
in embryos. Myog -/- mice continue to specify the muscle lineage through the formation
of myoblasts but show perinatal lethality due to defects in muscle fiber formation (Hasty
et al., 1993; Nabeshima et al., 1993) suggesting importance during differentiation. Mrf4
is considered both a determination and a differentiation factor. MyoD-/-Mrf4-/- show
postnatal lethality and a phenotype similar to that of the Myog

-/-

mice (Rawls et al.,

1998), suggesting that Mrf4 and MyoD play a redundant role in mediating skeletal
muscle differentiation during development.
Temporally, Myf5 and MyoD expression is induced in proliferating myoblasts (or
activated satellite cells), which is followed by the simultaneous downregulation in
expression of Myf5 and induction of Myog during cell cycle exit, leading to a ‘point of
no return’ where cells are committed to go down the path of differentiation. Downstream
activity of MyoD and Myog leads to the expression of the Mrf4 gene and other late
muscle differentiation genes to allow the formation of multinucleated fibers. Lastly in
mature muscle fibers, MyoD and Myog are downregulated, whereas Mrf4 continues to be
expressed at high levels acting as the main MRF in mature differentiated muscle. Studies
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looking at genome wide binding of MyoD have shown that it stably binds in genes that
are known to be downregulated or upregulated during differentiation at both the myoblast
and the differentiated phase and additionally the majority of the binding sites contain Ebox sites (a DNA response element that acts as a protein-binding site and has been found
to regulate gene expression) (Cao et al., 2010; Mousavi et al., 2013). More recently it was
shown that the genome-wide binding profiles of Myf5 and MyoD were identical, and the
studies support a model where Myf5 functions to facilitate chromatin remodelling in
muscle progenitors by inducing histone H4 acetylation while MyoD recruits RNA Pol II
and activates transcription of the same target genes (Conerly et al., 2016). Another study
examining the role of Myog in differentiation identified genes involved in cell cycle
progression as key transcriptional targets that are downregulated by Myog (Liu et al.,
2012), suggesting that Myog reduces the expression of genes that mediate cell cycle
progression.
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Figure 1.6 Master regulators controlling myogenesis
Scheme of the expression pattern of the main myogenic transcription factor during
postnatal myogenesis. Image from (Bentzinger et al., 2012)

1.6 The role of myogenic regulatory factors in cell cycle progression
To successfully differentiate, myoblasts must withdraw from cell cycle. Besides their role
in differentiation, MRFs have been shown to modulate cell cycle progression (Singh
Kulwant and Dilworth F. Jeffrey, 2013) (Figure 1.7). Both MyoD and Myf5 can promote
expansion of the muscle progenitor population (Megeney et al., 1996; Ustanina et al.,
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2007; Zhang et al., 2010) and show opposing expression patterns during the different
phases of the cell cycle (Kitzmann et al., 1998). Myf5 protein level peak in G0, decrease
at G1, and go up again at the end of G1, remaining stable through mitosis. MyoD protein
level peaks in mid-G1, decreases to its minimum level in the G1/S transition, and go up
again from S to M. The levels of both proteins during cell cycle are controlled by
phosphorylation-dependent degradation via the 26S proteasome. The importance and
consequences of changing levels of MyoD and Myf5 during cell cycle progression is not
completely understood. What is knows so far is that MyoD binds to the transcriptional
regulatory region of genes with roles in the cell cycle in proliferating myoblasts (Blais et
al., 2005; Cao et al., 2006, 2010), and activates expression of Cdc6 and Mcm2, involved
in preparing chromatin for DNA replication and progression through S-phase of the cell
cycle (Zhang et al., 2010). In response to differentiation signals, MyoD induces
expression of Myog and initiates a gene expression program that commits myoblast to
exit the cell cycle through the activation (and potentially through direct binding) of
p21/cdkn1a, p57/cdkn1c and retinoblastoma protein (pRB) (Falco et al., 2006; Figliola
and Maione, 2004; Zhang et al., 1999).
MyoD and Myog synergize to lead to cell cycle exit through 3 main mechanisms
(1) upregulation of p21/cdkn1a and p57/cdkn1c which suppress the activity of Cdk(s) and
cyclins (Zhang et al., 1998), (2) upregulation of pRB which establishes repressive histone
methylation at cell cycle genes (Blais et al., 2007), (3) the suppression of E2F family
members, which are major regulators of the expression of Cdks and cyclins. Inhibition of
E2F family members has been shown to be achieved through multiple mechanisms:
Myog upregulates the expression of miR-20a targeting transcription factors E2F1, E2F2,
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E2F3 (Sylvestre et al., 2007); Myog reguates Lats2 (Liu et al., 2012), a protein kinase
implicated in targeting of the transcriptional repressor complex DREAM and pRB to E2F
target genes to block cell cycle progression (Tschöp et al., 2011).
In summary, current research suggests that the MRFs that play a role in
determination (MyoD and Myf5) facilitate cell cycle progression, whereas the MRFs that
mediate differentiation (Myog) induce cell cycle exit. Current research shows that Myog
mediates cell cycle exit indirectly, through regulating the expression of target genes
involved in blocking cell cycle progression.

Figure 1.7 The role of myogenic regulatory factors in cell cycle progression
Scheme showing how MRFs affect cell cycle arrest necessary for proper myogenesis.
Image from Singh Kulwant and Dilworth F. Jeffrey, 2013
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1.7 Statement of the problem
APOBEC2 is one of the most ancestral members of the AID/APOBEC family and it has
been under purifying selection suggesting that it has an important function (Conticello et
al., 2005, 2007b). Previous research has demonstrated that APOBEC2 has a biological
role in various organisms. So far it is unknown how APOBEC2 is mediating its
biological function(s), what its physiological targets are, whether it is acting as a
deaminase in polynucleotides, or whether it is deaminating cytidine.
The main goals of the research presented here is to utilize high throughput next
generation sequencing methods to elucidate how APOBEC2 mediates its physiological
role(s) and whether it is important for (1) gene expression regulation, (2) DNA
methylation, (3) RNA editing and (4) whether it can bind DNA. For these studies I have
chosen to focus on muscle, since it is the tissue where APOBEC2 is expressed
physiologically, highly, and in an inducible manner. The ultimate goal of my thesis work
is to identify physiological binding targets that can be utilized to shed light into the
existence (or not) of an enzymatic activity for APOBEC2, and thus decipher its broader
role beyond muscle, with potential implications in gene expression regulatory
mechanisms and/or in driving genome biological diversity.
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CHAPTER 2. Characterizing the role of APOBEC2 during muscle differentiation
As described in the introduction, the role of APOBEC2 in muscle biology has been
widely described. Mouse APOBEC2 is highly expressed in skeletal muscle. Its deficiency
results in a mild phenotype in adult skeletal muscle, where APOBEC2-/- mice are smaller
in size, have smaller muscles, show higher levels of slow-twitch fibers, and with age,
show signs of myopathy through the presence of abnormally nucleated myofibers in 6
month old mice (Sato et al., 2010). Additionally APOBEC2 expression levels go up in
the aging skeletal muscle in rats, linking APOBEC2 to sarcopenia (muscle wasting
during aging) (Piec et al., 2005).

Despite many studies supporting APOBEC2’s

biological function in muscle, there is still a lack in knowledge about its physiological
target(s) or presence of enzymatic activity (Harris et al., 2002; Lada et al., 2011). As
mentioned the primary goal of my thesis work is to discover the direct substrates of
APOBEC2 with the hope that this would give us insights and bring us closer to the
identification of its potential enzymatic activity. To do this I chose a simple system of
muscle differentiation in culture as a model for investigating substrate(s) of APOBEC2.
In the first part of this chapter, I describe phenotypic data related to the cell culture
differentiation model and in the second part of the chapter, I describe further studies
using APOBEC2 null mice.

2.1 C2C12 cell culture system as a model to study APOBEC2 function
C2C12 is a widely used model to study skeletal myogenesis. C2C12s were originally
derived from mouse satellite cells activated to proliferate after muscle injury in adult
mice (Blau et al., 1985; Yaffe and Saxel, 1977). The advantages of using this system are
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that these cells proliferate as myoblasts in high-serum conditions and can be induced to
differentiate into myotubes in cell culture in low-serum conditions. Unlike primary
myoblasts, which have a limited proliferative capacity, C2C12 is an immortalized cell
line that provides an alternative and widely used model to study myogenesis. Because
C2C12s proliferate indefinitely while retaining the ability to differentiate, they provide a
convenient and faster system to use. The limitations of the system are (1) the cells are
intrinsically different from primary myoblasts metabolically and in their ability to
contract forming myofibrils and (2) you lack the cell niche (potential other external
factors) compared to using a mouse model. The system is ideal for our studies on the
identification of APOBCEC2 substrates because (1) it had previously been demonstrated
that Apobec2 mRNA expression is induced upon differentiation in C2C12s (Vonica et al.,
2011) and (2) levels of the Apobec2 mRNA increase during differentiation suggesting
APOBEC2 is exerting its physiological effects and (3) these cells are a commonly used
system for recapitulating the first steps of muscle differentiation in culture.
I first confirmed the progressive increase in the levels of APOBEC2 protein
during "myogenesis" in the C2C12 model system (Figure 2.1a), which would suggest a
potential biological and/or enzymatic activity of the protein during C2C12 differentiation.
I also confirmed that under the conditions I used, I could reliably induce terminal
differentiation of myoblasts into myotubes, by calculating the fusion index (percentage
MyHC-positive myotubes with > 2 nuclei). As previously demonstrated, I showed that
the number of MyHC multinucleated fibers increase after induction of differentiation as
indicated by an increase in the fusion index (Figure 2.1b). I could thus recapitulate
previous findings in the literature.
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Figure 2.1 APOBEC2 expression in C2C12 increases during differentiation
Myogenic differentiation was induced by switching the cells to the differentiation
medium(DM). Days indicate the time the cells were in DM. a) Whole cell extracts of
mouse C2C12 myoblasts and myotubes were analyzed by Western blotting using antiApobec2 antibodies. MyHC and TroponinT were used as markers of late differentiation,
alpha-tubulin was used as loading control b) C2C12 cells were cultured in DM for 0,2
and 5 days, fixed, and stained with antibody to MyHC (green). Nuclei were visualized by
DAPI staining (blue). Below the quantification of differentiation expressed as fusion
index, which is the percentage MyHC-positive myotubes with >2 nuclei. Results are
presented as means from quantification of at least 6 images/sample. Error bars indicate
SD. Image scale 50um.
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2.2 Knockdown of APOBEC2 during C2C12 myogenesis interferes with
differentiation
To explore APOBEC2’s biological role and enzymatic activity during myogenesis I
depleted APOBEC2’s protein levels, using short hairpin RNAs (shRNA) that are
constitutively expressed once successfully integrated in the genome. When successfully
bound to their target mRNA (the mRNA for Apobec2), these shRNAs will lead to its
degradation.
I tested four hairpins, two of which (#1 and #4) showed abundant knockdown at
the protein level when compared to the knockdown controls (Figure 2.2a,b). The target of
shRNA#1 on Apobec2 mRNA is at the 3’ untranslated region (3’UTR) while the target of
shRNA#4 on Apobec2 mRNA is within the second exon. Cells constitutively expressing
the hairpins were selected, seeded in equal numbers and 12 hours after seeding were
induced to differentiate in cell culture. My results demonstrate that knock-down of
APOBEC2 leads to a reduction in the fusion of myotubes as indicated by decreased
fusion index (Figure 2.2c) and a delay in the expression of differentiation markers,
TroponinT and MyHC (Figure2.2d). Thus overall proper formation of myotubes is
impaired. These results are corroborated by a recent publication where it was shown that
expression of APOBEC2 increases during differentiation of embryonic stem cell-derived
myogenic precursors into myotubes in cell culture. Similarly to my data, knockdown of
APOBEC2 reduced differentiation and the expression of differentiation markers such as
Myog (Carrió et al., 2016).
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Figure 2.2 Knockdown of APOBEC2 in C2C12 cells leads to problems in
differentiation
a) Schematic representation of Apobec2 gene. Lines as introns and boxes as exons, black
boxes as coding regions. Image scale=100bases. Location of the zinc deaminase domain
and the site of the binding of A2sh#1 and A2sh#4 shRNAs are shown. Produced using
http://wormweb.org/ b) Lysates of C2C12 from cells with no hairpin (no shRNA), control
shRNA (GFPsh) and APOBEC2 shRNA (#1-#4) cultured in DM for 4 days were
analyzed by Western blotting (WB) using anti-Apobec2 antibodies. Alpha-tubulin was
used as loading control c) C2C12s were fixed and immunostained using antibodies
specific MyHC (green), DAPI (blue) was used to stain for DNA. Quantification of
differentiation expressed as fusion index is shown. Error bars indicate SD d) C2C12
lysates in DM at day 0-4 were analyzed by WB. MyHC and TroponinT were used as
markers of late differentiation; alpha-tubulin, as loading control.
Statistics: t test. At least 6 fields of view were measured and data is shown as means.
Error bars indicate SD (n=3). *p < 0.05; **p < 0.01; ***p < 0.001
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Muscle differentiation is closely coordinated with cell cycle progression. During the
differentiation of myogenic precursors into mature myotubes, cells withdraw irreversibly
from the cell cycle. Cell cycle exit occurs early during the differentiation program and is
required for fusion and proper myotube formation (Walsh and Perlman, 1997). Cells
commit to differentiation as indicated by Myog induction and they commit to irreversible
cell cycle arrest as indicated by induction of p21/cdkn1a, the cyclin-dependent kinase
inhibitor (CDI) whose expression levels correlate with blockage of DNA synthesis and
cell cycle exit (Guo et al., 1995)(Andrés and Walsh, 1996). This is followed by
expression of myosin heavy chain (MHC) and fusion. Given the importance of cell cycle
withdrawal in proper differentiation, I next investigated whether APOBEC2 affects cell
cycle withdrawal through differentiation.
Therefore, I quantified the proportion of cells in G0/G1, entering S, and in G2/M
phases of the cell cycle as they are induced to differentiate. I used a modified thymidine
analogue (EdU or 5-ethynyl-2'-deoxyuridine) in combination with PI (propidium iodide)
or PI(alone). Both molecules incorporate into the DNA, EdU is incorporated into newly
synthesized DNA and can be fluorescently labeled, and PI binds to DNA by intercalating
between the bases. The combination of the two allows for the FACS-based, clear
differentiation between all the different cell cycle phases proportional to the amount of
DNA stained. As expected from the literature, during differentiation of C2C12 the
proportion of the cells in G0/G1 increases while fewer cells are entering S phase and are
in G2/M phase. Interestingly knocking down APOBEC2 in C2C12s leads to a decrease in
the proportion of cells in G0/G1 phase and an increase in the proportion of cells entering
S phase during differentiation (Figure 2.3a,b). The data shown here represent a mixture of
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cells at different stages of the cell cycle. In the future, we would like to repeat the cell
cycle experiment following C2C12 cell cycle synchronization, so that the cells at
different stages of the cell cycle in a culture are brought to the same phase. Overall the
data suggests that APOBEC2 is necessary for timely cell cycle withdrawal and
consequently for terminal differentiation.
In the future, we like to confirm that the phenotype observed due to knockdown
of APOBEC2 is protein specific and reproduce the cell cycle phenotype using the
A2sh#1 hairpins and rescue the phenotype observed to rule out off target affects. My
initial attempts to rescue the phenotype of delayed differentiation (using synonymous
mutations in the construct in a constitutive expression and an inducible expression
system) showed conflicting results, even though western blot analysis confirmed that this
construct is resistant to shRNA-mediated depletion. Moreover it is not uncommon for
RNAi rescue experiments to fail for multiple reasons (known and unknown) unrelated to
the off-target affects (Datler and Grimm, 2013). Some of the challenges in the C2C12 cell
culture system are being able to achieve expression of the rescue construct at the levels
and dynamics of the endogenous protein. Thus since during differentiation a lot of events
need to be coordinated in a timely manner, the amount of construct expressed might be
too much or too little and not at the optimum time points. In the future these systems will
be optimized to test the rescue of the cell cycle phenotype observed.
Overall, I demonstrated that APOBEC2 in C2C12s is important for timely
progression to cell cycle exit and terminal differentiation of myoblasts into myotubes.
This provides a good model system to further investigate the potential substrates and
enzymatic activity of APOBEC2.
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Figure 2.3 Knockdown of APOBEC2 in C2C12 cells leads to defects in cell cycle
withdrawal during differentiation
a) C2C12 stably expressing A2sh#4 or GFPsh (control) cultured in DM for different days
(d0,1,2) were stained with PI and EdU. FACS plots shows the time-course effect of
differentiation on cell cycle profile in C2C12 cells. Results are presented as means. Error
bars indicate SD (n = 3, corresponding to three independent experiments). Data shown as
means ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. Color of the line corresponds to the
cell cycle phase shown.
b) C2C12 cultured in DM for different days (d0, 1, 2) were stained with EdU and PI to
mark cells in the different stages of the cell cycle (G0/G1, entering S and G2/M). The
FACS plots show the time-course effect of differentiation on cell cycle profile in C2C12
cells.
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2.3 APOBEC2 deficiency leads to defects in fiber maturation and nuclear
positioning
Previous research on APOBEC2 in muscle has shown minor phenotypic affects due to
APOBEC2 deficiency but no major overall defects in muscle development, health,
fertility, or survival (Mikl et al., 2005; Sato et al., 2010). This could be due to genetic
redundancy where another (or more) gene(s) compensates (partly or fully) for its absence
by performing a similar function and as a result APOBEC2’s deficiency has no drastic
effect on the biological phenotype. Indeed there are many examples of this occurring
through development including in muscle (Haldar et al., 2008; Kafri et al., 2009). An
example is Myf-5 and MyoD that functionally substitute for one another (at least partly)
during myogenesis and only when both of them are deleted does one observe a block in
muscle development (Rudnicki et al., 1993). Another possibility is that APOBEC2 could
have a potential role mainly during postnatal muscle growth, maintenance of tissue
homeostasis or muscle regeneration after injury. Given that previous work on the
APOBEC2 null mice does not show major defects in embryonic muscle development, I
next investigated whether there are any defects during myotube formation during de novo
myogenesis in adult mice.
Nuclear migration is an important event throughout development and it is
characteristic of muscle fibers. During muscle formation nuclei undergo mechanistically
and temporally distinct movements which leads to nuclei being evenly spaced at the
periphery of the myofiber to maximize the distance between them (Bone and Starr,
2016). For our studies we use a different APOBEC2 null mouse not previously published
where no APOBEC2 protein is detected (Figure 2.4a). First I characterized muscles from
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the APOBEC2-/- in the centrally nucleated phenotype. Previous work has linked
APOBEC2 with muscle wasting and an increase in the proportion of slow to fast fiber
type ratio, suggesting that the fast fiber types might be affected due to APOBEC2
deficiency. Therefore I carried experiments using the tibialis anterior (TA) muscle,
which is a fast-twitch muscle. My experiments show that in the TA muscle there is a
higher proportion of abnormally nucleated fibers in 10 week old APOBEC2-/- mice
(Figure 2.4b), suggesting that abnormalities in muscle from APOBEC2-/- mice start much
earlier than what was previously shown (Sato et al., 2010). Moreover mice deficient in
APOBEC2 have smaller myofibers as shown by measuring fiber cross section area (CSA)
and minimum feret diameter accompanied but increase in the number of myotubes
(Figure 2.4c-e), in accordance with a recent publication (Ohtsubo et al., 2017a).
Furthermore, muscle strength was tested by grip test where time to release from an
inverted grid was recorded. My data show that in the four-limb grip test, APOBEC2
deficient mice show a reduction in the total hang time in the grid indicative of reduction
in muscle strength (Figure 2.4f). Overall, steady state muscle is qualitatively and
quantitatively different in APOBEC2-/- animals.
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Figure 2.4 APOBEC2-/- muscle fibers are small and abnormally nucleated in mice
a) Expression of APOBEC2 and MyHC, alpha-tubulin, as loading control is shown
through Western Blot analysis in skeletal muscle b) Representative image of the crosssections of the Tibialis Anterior (TA) in 10-12 week old WT and APOBEC2

-/-

(A2-/-)

mice. WGA in green (delineates the myofiber boundaries) and DAPI in blue stains the
nuclei. The images are used to automate the calculation of the number of fibers with
nuclei not present around the fiber (abnormally nucleated) using ImageJ macros. Plotted
on the right is the percent of abnormally nucleated fibers. Data are represented as means
± SD c) TA fiber size quantification using minimal feret diameter (in μm). Mean values
on the left, distribution of diameter on the right d) Fiber size quantification using cross
sectional area (in μm2). Mean values on the left, distribution of area on the right f)
Number of myofibers in TA for equal areas analyzed e) An inverted grip-hanging test
was performed on in 3-5 month old WT and APOBEC2-/- mice. Average values of 5 trials
are shown
Statistics: Unpaired t test. N > 5. At least 250 individual myofibers are analyzed for each
cross section of TA muscle and average values for each mouse are plotted here. Unless
noted otherwise data are represented as means ± SEM. *p < 0.05; **p < 0.01; ***p <
0.001; no star, statistically non significant. Scale bar = 100um. Unless noted otherwise
statistical test: Unpaired t test with Welch's correction.
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The regenerative capacity of muscle is due to satellite cells, the myogenic stem
cell population residing in adult skeletal muscles (C2C12 cells derive from satellite cells).
In healthy adult muscle the satellite cells are quiescent (G0 state, non-dividing).
Following injury, the cells become activated and re-renter cell cycle (G0 to G1/S/G2/M)
increasing the number of myoblasts, and subsequently exit the cell cycle to self-renew
(G1 to G0) or to differentiate (Relaix and Zammit, 2012). I used a model of muscle
regeneration following injury to determine whether deficiency of ABOBEC2 leads to any
defects in differentiation during myogenesis in the adult mouse.
I induced injury in the TA muscle by injecting BaCl2 in both wild type and
APOBEC2-/- mice, using one of the two TA muscles as control (inject saline). Muscle
cross sections were analyzed 14 days after inducing injury, during which I expected
myotube formation to be complete in wild type mice (Hardy et al., 2016). My results
show that mice deficient in APOBEC2 form myotubes at 14 days after injury but they are
smaller in size when measuring fiber cross section area (CSA) and minimum feret
diameter and have more fibers per area analyzed (Figure 2.5). Therefore APOBEC2-/muscle fibers start off different in size and number, and re-set to that baseline, even after
injury. These data suggest that lack of APOBEC2 does not delay myofiber formation
after injury, but might be relevant for proper muscle maturation and growth.
Collectively, the data so far suggests a role of APOBEC2 in cell cycle regulation.
In C2C12s failure to properly exit cell cycle is accompanied with defects in proper
differentiation. I decided to use the C2C12 system to further investigate potential
APOBEC2 substrates.

45

Figure 2.5 APOBEC2-/- muscle fibers are smaller in mice 14 days post-injury
a) Cross-section of the Tibialis Anterior (TA) muscle in WT and APOBEC2-/- (A2-/-)
mice. WGA in green (delineates the myofiber boundaries) and nuclei were visualized by
DAPI staining. Scale bar is 100um b) Fiber size quantification using minimal feret
diameter (in μm). Mean values on the left, distribution of diameter on the right c) Fiber
size quantification using cross sectional area (in μm2). Mean values on the left,
distribution of area on the right. N = 7
At least 250 individual myofibers are analyzed for each cross section and average values
for each mouse are plotted here. Data are represented as means ± SEM. *p < 0.05; **p <
0.01; ***p < 0.001; no star, statistically non significant. Statistical test: Unpaired t test
with Welch's correction. Scale bar in images is 100um
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CHAPTER 3. Evaluating the role of APOBEC2 in gene expression and RNA
editing.
Thus far, through cell biological observations I have demonstrated that APOBEC2 has a
role in differentiation to muscle cells because when deficient there is a delay in
differentiation concurrent with an inability to properly exit cell cycle. To begin to assess
how loss of APOBEC2 resulted in this phenotype, and keeping in mind the postulated
role of this protein in CpG demethylation, I decided to look at transcriptional changes
that would correlate with the cell biological findings.
Toward this, I performed poly (A)+ RNA high throughput sequencing (or mRNASeq). This method can be used to quantify the changing expression levels of each
transcript (perhaps allowing me to establish transcriptional outcomes of the putative
demethylase). It additionally provides information about the transcript’s sequence at base
pair resolution. Thus mRNA-Seq would allow me to investigate another possible role of
this orphan deaminase in RNA editing. RNAseq analysis of APOBEC2 dependent
changes would provide initial evidence toward which of the two potential molecular
mechanisms (DNA demethylation versus RNA editing) established for other members of
the AID/APOBEC family might be descriptive of APOBEC2 activity.

3.1 RNAseq analysis pipeline and validations
To generate libraries toward mRNA-seq, I first generated single cell clones (3 replicates)
of C2C12 cells transfected with a control knockdown vector (shGFP). I also generated
additional single cell clones (3 replicates) expressing a hairpin, which could efficiently
knock down APOBEC2 (A2sh4).
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I used the RNA to prepare stranded libraries using the TruSeq RNA-Seq library
preparation protocol, which allows us to differentiate between sense and antisense
transcription. Multiplexed samples underwent paired-end sequencing, which allows for
sequencing in both ends of a fragment, thus improving the coverage of the transcripts and
the likelihood of detecting splicing events or genomic rearrangements. In brief, as shown
in the diagram in (Figure 3.1) the subsequent analysis pipeline involves filtering for reads
that do not pass quality control measures, adaptor trimming and alignments of the reads
to a reference genome and transcriptome. Only reads that uniquely map to exactly one
location in the genome are considered for differential gene expression analysis. Reads are
assigned to a specific genomic feature such as genes and counted for downstream gene
expression analysis (Liao et al., 2013). The total number of counts for each gene is
normalized by total library size for each sample before being used to determine gene
expression fold change differences for each of the genes (Anders et al., 2012; Love et al.,
2014). To estimate the relative abundance of a gene in a sample the number of read
counts is normalized by the effective transcript length, which accounts for the length of
the transcripts and the differences in read distribution along the transcript to compute
transcripts per million (TPM). The latter represents the number of copies of a transcript
that would be expected in a collection of one million transcripts and serves as a relative
measure of the amount of transcript in the sample (Patro et al., 2017).
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Figure 3.1 Schematic representation of the RNAseq analysis pipeline

The efficiency of ABOBEC2 knockdown for each of the single cell clones was
evaluated using a western blot on the C2C12 lysates at different time points in
differentiation medium. APOBEC2 itself was clearly expressed at the expected level for
each clone analyzed. The results indicate cells differentiating as expected and a
successful knockdown (Figure 3.2a). These single cell clones were induced to
differentiate, and I collected RNA from all 6 replicates at day 0, 1, and 2 post
differentiation. The days selected represent time points where the expression levels of
APOBEC2 are highly changing from very low at day 0 to high at day 2. As a first quality
control I assayed the levels of the Apobec2 mRNA transcript (using the RNA-Seq
analysis pipeline) and confirmed the expected knockdown of APOBEC2 (Figure 3.2b).
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Moreover I compared the gene expression changes between the GFPsh control and
C2C12s that are not expressing any shRNAs and no differences were detected (data not
shown).

Figure 3.2 RNAseq analysis pipeline and validations
a) C2C12 lysates from single cell clones that were used in the RNAseq experiment in
DM at day 0,1,2,3 were analyzed by WB using anti-APOBEC2 antibodies. alpha-tubulin
was used as loading control. 3 clones were used for each group b) Graph representing the
relative levels of APOBEC2 during d 0, 1, 2 time points, using the RNAseq data.
Transcripts per million (TPM) is a measurement of the relative abundance of genes
within the sample. Data represented as mean and SEM of the 3 biological replicates. * padjusted (as determined by DESeq2) < 0.1
3.2 Analysis of gene expression changes and pathway enrichment analysis during
myogenesis
As a second quality control I identified genes and gene sets that change through
differentiation in the control context. Because I already knew that APOBEC2 protein
levels increase with differentiation from very low (day 0) to highly expressed (day 2), I
chose day0, day1 and day2 as the relevant time points for the RNA seq analysis. Looking
at the RNA-Seq data set from the control samples (GFPsh), I could identify many gene
expression changes through differentiation. Specifically from day 0 to day 1 after
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inducing differentiation there are a total of 3919 genes that are significantly differentially
expressed (significance: adjusted p value <0.1 as defined from DESeq2) from which
1955 are up-regulated and 1964 are down-regulated. From day 1 to day 2 of the
differentiation there are a total of 2421 significantly differentially expressed from which
1376 are upregulated and 1045 are downregulated (Figure 3.3).
To extract biological meaning from these RNA-Seq datasets, I used Gene Set
Enrichment Analysis (GSEA), an approach that identifies groups of genes that share
common biological function or regulation, or pathways that are coordinately changing
due to APOBEC2 knockdown (Mootha et al., 2003; Subramanian et al., 2005). The
advantages of the method are that (1) produces results that can more easily be interpreted
in regard to the relevant biological processes (2) it is designed to detect subtle but
coordinated changes in the expression of a group of functionally related genes that would
be missed otherwise. The strength of this method also lies in the availability the
Molecular Signatures Database (MSigDB), which contains a large number of repositories
of gene sets (extracted from research publications or other specialized resources),
acquired through manual and computational means (Liberzon et al., 2011). MSigDB
includes the "Hallmark" gene sets, that forms a refined collection of gene sets that is
computationally defined and manually curated and annotated, thus reducing potential
variation and redundancy by summarizing common information across multiple gene sets
(Liberzon et al., 2015).
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Figure 3.3 Gene expression changes of myogenesis
Barplot on the left shows the number genes significantly up/downregulated through
differentiation. Scatter plot on the right shows the log2 fold changes between da0 and
day2 time point, over the log10 of the mean of normalized counts for all the sample.
Significantly differentially expressed genes with p adjusted value <0.1 are shown in red
(upregulated) or blue (downregulated) and not significantly differentially expressed genes
in gray. APOBEC2 is shown in green
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To determine what biological pathways are important during the differentiation
process (at the chosen time points), I examined what MSigDB Hallmark gene sets are
enriched in the list of genes that are differentially expressed using GSEA. Some of the
top significant gene sets are listed in Table 3.1. They include groups of genes important
in myogenesis (HALLMARK_MYOGENESIS gene set), which are enriched in the list of
genes that are upregulated during day0 to day2 transition confirming the importance of
this gene set network during C2C12s differentiation in cell culture (Figure 3.4a).
Interestingly

genes

encoding

targets

of

E2F

transcription

factors

(HALLMARK_E2F_TARGETS), important for the regulation of cell cycle are enriched
in the list of genes whose expression is down regulated through differentiation, during
time points day 0 to day2 (Figure 3.4b). The E2F transcription factors have been widely
shown to be required for the regulation of DNA replication and cell cycle regulation
(Bracken et al., 2004), which are in turn important requirements for the progression of
proper differentiation for muscle fibers. More statistically significant gene sets in the list
of genes that are upregulated during differentiation include: MYC targets and metabolic
gene sets, while gene sets that are enriched in genes downregulated during differentiation
include pathways in cell cycle checkpoints and interferon alpha and gamma response
(Table 3.1).
One of the advantages of the MSigDB is that it contains many gene sets that
represent many biological processes, but this also brings challenges. For example, the
growth of the number of the gene sets has also lead to the problem of (1) redundancy
(e.g. gene sets with many overlapping genes can dominate the top of the significant sets
hiding other relevant hits) and (2) heterogeneity (a gene set not always behaving
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consistently based on biological context or due to poor biological resolution). So in
addition to utilizing the ‘Hallmark’ gene sets (Liberzon et al., 2015), and to better
establish the most biologically relevant results while reducing gene set heterogeneity I
decided to create a list of customized gene sets. Toward that, from the MSigDB gene sets
I extracted the subset of genes that are significantly unregulated, downregulated or nonsignificant (ns) during the differentiation process of control C2C12 cells generating
C2C12-specific pathways. I used these, to determine the C2C12 differentiation-related
gene sets significantly enriched due to APOBEC2 knockdown.

55

Table 3.1 List of Gene Sets significantly changing during myogenesis
Gene lists, ranked by expression changes during differentiation from d0 to d2, were fed to
the GSEA. Top significant gene sets from MSigDB Hallmark database are shown. Gene
listed are only those with adjusted p value <0.1. The false discovery rate (FDR) is the
estimated probability that a gene set with a given NES represents a false positive finding.
NAME

HALLMARK_E2F_TARGETS

HALLMARK_G2M_CHECKPOINT

HALLMARK_INTERFERON_ALPHA_RESPONSE

HALLMARK_INTERFERON_GAMMA_RESPONSE

GENES

NES

FDR

Tfrc, Cdkn1a, Ipo7, Cbx5, Rad51c, Mthfd2, Prdx4, Msh2, Rpa1, Tbrg4, Tubb5, Rfc3,
Tk1, Pa2g4, Lig1, Slbp, E2f8, Dut, Eif2s1, Tcf19, Prim2, Rfc2, Cit, Rad50, H2afx, Shmt1,
Atad2, Cks1b, Melk, Cdkn2c, Mcm6, Aurkb, Mcm4, Hn1, Spc25, Donson, Chek2, Smc4,
Cdkn1b, Zw10, Wee1, Nup153, Cdk1, Birc5, Hmgb2, Ube2t, Tmpo, Wdr90, Cse1l,
Mxd3, Nop56, Tipin, Plk1, Rfc1, Dek, Ctps, Pold1, Kif2c, Stmn1, Timeless, Gins1,
Aurka, Ccp110, Trip13, Rrm2, Dck, Gins3, Brca2, Tra2b, Ccne1, Pold3, Lbr, Brca1,
Cdca3, Tacc3, Bub1b, Plk4, Cdc20, Orc2, Mybl2, Mki67, Pcna, Spag5, Mcm3, Hmmr,
Lmnb1, Mcm5, Ctcf, Racgap1, Diaph3, Ranbp1, Xpo1, Dnmt1, Cdca8, Cenpe, Gspt1,
Mms22l, Rpa3, Chek1, Spc24, Hnrnpd, Top2a, Depdc1a, Cdk4, Kif22, Cks2, Hus1,
Pold2, Bard1, Mcm7, Phf5a, Ube2s, Pnn, Pds5b, Cdc25a, Hmga1, Tubg1, Paics

-6.57

<0.001

-4.78

<0.001

-4.20

<0.001

Ripk2, Cdkn1a, Pnp, Samhd1, Helz2, Vamp5, Sri, Nfkbia, Btg1, Irf5, Ifitm2, Ifitm3,
Mthfd2, Itgb7, Ube2l6, Isoc1, Trim25, Nampt, Ripk1, Mvp, Parp12, Wars, Cmklr1, Sod2,
Pml, Psme1, Jak2, Casp8, Ddx58, Tap1, Il7, Socs1, Eif4e3, B2m, Il6, Trim26, Hif1a, Fas,
Nod1, Gch1, Vamp8, Vcam1, Myd88, Eif2ak2, Psme2, H2-Q7, H2-D1, Ifi35, Csf2rb,
Pde4b, C1ra, Trim21, Rtp4, Stat3, Parp14, Irf1, Ncoa3, Upp1, Znfx1, Lgals3bp, Pla2g4a,
Isg20, Stat1, Zbp1, Tapbp, Ddx60, C1rb, Bpgm, Adar, H2-M3, St3gal5, Rapgef6, Ptpn2,
Cd74, Lap3, Ifit2, Il2rb, Irf2, Ifi30, H2-K1, Socs3, Nfkb1, Irf9, Ifih1, Auts2, Arl4a

-3.94

<0.001

GENES

NES

FDR q-val

7.79

<0.001

4.55

<0.001

3.86

<0.001

3.11

<0.001

Slc12a2, E2f2, Hoxc10, Top1, Meis2, Slc7a5, Wrn, E2f4, Ccnd1, Slc7a1, Kif5b, Dmd,
Efna5, Prmt5, Gins2, Notch2, Odc1, Ccnt1, Pml, Prim2, Abl1, G3bp1, Mapk14, Exo1,
H2afx, Smarcc1, Pbk, Hif1a, Dkc1, Cul5, Bcl3, Cks1b, Cdkn2c, Mcm6, Aurkb, Cul4a,
E2f1, Hn1, Smc4, Cdkn1b, Pafah1b1, Cdk1, Birc5, Tmpo, Tnpo2, Plk1, Stil, Odf2,
Cdc45, Ndc80, Ncl, Kif2c, Stmn1, Rbl1, Mtf2, Aurka, Dbf4, Rbm14, Cul1, Cdc27, Brca2,
Smc2, Tra2b, Ccnf, Kif15, Knl1, Lbr, Chaf1a, Tacc3, Plk4, Cdc20, Mybl2, Kif11, Mki67,
Prpf4b, Prc1, Mcm3, Mnat1, Hmmr, Lmnb1, Mcm5, Ythdc1, Ctcf, Racgap1, Rps6ka5,
Xpo1, Upf1, Kif20b, Cenpe, Gspt1, Chek1, Egf, Fbxo5, Sap30, Hnrnpd, Top2a, Cdk4,
Kif22, Cks2, Rad54l, Hus1, Cdc7, Bard1, Incenp, Ube2c, Ube2s, Ttk, Pds5b, Cdc25a,
Hmga1, Bub1, Arid4a, Nek2
Ripk2, Helz2, Cd47, Ifitm2, Ifitm3, Mov10, Ube2l6, Trim25, Mvb12a, Parp12, Csf1,
Wars, Ncoa7, Psme1, Casp8, Elf1, Tap1, Il7, B2m, Trim26, Procr, Uba7, Eif2ak2, Psme2,
Ifi35, Trim21, Rtp4, Parp14, Irf1, Lgals3bp, Isg20, Parp9, Ddx60, Fam46a, Adar, Gmpr,
Cd74, Lap3, Ifit2, Irf2, Ifi30, Irf9, Ifih1

NAME

HALLMARK_MYOGENESIS

HALLMARK_OXIDATIVE_PHOSPHORYLATION

HALLMARK_MYC_TARGETS_V2

HALLMARK_MYC_TARGETS_V1

Itga7, Pygm, Tnnc2, Myl6b, Atp2a1, Pgam2, Ckm, Acta1, Erbb3, Casq2, Tnnt3, Actn2,
Myom2, Tnni2, Chrng, Myh2, Myh1, Mylpf, Tnnt2, Tead4, Ache, Myh3, Tnnc1, Ryr1,
Myom1, Dtna, Cox6a2, Mybph, Mef2a, Ncam1, Ckb, Actc1, Myh8, Sgcg, Fst, Mef2c,
Tnni1, Pfkm, Myog, Mef2d, Akt2, Cav3, Nqo1, Myl1, Hspb2, Csrp3, Klf5, Cdkn1a,
Myh7, Mb, Myh4, Myl4, Tcap, Gadd45b, Eno3, Bin1, Ankrd2, Chrnb1, Cryab, Pkia,
Tnnt1, Pde4dip, Fabp3, Nav2, Wwtr1, Agl, Svil, Camk2b, Cd36, Eif4a2, Myl2, Chrna1,
Igfbp7, Ldb3, Rb1, Myoz1, Gsn, Kifc3, Dmpk, Bhlhe40, Casq1, Mapk12, Acsl1, Gja5,
Reep1, Dmd, Notch1, Adam12, Schip1, Prnp, Hbegf, Ptp4a3, Bag1, Des, Cacng1, Hspb8,
Stc2, Sirt2, Large1, Dapk2, Myh9, Ak1, Tpm3, Myo1c, Apod, Ckmt2, Aebp1, Ablim1,
Pcx, Flii, Cdh13, Cacna1h, Sh2b1, Efs, Gnao1, Ephb3, Syngr2, Sgca, Myf6, Kcnh1, Fgf2,
Pvalb, Igfbp3, Adcy9, Fdps, Pdlim7, Sptan1, Mras, Crat, Fxyd1, Foxo4, Clu, Pick1, Tsc2,
Col4a2
Ndufs4, Timm10, Pdhx, Rhot1, Echs1, Nqo2, Atp6v1d, Slc25a11, Cox15, Atp5d,
Tomm70a, Isca1, Dld, Afg3l2, Lrpprc, Acadm, Idh1, Cyb5a, Cyc1, Timm9, Ndufs1, Opa1,
Aco2, Cox6a1, Sucla2, Pdk4, Hspa9, Oat, Atp1b1, Ndufs2, Atp5g1, Atp6v1e1, Ndufs3,
Ndufs8, Pdp1, Ndufv1, Cox17, Atp5o, Bax, Mrpl15, Uqcrfs1, Acaa1a, Ldha, Glud1,
Alas1, Cpt1a, Mtx2, Iscu, Uqcrq, Pdhb, Prdx3, Ndufab1, Ndufa6, Idh3g, Idh3a, Pdha1,
Mrps22, Atp6v0b, Htra2, Suclg1, Uqcr11, Timm17a, Mtrr, Ndufa3, Ndufa7, Supv3l1,
Aifm1, Tomm22, Pmpca, Retsat, Uqcrc2, Phyh, Hccs, Uqcr10, Atp5g3, Slc25a5, Sdhd,
Ndufs7, Hadha, Cycs, Abcb7, Cox6b1, Fdx1, Bdh2, Phb2, Atp5j, Hsd17b10, Atp6v1g1,
Polr2f, Atp5a1, Mdh1, Cox5a
Rrp12, Nip7, Gnl3, Rrp9, Sord, Mybbp1a, Grwd1, Wdr43, Ppan, Pes1, Aimp2, Bysl,
Nop16, Wdr74, Slc29a2, Pus1, Nop2, Noc4l, Mphosph10, Phb, Pprc1, Tbrg4, Tfb2m,
Pa2g4, Utp20, Ipo4, Mrto4, Ndufaf4, Mcm4, Ddx18, Farsa, Las1l, Nop56, Plk1, Supv3l1,
Imp4, Cbx3, Plk4, Srm, Hk2, Mcm5, Map3k6, Cdk4
Gnl3, Rrp9, Nhp2, Rsl1d1, Ddx21, Aimp2, Tomm70a, Iars, Cdk2, Nop16, Prdx4, Eif2s2,
C1qbp, Eprs, Ywhaq, Cyc1, Abce1, Xpot, Phb, Eif3d, Eif3j1, Cct5, Etf1, Odc1, Pa2g4,
Pabpc4, Cops5, Dut, Eif2s1, Tyms, G3bp1, Ldha, Ppia, Smarcc1, Eif3b, Ncbp2, Mcm6,
Eef1b2, Mcm4, Ap3s1, Prdx3, Ddx18, Mrps18b, Cnbp, Ndufab1, Stard7, Cct3, Rplp0,
Eif4g2, Pwp1, Psmb3, Nop56, Psmd7, Dek, Cdc45, Psmc6, Ctps, Psmc4, Sf3b3, Apex1,
Cul1, Uba2, Prps2, Cbx3, Pgk1, Tra2b, Ncbp1, Psmd8, Cdc20, Cct4, Orc2, Srm, Ssbp1,
Eif1a, Pcna, Psmd1, Mcm5, Rpl14, Ranbp1, Xpo1, Pabpc1, Acp1, Gspt1, Rps2, Hnrnpd,
Psmd3, Cdk4, Rfc4, Pold2, Phb2, Mcm7, Mrpl9, Cox5a
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Figure 3.4 Gene set enrichment analysis for gene expression changes during
myogenesis
GSEA score curves of the RNA-seq output. Two genesets that were significantly
enriched through C2C12 differentiation are shown. False Discovery Rate (FDR) is
calculated by comparing the actual data with 1000 Monte-Carlo simulations. Black bars
represent the position of members of the category in the ranked list together with the
running enrichment score (plotted in green). Bar plots below shows log2 fold changes
between day0 and day2 time point for all expressed genes (grey). Highlighted are genes
that are part of the geneset and upregulated (red) or downregulated (blue) through
differentiation. In green is APOBEC2 a) Myogenesis signature genes enriched in the list
of genes that are significantly upregulated during differentiation b) E2F targets enriched
in the list of genes that are significantly downregulated during differentiation
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3.3 Identification of APOBEC2 dependent gene expression changes
Having derived a list of gene expression changes that correlate with the differentiation of
C2C12 cells into myotubes, I then defined the cohort of gene expression changes that
were likely APOBEC2 dependent.
As expected, mRNA levels for APOBEC2 itself were clearly downregulated in
the APOBEC2-knockdown cells. In addition there were many other genes that were also
significantly differentially expressed with adjusted p-value < 0.1. That list includes: for
day0, 878 genes (330 unregulated and 548 downregulated); for day1, 2505 genes (1106
unregulated and 1399 downregulated); for day2, 2525 genes (1118 unregulated and 1407
downregulated) (Figure 3.5). To determine the biological pathways affected by
APOBEC2 knockdown, I ran GSEA on the list of genes that are differentially expressed
at any of the time points and used the customized Hallmark MSigDB gene sets (the
C2C12 differentiation specific ones which were generated as described above). Some of
the top gene sets that are affected due to APOBEC2 knockdown are listed in Table 3.2).
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Figure 3.5 Lack of APOBEC2 in C2C12 cells leads to gene expression changes
Barplot on the left shows the number genes significantly up/downregulated when we
knockdown APOBEC2. Scatter plot on the right shows the log2 fold changes due to
APOBEC2 knockdown at day 2 after differentiation, over the log10 of the mean of
normalized counts for all the samples. timepoint. Significantly differentially expressed
genes with p adjusted value <0.1 are shown in red (upregulated) or blue (downregulated)
and not significantly differentially expressed genes in gray. APOBEC2 is shown in green
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Table 3.2 List of Gene Sets significantly changing due to APOBEC2 knockdown
Gene lists, which were ranked based on expression changes due to APOBEC2
knockdown at day2, were fed to the GSEA. Top significant gene sets from MSigDB
Hallmark database are shown. Gene listed are only those with adjusted p value <0.1. The
false discovery rate (FDR) is the estimated probability that a gene set with a given NES
represents a false positive finding.
NAME
HALLMARK_MYOGENESIS_D2D0DEG_UP

HALLMARK_OXIDATIVE_PHOSPHORYLATION_D2D0DEG_UP

HALLMARK_MYC_TARGETS_V1_D2D0DEG_UP

HALLMARK_TNFA_SIGNALING_VIA_NFKB_D2D0DEG_UP

HALLMARK_MTORC1_SIGNALING_D2D0DEG_UP
HALLMARK_MYC_TARGETS_V1_D2D0DEG_NS

GENES
Itga7, Stc2, Pfkm, Pde4dip, Dtna, Ncam1, Gadd45b, Sgcg, Bhlhe40, Fst,
Prnp, Hbegf, Cdkn1a, Myoz1, Myh4, Eno3, Atp2a1, Ckb, Mef2d, Wwtr1,
Myh2, Tead4, Syngr2, Gja5, Pgam2, Sgca, Actn2, Myl6b, Des, Tsc2,
Bin1, Mef2a, Schip1, Ptp4a3, Tnni2, Acta1, Adam12, Cdh13, Akt2, Ak1,
Myh7, Tnnt3, Tnnc2, Mb, Ryr1, Myom1, Myh1, Pick1
Rhot1, Ndufs4, Atp5d, Atp5o, Atp6v1d, Pmpca, Tomm70a, Cox17,
Ndufs3, Aco2, Tomm22, Atp5j, Cox5a, Dld, Afg3l2, Isca1, Slc25a5,
Atp5g1, Aifm1, Mtrr, Uqcr11, Atp5a1, Sdhd, Uqcr10, Cyc1, Iscu, Mdh1,
Timm10, Timm9
Tomm70a, Eif2s1, Rpl14, Smarcc1, Eprs, Cox5a, Pa2g4, Eif3d, Eif2s2,
Rsl1d1, Cct5, Eif3b, Abce1, Eif3j1, Rrp9, Eif1a, Xpot, Eif4g2, Pwp1,
Psmd3, Cyc1, Gspt1, Aimp2, Ncbp2, Psmb3, Nop16, Phb, Ctps, Nhp2
Junb, Egr3, Egr2, Mcl1, Pmepa1, Lif, Nr4a1, Ier2, Egr1, Klf10, Slc2a6,
Trib1, Tnc, Gadd45b, Bhlhe40, Hbegf, Btg1, Cdkn1a, Bcl6, Rhob, Spsb1,
Fos, Fosb, B4galt5, Rcan1, Panx1, Hes1
Tfrc, Egln3, Atp2a2, Atp6v1d, Acsl3, Bhlhe40, Eprs, Wars, Cdkn1a,
Hspa4, Eif2s2, Mllt11, Psmc2, Abcf2, Rrp9, Pno1, Atp5g1, Uso1, Shmt2,
Cct6a, Psmd13, Psmd12, Ufm1
Hspd1, Psma1, Ptges3, Hdac2, Psma6, Lsm7, Ube2l3, Ifrd1, Psma4,
Kpnb1, Syncrip, Cct2, Snrpd3

NAME
HALLMARK_INTERFERON_GAMMA_RESPONSE_D2D0DEG_DOWN

HALLMARK_INTERFERON_ALPHA_RESPONSE_D2D0DEG_DOWN

HALLMARK_XENOBIOTIC_METABOLISM_D2D0DEG_DOWN

GENES
Helz2, Parp12, Ube2l6, Pml, Ifih1, Samhd1, Trim21, Psme1, C1ra,
Eif2ak2, Tap1, Pnp, C1rb, Trim26, Nfkbia, Lgals3bp, Parp14, Tapbp,
Ripk2, Stat1, Ddx58, H2-M3, Casp8, Sri, Vcam1, Psme2, Adar, Nfkb1,
Irf9, B2m, Isg20, Socs1, Upp1, H2-Q7, Ncoa3, Cd74
Helz2, Parp12, Ube2l6, Ifih1, Trim21, Psme1, Eif2ak2, Tap1, Uba7,
Trim26, Lgals3bp, Parp14, Mov10, Ripk2, Elf1, Casp8, Psme2, Parp9,
Adar, Irf9, B2m, Isg20, Csf1, Cd47, Cd74
Ptgr1, Aldh9a1, Aldh3a1, Aldh2, Atoh8, Ugdh, Car2, Nqo1, Pdk4, Idh1,
Ets2, Casp6, Il1r1, Bphl, Xdh, Crot, Ddah2, Dcxr, Epha2, Maoa, Upp1,
Dhrs1, Retsat
Vwa5a, Tap1, Tspyl2, Eps8l2, Apaf1, Tm7sf3, S100a10, Ddb2, Ptpn14,
Cebpa, Socs1, Hdac3, Dcxr, Epha2, Upp1, Ada, Retsat

NES

FDR

-6.55

<0.001

-5.40

<0.001

-4.87

<0.001

-4.72

<0.001

-4.56

<0.001

-3.79

<0.001

NES

FDR

5.36

<0.001

5.17

<0.001

4.61

<0.001

4.32

<0.001

4.27

<0.001

HALLMARK_MITOTIC_SPINDLE_D2D0DEG_DOWN

Ccnd1, Pml, Efna5, Tmpo, Wrn, Tra2b, Cdkn1b, Exo1
Cep250, Fscn1, Hdac6, Cd2ap, Net1, Arhgef11, Llgl1, Synpo, Tubgcp2,
Alms1, Farp1, Arl8a

4.16

<0.001

HALLMARK_E2F_TARGETS_D2D0DEG_DOWN

Tmpo, Chek2, Tra2b, Cdkn1b

4.01

<0.001

HALLMARK_P53_PATHWAY_D2D0DEG_DOWN
HALLMARK_G2M_CHECKPOINT_D2D0DEG_DOWN
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The genes that are involved in development of skeletal muscle during myogenesis
and that are significantly upregulated during C2C12 differentiation were enriched in the
list of genes that are downregulated at day2 due to APOBEC2 knockdown. This is in
accordance with the phenotype observed of a delay in differentiation. Furthermore, the
subset of gene targets of E2F transcription that are significantly downregulated during
differentiation are enriched in the list of genes that are upregulated due to APOBEC2
knockdown at day2. A similar inverse pattern is observed with genes important in the
G2/M checkpoint (Figure 3.6a). Therefore APOBEC2 expression correlates with cell
cycle regulation and myogenesis.
Given the strong correlation between the gene sets that we've identified whose
expression was being modulate in the absence of APOBEC2, and the cellular phenotypes
we observed (e.g. inability to properly exit cell cycle in the absence of APOBEC2), we
decided to take a closer look at the genes of the E2F target gene set and the Myogenesis
geneset. Interestingly Myog and p21/cdkn1a, crucial during the induction of myogenesis
and cell cycle withdrawal are both downregulated due to APOBEC2 deficiency and could
account at least partially for the phenotypes observed (Figure 3.6b).
Overall, deficiency in APOBEC2 leads to substantial gene expression changes
upon initiation of differentiation (and even prior) affecting gene networks important in
myogenesis and cell cycle regulation. This result is unique to other cytidine deaminases
knockouts, none of which lead to alterations of gene expression levels (Salter et al.,
2016). The rest of the thesis will be focused on our attempt to determine how these gene
expression changes come about.
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Figure 3.6 Lack of APOBEC2 in C2C12 cells leads to changes in gene networks
a) Gene set enrichment analysis (GSEA) score curves of the RNAseq output. Groups of
genes that normally are upregulated as a set (Myogenesis Gene set) are enriched in the
list of genes downregulated when APOBEC2 is deficient. Groups of genes that normally
are downregulated as a set (E2F target Gene set) are enriched in the list of genes
upregulated when APOBEC2 is deficient. While for the G2M gene set, the subset of
genes that go up is enriched in the list of genes that are downregulated while the subset of
genes that go down with differentiation are enriched in the list of genes that are
upregulated due to APOBEC2 knockdown b) Graph representing the amount of Myog
and Cdkn1a/p21 using the RNAseq data. Transcripts per million (TPM) is a measurement
of the relative proportion of transcripts within the sample. Data represented as mean and
SEM of the 3 biological replicates.
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3.4 Identification of APOBEC2 dependent RNA editing
An RNA editing event is one where the RNA’s sequence is changed, excluding changes
due to processes such as RNA splicing and alternative polyadenylation. The sequence is
altered through deamination, converting an A to an I or a C to a U. A-to-I editing
(catalyzed by the ADAR family of deaminases) has been correlated to loss of RNA
stability leading to apparent gene expression differences (Wang et al., 2013). In contrast,
C-to-U editing (catalyzed by the AID/APOBEC family member APOBEC1) does not
lead to gene expression changes at the level of mRNA but seems important in regulating
genes by modulating translation (Chen et al., 1987; Powell et al., 1987; Rayon-Estrada et
al., 2017; Rosenberg et al., 2011). Since certain proteins which contain cytidine
deaminase motifs mediate A to I rather than C to U RNA editing (Rubio et al., 2007), I
decided to assess if APOBEC2 could function as an RNA editor (on A or C)
The RNA-Seq dataset described in the previous sections also contains information
about the mRNA transcripts at single nucleotide resolution, thus making it optimal for
answering this question in a rigorous manner. I used the same analysis pipeline that has
been previously described (Harjanto et al., 2016) to examine whether there are any
APOBEC2 dependent RNA editing events (either C-to-U or A-to-I) in the C2C12
differentiation model. In brief, we identify putative RNA editing events by searching for
single nucleotide mismatches to the reference genome. The mismatch datasets are then
filtered against several parameters (based on sequencing depth and editing rates). The
analysis is run using different filter parameters ranging from no filters at all to very
stringent filters. The ideal potential RNA editing hits are sites that are present in control
mRNA sequences but absent from deaminase-deficient mRNA sequences. Importantly,
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the inverse comparison is also performed; the number of editing events that were present
in the deaminase-deficient (APOBEC2 knockdown) sample but not in the control sample.
This inverse comparison provides a measurement of the background noise of the
technique (as a result of mismapping or reference genome sequence differences). This
also allows for computation of an inferred false positive rate (IFPR), as number of events
in the deaminase-deficient sample / number of events in the control sample. The number
of the putative RNA editing hits being similar or lower than the number of the inverse
hits suggests the presence of noise and lack of editing.
The RNA editing analysis showed that the number of putative editing sites
detected for A-to-I or C-to-U in any of the time points (control vs. APOBEC2
knockdown comparison), is not significantly different from the sites detected in the
inverse analysis (APOBEC2 knockdown vs. controls comparison). Figure 3.7 shows the
numbers of hits for the minimally filtered analysis. By comparison APOBEC1+/+ versus
APOBEC1-/- analysis shows generally higher number of hits compared to the inverse
analysis (APOBEC1-/- versus APOBEC1+/+) even when stringent filters are applied. If Ato-I or C-to-U editing had a dependence on APOBEC2, we would expect fewer hits
consistently in the inverse analysis. The latter is not what we observe.
Depending on the time point analyzed and the stringency of the filters used for
APOBEC2- dependent C-to-U editing the IFPR rate was between 98-107%, while for Ato-I editing the IFRP rate was between 50% and 200%. On the other side, using the same
analysis pipeline on the APOBEC1 dependent C-to-U editing, the IFRP rate was between
2-4%. This suggests that the few potential editing sites that were picked up in our
analysis are most likely to be background noise.
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Based on these data, we can conclude that in the C2C12 differentiation model
there are no detectable C-to-U or A-to-I RNA editing events dependent on APOBEC2, in
confirmation of a recent publication which demonstrates that muscle is one of the few
tissues with very low levels of A-to-I RNA editing (Tan et al., 2017). Given our analysis,
it is highly unlikely that APOBEC2 is acting as an A-to-I and C-to-U RNA editing
enzyme during C2C12 differentiation.

Figure 3.7 Evaluation APOBEC2’s potential role in RNA editing
Candidate RNA editing sites called from APOBEC2 knockdown samples, control
(GFPsh) at day 0, 1, and 2 in DM in C2C12s and wild-type and APOBEC1-/macrophages. Putative hits (A-to-I and C-to-U) undergo various filtering parameters. For
C2C12s, the minimum filtered sites are shown; for macrophages both minimum and
stringently filtered sites are shown. Hits (H) represent candidate editing sites present in
control (GFPsh) but not in APOBEC2 knockdown dataset, or hits present in the wild-type
but not in the APOBEC1-/- dataset. Inverse hits (IH) represent hits yielded when the
inverse comparison is made, thus edit sites present in the APOBEC2 knockdown dataset
but not in the control (GFPsh) and edit sites that are present in APOBEC1-/- dataset but
not in wild- type. Data are represented as means ± SD using outputs of 3 RNA-Seq
datasets.
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CHAPTER 4. Assessing the involvement of APOBEC2 in methylome changes
As demonstrated in the previous chapter, the transcriptome analyses showed that there
are many APOBEC2 dependent gene expression changes during myogenesis in C2C12s.
Furthermore, I showed that these changes are unlikely to result from RNA editing
activity. I wanted to assess whether loss of APOBEC2 correlated with changes in DNA
methylation.
The DNA mark 5mC has been widely described as an important regulator of
transcription and is very important in mammalian development (Smith and Meissner,
2013). More recently, 5hmC has been discovered as significant in epigenetic regulation
(Branco et al., 2012). Interestingly AID, a member of the AID/APOBEC family of
enzymes has been implicated in multiple studies in gene-specific DNA demethylation
(Ramiro and Barreto, 2015). Previous data in zebrafish (Rai et al., 2008) and in an
embryonic stem cell (ES) -derived myogenic progenitors model (Carrió et al., 2016) had
also connected APOBEC2 with active 5mC demethylation, while overexpression
experiments demonstrated some ability to mediate 5hmC demethylation when expressed
in HEK293 cells (Guo et al., 2011). In contrast, other studies do not support the idea that
APOBEC2 mediates its biological role through active 5mC demethylation during
regeneration in zebrafish (Powell et al., 2013, 2014) or in biochemical studies (Nabel et
al., 2012). However, whether APOBEC2 is capable of directly mediating active DNA
demethylation through cytidine deamination under natural conditions, remained an open
question.
To determine whether the function of APOBEC2 during differentiation could be
mediated through the demethylation of 5mC we wanted to identify changes in the levels
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of modified cytosines in the DNA within C2C12 cells as they develop from myoblasts to
myotubes. This is an ideal system to study a possible role of APOBEC2 in active DNA
demethylation because differentiation requires cell cycle arrest. Thus any potential
APOBEC2-dependent changes in amounts of modified cytosines could be linked to
active DNA demethylation (as opposed to passive changes propagated through cell
division). I therefore proceeded to compare the genome wide cytosine modifications
between control C2C12s to those where APOBEC2 is knocked down at different time
points during the differentiation.

4.1 RRBS analysis pipeline and validations
Methods of methylome analysis (reviewed in (Plongthongkum et al., 2014)) involve
genomic DNA undergoing bisulfite conversion, where cytosines (C) are converted to
thymines (T), but modified cytosines (such as 5hmC and 5mC) are left unchanged. The
bisulfite converted DNA is then sequenced and mapped to a reference genome. The
percent of non-converted cytosines (modified Cs) at a given site is calculated as the ratio
of reads containing Cs over the total number of reads covering the specific site. To
identify genome scale methylation changes we choose to use enhanced Reduced
Representation Bisulfite Sequencing (eRRBS). This method is a modified version of the
original RRBS approach (Gu et al., 2011; Meissner et al., 2005) and leads to an increase
in the detection and coverage of CpG sites (Akalin et al., 2012a; Garrett-Bakelman et al.,
2015). RRBS includes an initial step that enriches for CG-rich genomic fragments by
cutting genomic DNA with the MspI (C^CGG) restriction enzyme, a methylationinsensitive enzyme (thus making it ideal to unbiasedly cut fragments containing modified
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or unmodified Cs) resulting in short fragments that contain CpG dinucleotides at the
ends. This is followed by size selection of the fragments, bisulfite conversion, PCR
amplification and sequencing. eRRBS on the other hand has improved the original RRBS
method by increasing the number of CpGs detected and improving coverage of genomic
regions.
The advantages of RRBS and eRRBS compared to whole genome bisulfite
sequencing (WGBS) is the increase in coverage of the CpG dense regions (such as
promoters and CpG islands), the depth of sequencing required is less, thus making this
choice more cost effective while also providing single-nucleotide resolution of the well
covered areas. The limitation of the method is that the coverage in CpG poor regions is
still low, limiting the analysis and interpretation only to the well-covered regions.
Another limitation of the method, which in our experiment serves to our advantage, is
that RRBS does not discriminate between 5mC and other DNA modifications such as 5hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC).
This would allow us to simultaneously examine cytosine modification changes but
without distinguishing among them.
The RRBS analysis pipeline (Figure 4.1) outlines the steps taken for this analysis.
We used 5 different single cell clones for each group that is being compared (C2C12s
expressing GFPsh as a control and A2sh#4 for knocking down Apobec2) at 3 different
time points after differentiation. eRRBS library preparation and alignments of the reads
were done by the Weill Cornell Medical College Epigenomics Core as previously
described (Garrett-Bakelman et al., 2015). In brief, multiplexed samples underwent
single-end sequencing. Sequencing reads then passed through quality control filters and
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adaptor trimming. These reads were then aligned to a bisulfite converted reference mouse
genome with specialized mapping tools that allow for mapping of bisulfite converted
reads (Krueger and Andrews, 2011). The methylation context for each cytosine was
determined with scripts from the core facility. Then we analyze modification differences
of well-covered CpG sites using published and validated bioconductor packages (Akalin
et al., 2012b; Li et al., 2013). For more details about the methylation analysis pipeline
refer to the Materials and Methods chapter.

Figure 4.1 Schematic representation of the ERRBS analysis pipeline
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As starting material for this analysis, I used C2C12s expanded from individual
single cell clones (which I also validated for knockdown efficiency using Western
blotting (Figure 4.2a). eRRBS resulted in 67-73% mapping efficiency for trimmed reads
and bisulfite conversion rates were ~99% for both forward and reverse strands,
suggesting that this potential source of error is not a factor in the interpretation of the
dataset. The enhanced RRBS (eRRBS) method yielded the expected high coverage for
CpG islands and promoters (Akalin et al., 2012a). On average about ~89% of CpG
islands, ~55% of CpG island shores (+/- 2kb from the CpG island) and ~62% of the
annotated promoters (+/- 2kb from the TSS) have at least one well-covered (>10x) CpG
site (Figure 4.2b). To be included in subsequent analyses it was required that a CpG be
covered at least 10x in at least 3 out of 5 biological replicates which resulted in ~1 M
represented CpGs for the dataset. These values agree with the DNA methylation
standards recommended from ENCODE (Encyclopedia of DNA elements) (ENCODE
and modENCODE, 2011).
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Figure 4.2. RRBS analysis pipeline, validations and coverage
a) C2C12 lysates from single cell clones that were used in the ERBBS sequencing
experiment in DM at day0,1,2,3 were analyzed by Western blotting using anti-Apobec2
antibodies. alpha-tubulin was used as loading control. Only one representative clone is
shown for the control GFPsh samples b) Average percent coverage of different genomic
regions by ERRBS (n = 3, used CpGs covered >10x in at least 3 out of 5 biological
replicates during comparisons between the groups for 3 different timepoints (d0, d1, d2)
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4.2 Analysis of APOBEC2 dependent differences in DNA methylation
To determine whether APOBEC2 has genome wide or gene-specific effects on the
methylome, the distribution and frequency of methylation for each well-covered CpG site
was compared between control C2C12s (expressing GFPsh) and APOBEC2 knockdown
C2C12s (expressing sh#4), at various time points after induction of differentiation.
Additionally, I used the Methylkit (Akalin et al., 2012b) package to determine significant
differentially methylated cytosines (DMCs). Overall for all CpGs that were well covered,
the expected bimodal distribution of methylation was observed and there was no apparent
difference in DNA methylation distributions associated with APOBEC2 expression. The
mean methylation frequency for CpGs was highly similar for each genotype (Figure
4.3a). Here out of the ~1 million well-covered CpG sites only about 1% (~11000) of
CpGs were differentially methylated at any of the time points and such changes mostly
represent hypomethylated CpGs (Figure 4.3b). Annotation of the DMCs based on gene
feature (promoter, 5’UTR, 3’UTR, exon, intron, downstream of the gene, intergenic)
shows that most of these methylation changes happen in intergenic, introns and
promoters. Also most of them do not fall in CpG islands or CpG shores (Figure 4.3c).
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Figure 4.3 APOBEC2 dependent differences in DNA methylation in C2C12s across
CpGs
a) Distribution of DNA methylation frequencies in C2C12s as determined by eRRBS for
individual CpGs. Violin plots represent the distribution of DNA methylation frequencies
for each feature. Median and first and third quartiles are shown with the box plots b)
Number of DMC(s). Significant Hypomethylated DMCs (dark blue), significant
hypermethylated DMCs (red), nonsignificant DMCs (gray) c) Graphs representing
annotations of the DMCs with genomic features or with CpGisland/shores
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To further analyze the biological meaning of the DMCs and detect any genespecific methylation changes I chose two strategies. First, I summarized the methylation
values over a specific region such as a CpG island or a promoter (containing a minimum
of 3 of well-covered CpGs) and determined if there are any region specific significant
methylation changes. The mean methylation frequency for each feature was highly
similar for each genotype (Figure 4.4a). Here, out of ~14 thousand CpG islands included
in the analysis about 3-9, depending on the time point analyzed were differentially
methylated. While out of the ~50 thousand promoters analyzed, about ~5-8 were
differentially methylated. Very few of these promoters show significant gene expression
differences with hypomethylation correlating with a reduction in gene expression,
suggesting that the gene expression changes observed do not correlate with methylation
changes in the corresponding genes (Figure 4.4b).
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Figure 4.4 APOBEC2 dependent differences in DNA methylation across promoters
and CpG islands
a) Distribution of DNA methylation frequencies (weighted means of all replicates) in
C2C12s as determined by eRRBS for individual, CpG islands and promoters. Violin plots
represent the distribution of DNA methylation frequencies for each feature. Median and
first and third quartiles are shown with the box plots. Promoters are defined at -/+ 2Kb
around the TSS in Ensemble annotations. CpG islands were taken from the cpgIslandExt
track of the UCSC table browser b) Graph representing genes with significant
methylation changes in the promoter genes and the corresponding log2 fold change at
day2 post differentiation. Dark red is significantly differentially expressed (p adjusted <
0.1)
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Secondly, I wanted to determine whether these DMCs fall in close proximity to
one another, which would make them potential interesting gene regulatory regions to
follow up on. For that I used eDMR (Li et al., 2013) to empirically determine
differentially methylated regions (DMRs). DMRs are traditionally defined as genomic
regions that have different methylation statuses among multiple samples, contain clusters
of CpGs and are potential functional regions involved in gene transcriptional regulation.
The eDMR method takes into consideration the distribution of the distances between
well-covered CpGs in the dataset across the genome to optimize the definition of an
empirical determined region size. The latter determines the minimum distance adjacent
CpGs can be separated by, in order to define them as being part of the same DMR.
My analysis detected very few significant DMRs, which are mainly
hypomethylated due to APOBEC2 knockdown. When the significant DMRs are
annotated based on gene feature (promoter, 5’UTR, 3’UTR, exon, intron, downstream of
the gene, intergenic), they mainly fall in promoters or intergenic regions depending on
the timepoint analyzed (Figure 4.5a). For the statistically significant hypomethylated
DMRs the average percent hypomethylation is between 20%-23% and the regions
contain on average 4-5 DMCs depending on the time point analyzed. Only 2 of the
DMRs reside in genes that show significant gene expression changes. (Figure 4.5b)
Interestingly DNMT3, a de novo methyltransferase, is downregulated due to APOBEC2
knockdown throughout differentiation suggesting that it could account for the few
hypomethylation events detected (Figure 4.5c).
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Figure 4.5 APOBEC2 dependent differences in DNA methylation across DMRs
a) Number of Differentially Methylated Cytosines was calculated using the eDMR
package. Significant Hypomethylated DMR (dark blue), significant hypermethylated
DMR(red), nonsignificant DMR (gray). A DMR is empirically determined and it requires
at least 1 DMC in the region, as determined using methylKit, at least 3 CpGs included in
the region, and at least an absolute mean methylation difference greater than 20%.)The
significant DMR should have at least 5 CpGs where at least 3 of them are DMCs as
determined by methylKit and there is a minimum 20% methylation change for the region
and q.value < 0.001. Bargraph on the right representing annotations of the DMCs with
genomic features or with CpG island/shores b) Graph representing genes with significant
DMRs in promoter regions that corresponding log2 fold change at day2 post
differentiation. Dark red is significantly differentially expressed (p adjusted < 0.1) c)
Graph representing the amount of Dnmt3a using the RNAseq data. Transcripts per
million (TPM) is a measurement of the proportion of transcripts within the sample. Data
represented as mean and SEM of the 3 biological replicates.
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Given the very few changes I detected, I asked if they were simply due to inherent
variability between biological replicates. Therefore, I estimated the level of signal to
noise ratio as a measure of false positive rate. To do this I utilized the methylation dataset
and made two types of comparison using the same methylation analysis pipeline
mentioned above. (1) I randomly picked biological replicates from only the control
sample and analyzed methylation changes including only 2 biological replicates for each
group being compared (within group comparison) to determine the amount of noise in the
system. (2) I repeated the same analysis using randomly picked samples from both
control and knockdown samples (between groups comparison) including 2 biological
replicates for each group, to determine the amount of signal in the system. The results of
this analysis indicated that the percent of significant DMCs is very similar in both types
of comparisons (Table 4.1) and that the signal to noise ratio is close to 0.98.

Table 4.1 Estimating the false positive rate
Proportion of significant DMCs for multiple group comparisons (between controls with
knockdown) and within group comparisons (between biological replicates within the
same group)

Number of CpGs Number of
differentially
CpGs
Methylated
covered
(Thousand)
(Thousand)
33
1057
38
1082
55
1061
44
1083
43
1068
41
1063
78

% sig
DMCs
3.2%
3.5%
5.1%
4.1%
4.0%
3.8%

Between
groups
Within
groups

4.3 Correlation of APOBEC2-dependent changes in DNA methylation and mRNA
expression
As final analysis, I compared the methylation changes across all the represented
promoters in the eRRBS dataset with the expression changes of the same genes in RNASeq dataset for each of the time points. Each pairwise comparison between the control
and knockdown datasets showed that there is no linear relationship between the variables
(|r| < 0.06 in all cases) (Figure 4.6). This suggested that the observed modest differences
in DNA methylation of the promoters were not directly associated with changes in the
expression of the same genes. It is unlikely that these methylation changes are
biologically relevant.
Overall my analyses suggested that the level of "signal" in my dataset does not
surpass the level of "noise". This conclusion is strengthened by the notion that even
changes that seem to occur on relevant promoters, do not lead to consistent gene
expression differences. Thus if any APOBEC2 dependent methylation changes do exist,
they are likely buried under the inherent noise in the dataset. Alternatively, APOBEC2
dependent methylation changes could exist in regions of the genome not captured by
eRRBS. Nevertheless, my data thus far, together with the fact that any changes I see tend
toward hypomethylation (which is inconsistent with the notion of APOBEC2 functioning
as an active DNA demethylase) lead me to negate the hypothesis that APOBEC2
functions as a CpG demethylase, at least in C2C12 cells.
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Figure 4.6 Comparison of differences in DNA methylation with gene expression
Methylation changes across all the represented promoters in the eRRBS dataset compared
with the expression changes of the same genes in RNA-Seq dataset. Shown here are
datasets from the day 2 timepoint. r = Pearson’s correlation coefficient
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CHAPTER 5. Assessment of the ability of APOBEC2 to associate with and affect
chromatin
APOBEC2 is deemed an orphan deaminase because it showed no catalytic activity (or
even binding) toward single stranded DNA (methylated or not), or RNA. However,
functional data indicated that it is involved in muscle biology. Previous studies
hypothesized it might be involved in DNA demethylation or RNA editing. My data
clearly discount both of these possibilities. However, my data also show that deficiency
of APOBEC2 during myogenesis, substantially affects gene expression, suggesting a
direct effect on gene regulation. Thus, I decided to evaluate the hypothesis that
APOBEC2 might be regulating transcriptional activity of target genes, either directly by
binding to DNA genetic elements or indirectly through interaction with other direct
chromatin regulators. To do this, I attempted to firstly, determine the subcellular
localization of APOBEC2 in differentiating cells and its binding affinity to chromatin.
Secondly, I utilized chromatin immunoprecipitation, followed by high throughput
sequencing (ChIP-Seq) to identify genomic regions that might be preferentially bound by
APOBEC2. In this chapter I will present data from these studies, which bring us closer to
the identification of the mechanism for its transcriptional effects.

5.1 Supporting evidence for APOBEC2’s association with the chromatin
To determine the subcellular localization of APOBEC2 I first searched for the presence
of a putative nuclear localization signal (NLS) on the APOBEC2 protein sequence. I used
cNLS Mapper, a prediction system for nuclear localization signal (Kosugi et al., 2009).
The algorithm predicted the sequence: DPEKLKELIDLPPFEIVTGVRLPVNFFKFQFR
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with a score of 3.7 which indicates a low activity NLS and thus predicts that APOBEC2
will be localized at both the nucleus and the cytoplasm. I followed this up with
immunostaining of APOBEC2, which supported the notion that it is localized at both
nuclei and cytoplasm (Figure 5.1a).
Having shown that at least a fraction of APOBEC2 is nuclear, I wanted to
determine whether APOBEC2 bound chromatin. To do this I utilized sequential salt
extraction of chromatin proteins (Figure 5.1b). Nuclear proteins bind to chromatin with
different affinities and thus require different salt concentrations to be dissociated. At a
low salt concentration, loosely bound proteins will be easily dissociated from chromatin,
whereas tightly bound proteins will not (Porter et al., 2017). The salt-extraction profile of
APOBEC2 from nuclei of differentiated C2C12s indicates its presence in eluates where
high concentration of NaCl (0.75 and 1M) is used to wash the chromatin. As a
comparison H4 histone, which is normally strongly bound to DNA, is shown in the same
western blot to dissociate completely with 0.75M NaCl. (Figure5.1b). This data suggests
a strong association of a portion of nuclear APOBEC2 with chromatin in differentiated
C2C12s.
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Figure 5.1 Cellular localization and chromatin association of APOBEC2
a) Immunostaining of overexpressed Flag-Apobec2, Flag (red), Apobec2 (green) and
DAPI-positive (blue) nuclei in C2C12s cultured for 5 days in DM b) The NaCl-elution
profiles of endogenous Apobec2 and histone H4 are shown. alpha-tubulin is a
cytoplasmic marker. The amount of indicated proteins in eluates was measured by
Western blotting.
5.2 Validation and ChIP-Seq analysis pipeline
To assess whether chromatin-bound APOBEC2, occupies specific regions of the C2C12
genome, I performed a ChIP-Seq (Chromatin Immunoprecipitation Sequencing)
experiment. First, I validated the efficiency of the APOBEC2 antibody by doing an
immunoprecipitation, which shows that the antibodies are effective in depleting the input
(Figure5.2a). As the first step in ChIP-Seq, I stabilized the interactions by cross-linking
DNA and bound proteins with formaldehyde. I sheared the cross-linked chromatin into
small fragments by sonication and then immunoprecipitated the DNA-protein complexes
using APOBEC2 specific antibodies. The goal was to get an enrichment of DNA
fragments that are bound by APOBEC2. Given that shearing of the genomic DNA is not
uniform and downstream sequencing does not produce even coverage of the genomic
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DNA, a portion of the fragmented DNA, not immunoprecipitated by APOBEC2, is kept
to be used for the assessment of the background signal (the input control). I then reversed
the cross-linking to release the DNA fragments from the binding complex. For ChIP-Seq,
I used C1C12s at 2 different time points after inducing differentiation (14 hours and 34
hours post differentiation). I picked those time points because they (1) slightly precede
the RNA-Seq time points, where we observed many changes in gene expression and (2)
represent time points of low and high APOBEC2 protein abundance. The goal was to
maximize the chances of finding APOBEC2 occupancy (for example in case of transient
binding) and assess if the expression levels of APOBEC2 determine where the protein
binds. I used the input control fragments of DNA and APOBEC2-enriched DNA
fragments, to prepare libraries using the library preparation protocol from NEBNext
DNA library prep kit for high throughput sequencing. The latter includes PCR
amplification to increase the amount of starting DNA and multiplexing of the samples to
be able to combine multiple samples for sequencing.
Multiplexed samples underwent single end sequencing. In brief, as shown in the
diagram (Figure 5.2b) the subsequent analysis pipeline involves filtering for reads that do
not pass quality control measures, adaptor trimming and alignments of the reads to a
reference genome. Quality metrics for the ChIP-Seq data were assessed using ChIPQC
bioconductor package (Carroll et al., 2014), according to Encyclopedia of DNA Elements
(ENCODE) working standards and guidelines for ChIP experiments (Landt et al., 2012).

84

Figure 5.2 Validation and Chip-Seq analysis pipeline
a) Validation of Apobec2 antibodies using C2C12s whole cell lysates (at DM day5);
Lysates are immunoprecipitated (IP) with anti-APOBEC2 antibodies. Input (lysate preIP), depleted (lysate post-IP) and immunoprecipitated fractions are shown b) Schematic
of ChipSeq analysis pipeline
The mapping efficiency range was 88-90%, resulting in 18M-52M mapped reads
depending on the sample. The proportion of multimapped reads (reads that can be
assigned to more than one location) was between 14.9%-24.9% of all the mapped reads.
These numbers show high multimapping rates and low reads in peaks (RiP) values (not
shown), which are generally though to reflect low signal to noise ratios (and thus high
background). This suggests one of two things: either that binding observed is at the
background level (i.e. random) or that the binding complex/protein has very few true
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binding sites at the time points analyzed (and thus is highly specific). Moreover, high
multimapping reads could also be representative of true binding events in repeat regions.
Next I looked at the complexity of the libraries by checking duplication rates.
Library complexity is the fraction of DNA fragments that are non-redundant (example
due to PCR amplification). The proportion of duplicated reads (reads that map to the
exact position in the genome as at least one other read) ranges from 2.99% to 4.58% of
all the mapped reads. ChIP-Seq datasets for narrowly binding transcriptions factors are
expected to have regions of very high enrichment, which will include true fragments
originating at the same location. Sequencing of such "duplicated" fragments is expected
and biologically relevant in the regions, where the protein complex binds with high
affinity. On the other hand, when the depth of the sequencing library is high one can
reach a point where the complexity is exhausted and duplication events represent PCRamplified DNA fragments that are sequenced repeatedly rather than true identical
fragments that are biologically relevant. Thus, very high duplication rates sometimes are
indicative of low complexity libraries. The percent of non-redundant reads among unique
mapped reads (not multimapped) in our experiment ranges from 94% to 96%. These rates
are very high (relative to the recommended ENCODE standard of non-redundant
proportion of greater than 80%) and this could suggest high library complexity but also
potential issues with enrichment of potential APOBEC2 bound DNA.
Overall, given the high library complexity (low duplication rates), together with
the low signal to noise (low proportion of RiP observe), future ChIP-Seq experiments
with APOBEC2 could benefit from increasing sequencing depth or optimizing the
immunoprecipitation to increase enrichment of APOBEC2 bound fragments.
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Peaks of protein localization were called using Model-based Analysis of ChIP-

Seq (MACS2) (Feng et al., 2011; Zhang et al., 2008) where the input DNA sample was
used as a control for the background noise. Each experiment was performed in three
biological replicates. According to a previous study when multiple replicates are
generated using ChIP-Seq, selecting the peaks that are the same in the majority of the
biological replicates yields more reliable peaks, than the absolute match with fewer
replicates (Yang et al., 2014). Therefore I defined most reliable and reproducible
consensus peaks of localization, those peaks that were called by the MACS2’s algorithm
in at least 2 out of 3 replicates for each time point analyzed. For the 14-hour time point,
there are 1317, 2445 and 2370 localization peaks in each of the biological replicates with
859 consensus peaks (peaks in common in at least 2 out of 3 replicates). For the 34-hour
time point, there were 2208, 5024 and 1067 localization peaks in each of the biological
replicates with 2016 consensus peaks.
Previous publications have shown the existence of signal artifact blacklist regions:
these are genomic regions that contain high artificial read coverage in ChIP-seq
experiments that are conserved across different cell lines and conditions (The ENCODE
Project Consortium, 2012). These have been shown to influence the quality assessment
metrics (Carroll et al., 2014). We decided to filter blacklisted regions from our ChIP-Seq
localization peaks for downstream analysis of APOBEC2 binding regions. After filtering,
we had 818 consensus peaks from the 14-hour time point and 1980 for the 34-hour time
point. Therefore only a very small proportion of the peaks (2-5%), represent blacklisted
repeat regions.
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For downstream analysis, only those consensus peaks in 2 out of 3 replicates
cleaned for blacklisted regions were used. I used the ChIPSeeker (Yu et al., 2015) and
ChIPpeakAnno (Zhu, 2013; Zhu et al., 2010) bioconductor packages for downstream
annotation and clusterProfiler (Yu et al., 2012) for pathway enrichment analysis. For
more details about the ChIP-Seq analysis pipeline and methods refer to the Materials and
Methods chapter.

5.3 APOBEC2 occupies mostly promoter regions in the genome
First I wanted to determine the overall signal around the binding locations of APOBEC2,
which is called the peak summit (i.e. the location with the highest read coverage in the
peak(Zhang et al., 2008). Here I used the mean location of peak summits across the
different biological replicates. I then generated the mean signal expressed in number of
read counts per million mapped reads (normalized per library size) around all of the
binding sites in any of the time points (union of the peaks at the two different time
points). Overall the signal around the binding sites is higher in the 34-hour time point.
This could be due to an increase in APOBEC2 protein abundance, resulting in increase in
overall binding sites and/or increase in the amount of protein bound leading to an
increase in the proportion of RiP. The input, used as a control, shows no enrichment over
the peak summits (Figure 5.3a,b).
I annotated the peaks of localization (peaks that are present in any of the time
points) based on the nearest genes and the genomic feature they overlap with (such as
promoter, 5’ UTR, 3’ UTR, exon, intron, downstream of the gene and intergenic). For
both time points most of these binding regions, fall within promoter regions, defined as
regions 4kb (-2kb to +2kb) around the TSS. The proportion of APOBEC2 binding
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regions that are in promoters is 93% and 75%, for the 14-hour and 34-hour time point,
respectively. As expected given the enrichment in signal overall there are more binding
regions in the 34-hour time point (Figure 5.3c).

Figure 5.3 Annotation of APOBEC2 occupied regions
a) On the left heatmap of normalized signal 1100bp around peak summits. APOBEC2
binding regions were established by grouping consensus peaks (peaks in the majority of
replicates), filtered for blacklisted regions and called in any of the time points. Average
binding site location was determined from mean location of peak summits across
biological replicates and intensity of signal (shown in the Colorkey) is the mean of the
RPM normalized read counts. Both time points are in biological triplicates b) The mean
normalized APOBEC2 signal (plotted as read counts per million mapped reads) across all
the binding sites shown in a) This plot shows the global differences between the two time
points. Both time points are in biological triplicates c) Genomic annotations of the
APOBEC2 of the consensus binding regions in each of the time points (14hr and 34 hr).
Binding regions are annotated with based on genomic feature. The priority of assignment
to a genomic feature when there is annotation overlap is: Promoter (2kb around the TSS),
5’ UTR, 3’ UTR, Exon, Intron, Downstream (within 3kb downstream of the end of the
gene).
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Given that the majority of the binding sites fall near the TSS of genes I decided to
focus on this subset. My analysis showed that there are about ~1500 genes that are bound
by APOBEC2 near their transcription start sites in any of the time points. Of those, 580
genes are in common between both time points. Finally, APOBEC2 shows increased
signal over the TSS in the 34-hour timepoint (Figure 5.4a,b).

Figure 5.4 Comparison of APOBEC2 occupied genes
a) The mean normalized APOBEC2 signal (plotted as read counts per million mapped
reads) across all annotated genes. This plot shows the global differences in APOBEC2
binding between the two time points in TSS. Both time points are in biological triplicates
b) The venn diagram represents the number of genes that show APOBEC2 occupancy in
their promoters at 14 and 34 hour time points and their overlap.

I then utilized the MSigDB datasets (the Hallmark and Reactome pathways) to
determine the top enriched gene sets among the genes that are bound in any of the time
points. This analysis indicated that APOBEC2 bound genes show a high and significant
enrichment of cell cycle related pathways (E2F targets and Cell cycle) (Figure 5.5), Table
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5.1-5.2. Overall this analysis is suggestive of a direct role of APOBEC2 in affecting gene
expression changes through binding in promoter regions of the genome, specifically in
cell cycle related genes and E2F target genes. Given the observed phenotype of the delay
in cell cycle exit during differentiation due to APOBEC2 deficiency, I found this
intriguing and followed up on these findings.

Figure 5.5 Pathway enrichment analysis of APOBEC2 occupied genes
Genes that were bound by APOBEC2 in their promoters were established by grouping
binding regions called in any of the time points. Pathway enrichment analysis of these
genes using overrepresentation test on both MSigDB Hallmark and MSigDB Reactome
Pathways gene set collections. The enriched genesets are ranked by smallest adjusted p
value and largest overlap size and the top 5 gene sets are shown. The dots in the plot have
sizes proportional to the number of overlapping genes and colored according to the
adjusted p value.
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Table 5.1 Pathway enrichment analysis using APOBEC2 bound genes with MSigDB
Hallmark gene set
Pathway enrichment analysis of genes that are bound by APOBEC2 in their promoters in
any of the time points. Results show overrepresentation test on MSigDB Hallmark gene
set collections with the top 5 gene sets shown. Table of gene sets as shown in Figure 5.5.
Geneset

pvalue

p.adjust

Count

HALLMARK_E2F_TARGETS

3.98E-78

1.99E-76

140

HALLMARK_G2M_CHECKPOINT

6.14E-59

1.53E-57

122

HALLMARK_MITOTIC_SPINDLE

1.55E-13

2.58E-12

67

HALLMARK_MYC_TARGETS_V1

0.00020918 0.0026148

47

HALLMARK_MTORC1_SIGNALING

0.00199915 0.01999154

44

Genes
Mcm3/Prim2/Bard1/Cnot9/Mcm6/Ube2t/Lbr/Spc25/Bub1b/Pcna/Mybl2/Cse1l/Plk4/Exosc8
/Smc4/Cks1b/Dclre1b/Cenpe/H2afz/Depdc1a/Nbn/Mms22l/Melk/Usp1/Cdkn2c/Nasp/Kif2c
/Cdc20/Cdca8/Ak2/Rpa2/Stmn1/Slbp/Tacc3/Dck/Pole/Chek2/Ung/Cit/Ran/Rfc2/Mcm7/Pm
s2/Brca2/Rfc3/Lsm8/Ing3/Nup205/Ezh2/Mad2l1/Pole4/Mthfd2/Cdca3/Ncapd2/Rad51ap1/
Ube2s/Lig1/Ccne1/E2f8/Pold3/Wee1/Plk1/Kif22/Dctpp1/Mki67/Gins4/Hmgb2/Mcm5/Asf1
b/Rnaseh2a/Orc6/Nudt21/Gins3/Ctcf/Mre11a/Spc24/Chek1/H2afx/Zw10/Tipin/Ccnb2/Stag
1/Cdc25a/Mlh1/Asf1a/Cdk1/Tmpo/Nup107/Timeless/Pan2/Pa2g4/Hus1/Xpo1/Hmmr/Rad5
0/Shmt1/Aurkb/Spag5/Srsf1/Nme1/Top2a/Psmc3ip/Brca1/Kif18b/Kpna2/Jpt1/Birc5/Rrm2/
Brms1l/Ubr7/Dek/Cks2/Mxd3/Cdkn3/Dlgap5/Diaph3/Rad1/Rad21/Dscc1/Atad2/Myc/Xrcc6
/Cenpm/Racgap1/Espl1/Cbx5/Mcm4/Ranbp1/Tra2b/Wdr90/Tcf19/Tubb5/Msh2/Lmnb1/Pol
a2/Hells/Smc3/Suv39h1/Kif4/Smc1a
Mcm3/Prim2/Bard1/Dtymk/Mcm6/Rasal2/Exo1/Lbr/Cenpf/Nek2/Map3k20/Meis2/Knl1/Bu
b1/Tpx2/E2f1/Rbl1/Top1/Mybl2/Ube2c/Ccna2/Plk4/Smc4/Cks1b/Notch2/Cenpe/H2afz/Cas
p8ap2/Smc2/Cdkn2c/Stil/Rad54l/Nasp/Kif2c/Cdc20/Sfpq/Rpa2/Stmn1/Srsf10/Dbf4/Cenpa/
Tacc3/Nsd2/Ythdc1/Cdc7/Mtf2/Pole/Kmt5a/Brca2/Ezh2/Mad2l1/Ube2s/Prc1/Numa1/Plk1/
Kif22/Mki67/Tfdp1/Mcm5/Orc6/Ctcf/Gins2/Chek1/Hspa8/H2afx/Kif23/Smad3/Ccnb2/Ttk/S
tag1/Traip/Cdc25a/Kif15/Fbxo5/Cdk1/Tmpo/H2afv/Hus1/Xpo1/Hmmr/G3bp1/Aurkb/Pafah
1b1/Srsf1/Kpnb1/Cdc6/Top2a/Kpna2/Jpt1/Birc5/Mnat1/Hif1a/E2f3/Prpf4b/Cks2/Fancc/Pa
pd7/Cdkn3/Prmt5/Pbk/Rad21/Myc/Nup50/Ccnt1/Troap/Racgap1/Espl1/Tra2b/Polq/Ccnf/C
haf1a/Ndc80/Snrpd1/Ss18/Lmnb1/Pola2/Incenp/Kif20b/Kif11/Suv39h1/Kif4/Smc1a
Clasp1/Rasal2/Kifap3/Cenpf/Nek2/Cntrl/Ckap5/Bub1/Bcl2l11/Tpx2/Ect2/Smc4/Notch2/Sass
6/Cenpe/Cdk5rap2/Kif2c/Kntc1/Brca2/Alms1/Plekhg2/Prc1/Numa1/Plk1/Kif22/Katnb1/Anl
n/Kif23/Pif1/Myo1e/Ccnb2/Ttk/Kif15/Fbxo5/Wasf1/Cdk1/Fgd6/Ccdc88a/Rapgef6/Cntrob/P
afah1b1/Top2a/Sept9/Birc5/Dock4/Arf6/Net1/Nedd9/Cep72/Dlgap5/Cenpj/Myh9/Racgap1
/Espl1/Dlg1/Tiam1/Itsn1/Ezr/Ndc80/Lmnb1/Sac3d1/Incenp/Kif20b/Kif11/Smc3/Kif4/Smc1a
Hspe1/Ddx18/Mcm6/Pcna/Ccna2/H2afz/Pole3/Usp1/Cdc20/Ran/Mcm7/Ssbp1/Hnrnpa2b1/
Mad2l1/Serbp1/Psmc4/Rrm1/Psma1/Tfdp1/Mcm5/Xpot/Ptges3/Pa2g4/Ppia/Xpo1/Canx/G
3bp1/Eif4a1/Srsf1/Nme1/Kpnb1/Psmb3/Psmd3/Kpna2/Dek/Pabpc1/Myc/Xrcc6/Mcm4/Ran
bp1/Tra2b/Rfc4/Tcp1/Glo1/Lsm2/Snrpd1/Prdx3
Tcea1/Hspe1/Actr3/Cxcr4/Uchl5/Arpc5l/Bub1/Ube2d3/Pgm2/Pik3r3/Nfyc/Abcf2/Insig1/Pit
pnb/Ung/Nup205/Mthfd2/Slc6a6/Edem1/Tomm40/Psmc4/Sytl2/Plk1/Calr/Hmbs/Cdc25a/T
xnrd1/Hsp90b1/Ppia/Ccng1/Canx/Tmem97/Acaca/Atp5g1/Nmt1/Fdxr/Rrm2/Egln3/Mcm4/
Ccnf/Hspa9/Fads2/Fads1/Psat1
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Table 5.2 Pathway enrichment analysis using APOBEC2 bound genes with MSigDB
Reactome Pathways
Pathway enrichment analysis of genes that are bound by APOBEC2 in their promoters in
any of the time points. Results show overrepresentation test on MSigDB Reactome
Pathways gene set collections with the top 5 gene sets shown. Table of gene sets as
shown in Figure 5.5.
Geneset

pvalue

p.adjust

Count

REACTOME_CELL_CYCLE

3.83E-63

2.09E-60

174

REACTOME_CELL_CYCLE_MITOTIC

2.88E-56

7.87E-54

144

REACTOME_DNA_REPLICATION

6.79E-47

1.24E-44

102

REACTOME_MITOTIC_M_M_G1_PHASES

8.85E-41

1.21E-38

90

REACTOME_MITOTIC_PROMETAPHASE

3.06E-38

3.34E-36

61

Genes
Mcm3/Prim2/Sgo2a/Hjurp/Clasp1/Mcm6/Cenpl/Nuf2/Ahctf1/Lin9/Nsl1/Nek2/Mcm10/Tub
b4b/Cntrl/Spc25/Ckap5/Kif18a/Bub1b/Knl1/Oip5/Bub1/Pcna/Mcm8/E2f1/Dsn1/Rbl1/Mybl
2/Ube2c/Dido1/E2f5/Ccna2/Plk4/Pmf1/Cks1b/H2afz/Cdk5rap2/Itgb3bp/Orc1/Cdkn2c/Kif2c
/Cdc20/Cdca8/Rpa2/Nudc/Rcc2/Cenps/Dbf4/Cenpa/Cep135/Lin54/Cdc7/Pole/Chek2/Rfc5/
Anapc5/Kntc1/Rfc2/Mcm7/Mad1l1/Rfc3/Pot1a/Mad2l1/Alms1/Lig1/Psmc4/Ccne1/Pold3/N
uma1/Wee1/Psma1/Plk1/Tfdp1/Gins4/Cenpu/Mcm5/Orc6/Rbl2/Cenpt/Cenpn/Gins2/Cdt1/
Nup133/Cdkn2d/Spc24/Chek1/H2afx/Zw10/Ppp2r1b/Kif23/Zwilch/Ccnb2/Atr/Stag1/Cdc25
a/Syne1/Fbxo5/Nup43/Cdk1/Zwint/Nup37/Nedd1/Mdm2/Nup107/Hus1/Xpo1/Spdl1/Aurk
b/Wrap53/Mis12/Pafah1b1/Ska2/Psmb3/Psmd3/Cdc6/Brca1/Nup85/Birc5/Anapc11/Rrm2/
Mis18bp1/Pole2/Mnat1/Syne2/Hsp90aa1/Hist1h2ai/Hist1h2bm/Hist1h4k/Hist1h2bn/Hist1
h4i/Hist1h2ag/Hist1h4f/Hist1h2be/Hist1h2bc/Hist1h4a/Gmnn/E2f3/Cenpp/Cep72/Cenph/C
cnb1/Tinf2/Cenpj/Rb1/Skp2/Rad1/Rad21/Myc/Rangap1/Cenpm/Tuba1a/Mcm4/Rfc4/Mis1
8a/Dyrk1a/Pkmyt1/Tubb5/Cenpq/Sgo1/Ndc80/Kif20a/Cdc23/Cdc25c/Lmnb1/Cep76/Ska1/P
ola2/Incenp/Fen1/Smc3/Pola1/Ercc6l/Cenpi/Smc1a
Mcm3/Prim2/Sgo2a/Clasp1/Mcm6/Cenpl/Nuf2/Ahctf1/Lin9/Nsl1/Nek2/Mcm10/Tubb4b/Cn
trl/Spc25/Ckap5/Kif18a/Bub1b/Knl1/Bub1/Pcna/Mcm8/E2f1/Dsn1/Rbl1/Mybl2/Ube2c/E2f5
/Ccna2/Plk4/Pmf1/Cks1b/Cdk5rap2/Itgb3bp/Orc1/Cdkn2c/Kif2c/Cdc20/Cdca8/Rpa2/Nudc/
Rcc2/Cenps/Dbf4/Cenpa/Cep135/Lin54/Cdc7/Pole/Rfc5/Anapc5/Kntc1/Rfc2/Mcm7/Mad1l
1/Rfc3/Mad2l1/Alms1/Lig1/Psmc4/Ccne1/Pold3/Numa1/Wee1/Psma1/Plk1/Tfdp1/Gins4/C
enpu/Mcm5/Orc6/Rbl2/Cenpt/Cenpn/Gins2/Cdt1/Nup133/Cdkn2d/Spc24/Zw10/Ppp2r1b/
Kif23/Zwilch/Ccnb2/Stag1/Cdc25a/Fbxo5/Nup43/Cdk1/Zwint/Nup37/Nedd1/Nup107/Xpo1
/Spdl1/Aurkb/Mis12/Pafah1b1/Ska2/Psmb3/Psmd3/Cdc6/Nup85/Birc5/Anapc11/Rrm2/Pol
e2/Mnat1/Hsp90aa1/Gmnn/E2f3/Cenpp/Cep72/Cenph/Ccnb1/Cenpj/Rb1/Skp2/Rad21/Myc
/Rangap1/Cenpm/Tuba1a/Mcm4/Rfc4/Dyrk1a/Pkmyt1/Tubb5/Cenpq/Sgo1/Ndc80/Kif20a/
Cdc23/Cdc25c/Cep76/Ska1/Pola2/Incenp/Fen1/Smc3/Pola1/Ercc6l/Cenpi/Smc1a
Mcm3/Prim2/Sgo2a/Clasp1/Mcm6/Cenpl/Nuf2/Ahctf1/Nsl1/Mcm10/Spc25/Ckap5/Kif18a/
Bub1b/Knl1/Bub1/Pcna/Mcm8/E2f1/Dsn1/Ccna2/Pmf1/Itgb3bp/Orc1/Kif2c/Cdc20/Cdca8/R
pa2/Nudc/Rcc2/Cenps/Dbf4/Cenpa/Cdc7/Pole/Rfc5/Kntc1/Rfc2/Mcm7/Mad1l1/Rfc3/Mad2
l1/Lig1/Psmc4/Pold3/Psma1/Plk1/Gins4/Cenpu/Mcm5/Orc6/Cenpt/Cenpn/Gins2/Cdt1/Nup
133/Spc24/Zw10/Ppp2r1b/Kif23/Zwilch/Stag1/Fbxo5/Nup43/Zwint/Nup37/Nup107/Xpo1/S
pdl1/Aurkb/Mis12/Pafah1b1/Ska2/Psmb3/Psmd3/Cdc6/Nup85/Birc5/Pole2/Gmnn/E2f3/Ce
npp/Cenph/Rb1/Rad21/Rangap1/Cenpm/Mcm4/Rfc4/Cenpq/Sgo1/Ndc80/Kif20a/Ska1/Pol
a2/Incenp/Fen1/Smc3/Pola1/Ercc6l/Cenpi/Smc1a
Mcm3/Prim2/Sgo2a/Clasp1/Mcm6/Cenpl/Nuf2/Ahctf1/Nsl1/Mcm10/Spc25/Ckap5/Kif18a/
Bub1b/Knl1/Bub1/Mcm8/E2f1/Dsn1/Pmf1/Itgb3bp/Orc1/Kif2c/Cdc20/Cdca8/Rpa2/Nudc/R
cc2/Cenps/Dbf4/Cenpa/Cdc7/Pole/Kntc1/Mcm7/Mad1l1/Mad2l1/Psmc4/Psma1/Plk1/Cenp
u/Mcm5/Orc6/Cenpt/Cenpn/Cdt1/Nup133/Spc24/Zw10/Ppp2r1b/Kif23/Zwilch/Stag1/Fbxo
5/Nup43/Zwint/Nup37/Nup107/Xpo1/Spdl1/Aurkb/Mis12/Pafah1b1/Ska2/Psmb3/Psmd3/C
dc6/Nup85/Birc5/Pole2/Gmnn/E2f3/Cenpp/Cenph/Rad21/Rangap1/Cenpm/Mcm4/Cenpq/
Sgo1/Ndc80/Kif20a/Ska1/Pola2/Incenp/Smc3/Pola1/Ercc6l/Cenpi/Smc1a
Sgo2a/Clasp1/Cenpl/Nuf2/Ahctf1/Nsl1/Spc25/Ckap5/Kif18a/Bub1b/Knl1/Bub1/Dsn1/Pmf1/
Itgb3bp/Kif2c/Cdc20/Cdca8/Nudc/Rcc2/Cenps/Cenpa/Kntc1/Mad1l1/Mad2l1/Plk1/Cenpu/
Cenpt/Cenpn/Nup133/Spc24/Zw10/Ppp2r1b/Zwilch/Stag1/Nup43/Zwint/Nup37/Nup107/X
po1/Spdl1/Aurkb/Mis12/Pafah1b1/Ska2/Nup85/Birc5/Cenpp/Cenph/Rad21/Rangap1/Cenp
m/Cenpq/Sgo1/Ndc80/Ska1/Incenp/Smc3/Ercc6l/Cenpi/Smc1a
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5.4 Comparing the APOBEC2 occupied regions in DNA with expression changes
As I demonstrated above, APOBEC2 mostly binds to promoters of genes. Next, I wanted
to know whether APOBEC2 occupancy correlates with gene expression changes. I did
this by comparing APOBEC2 occupancy at 14-hour (or 34-hour) with gene expression
changes at 24-hour (or 48-hour), on the premise that occupancy will not result in
immediate gene expression changes (e.g. at 14-hour or 34-hour), but rather changes later
in time (though the precise time point of maximal gene expression changes that would
correlate with occupancy remains undetermined).
Within these constraints, I assessed the average APOBEC2 binding in genes that
show increase or decrease in expression through differentiation. I determined the average
profile of APOBEC2 signal (expressed as read counts per million mapped reads) on
binding regions that map in all promoters (up to 4kb around TSS), the ones that map in
promoters of genes that are upregulated through differentiation and the ones that map in
promoters of genes that are downregulated through differentiation. The results show that
APOBEC2 is bound to both genes that are upregulated and downregulated through
differentiation. Interestingly genes that are downregulated through differentiation show
higher APOBEC2 binding signal (Figure 5.6a). This result implies that APOBEC2 might
be primarily involved in inhibiting transcription and consequently increasing
concentrations of APOBEC2 would be needed to optimally inhibit transcription (this
could explain why there is lower binding in genes that still continue to show increase in
expression through differentiation). Alternatively, it is possible that APOBEC2 could
have different effects on gene transcription depending on other protein binding factors/
regulatory elements, with specific interactions leading to higher binding signal and gene
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inhibition and others with low abundance leading to gene activation. Also the APOBEC2
binding is higher in promoters of genes that are upregulated when the protein is knocked
down, suggesting that normally during differentiation the binding of APOBEC2 is
important for their inhibition (Figure 5.6a). Overall this analysis is suggestive of a role of
higher APOBEC2 binding signal in promoters leading to inhibition of gene activation.
The analysis above showed the average APOBEC2 binding profile in promoters
of occupied genes and how higher binding correlates with gene expression inhibition
through differentiation and activation when the protein is absent. I was interested in
further analyzing the APOBEC2 bound genes in relationship to the whole list of genes
that are expressed in C2C12s. I decided to determine if the APOBEC2 occupied genes
are randomly distributed in a list of genes that are ranked by expression changes (through
differentiation or through APOBEC2 deficiency) or if they are preferentially enriched at
the top or at the bottom of such ranked list. For this I performed a GSEA analysis. I
created an APOBEC2 occupied gene set, using genes that show consistent APOBEC2
occupancy at both 14-hour and 34-hour time points. My analysis showed that the
APOBEC2 occupied gene set is significantly enriched in the list of genes that are
inhibited through differentiation. Moreover, this trend is reversed when I looked at the
enrichment of the APOBEC2 occupied gene set in the ranked list of genes that are
differentially expressed due to APOBEC2 deficiency, with the gene set showing
enrichment in the list of genes that are upregulated (Figure 5.6b). This result reinforces
the hypothesis that APOBEC2 binding in promoters correlates with gene expression
inhibition. Overall our ChIP-Seq analysis indicates that APOBEC2 has a direct role in
gene inhibition.
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Figure 5.6 Correlation of APOBEC2 occupancy in promoters with subtle but
coordinated gene expression changes
a) The mean normalized APOBEC2 signal (plotted as read counts per million mapped
reads) across all binding regions at 34-hour, that fall in gene promoters. All of the peaks
(green) were split between the ones that fall in genes that are upregulated (log2 fold
change >0, purple), downregulated (log2 fold change<0, brown) through C2C12
differentiation (left) or due to APOBEC2 knockdown at day2 (right). Plot shows the
global differences in APOBEC2 binding in promoters of genes grouped by gene
expression differences. All conditions are in biological triplicates b) The genes that show
consistent APOBEC2 occupancy in their promoters at both time points were used to
create an APO2_OCCUPIED gene set as shown in the venn diagram. We used GSEA to
test the enrichment of the APO2_OCCUPIED gene set in the list of genes that are
differentially expressed through differentiation (left) or the ones that are differentially
expressed due to APOBEC2 knockdown at day2 (right). GSEA score curves of the gene
expression changes through differentiation from day0 to day2 (left) and due to
APOBEC2 knockdown at day2 (right). NES and FDR values are shown. The enrichment
profile over the whole ranked gene set is shown in green. Overlaps (hits) are shown in
black lines. A positive ES indicates gene set enrichment at the top of the ranked list; a
negative ES indicates gene set enrichment at the bottom of the ranked list.
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Previously I showed that the cell cycle related pathways are significantly enriched
in the list of APOBEC2 bound genes. Similarly to the analysis above, I decided to
determine the trends of gene expression changes and APOBEC2 overall occupancy in
these specific group of genes. I extracted the genes from the MSigDB Reactome cell cycle
(Croft et al., 2014; Fabregat et al., 2018; Liberzon et al., 2011) gene set and mapped the
average APOBEC2 binding on the promoters of these genes. As predicted, overall the
cell cycle genes that are downregulated through differentiation show higher APOBEC2
binding signal. Additionally, the average APOBEC2 binding is higher in cell cycle genes
that show increase in expression due to APOBEC2 deficiency (Figure 5.7a).
The GSEA analysis shows significant enrichment of the APOBEC2 occupied
geneset in the list of cell cycle genes that are downregulated during differentiation and in
the list of cell cycle genes that are upregulated due to APOBEC2 knockdown. Overall
this analysis indicates that APOBEC2 has an active role in the inhibition of cell cycle
genes during differentiation and it suggests that in its absence, these genes are not
downregulated properly, which could directly lead to the phenotype observed. (Figure
5.7b). Taking a closer look at the cell cycle genes that are upregulated in the absence of
APOBEC2 we detect (among many others) Rbl1, a pocket protein whose inactivation
facilitates G1/S transition; Cdc6 and Cdc7, which are important in G1/S transition and
initiation of DNA replication; Mcm3/4/6/5, important in DNA replication; Ckd1, Cdc25c,
important for the onset of mitosis; Ccnb1/Ccnb2 important in G2/M transition; Bub1b
and Mad2l1, important in mitotic checkpoint that ensure proper chromosome segregation
(Figure 5.7c). This suggests that normally APOBEC2 binds to and leads to inhibition of a
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diverse number of genes in multiple steps of the cell cycle. My data support the idea that
APOBEC2 is important in the inhibition of genes across all stages of cell cycle.
Collectively my experiments and analysis so far suggest a role of APOBEC2 in
gene expression inhibition during myoblast (C2C12) differentiation.
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Figure 5.7 Correlation of APOBEC2 occupancy in promoters with subtle but
coordinated gene expression changes in cell cycle pathway
a) The mean normalized APOBEC2 signal (as read counts per million mapped reads)
across all binding regions at 34 hours, located in promoters of the cell cycle related genes
as defined from the MSigDB Reactome Pathways gene set collection. All of the peaks
(green) were split between the ones that fall in genes that are upregulated (log2 fold
change >0, purple), downregulated (log2 fold change<0, brown) through C2C12
differentiation (upper graph) or due to due to APOBEC2 knockdown (lower graph). Plot
shows the global differences in APOBEC2 binding between the different gene lists. All
conditions are in biological triplicates b) The genes with consistent APOBEC2
occupancy in their promoters at both time points were used to create an APOBEC2
occupied geneset. We used GSEA to test the enrichment of APOBEC2 occupied geneset
in the list of the expressed genes of the MSigDB Reactome Cell Cycle gene set that are
differentially expressed through differentiation (left) or the ones that are differentially
expressed due to APOBEC2 knockdown at day2 (right). GSEA score curves of the gene
expression changes through differentiation from day0 to day2 (left) and due to
APOBEC2 knockdown at day2 (right). NES and FDR are shown. The enrichment profile
over the whole ranked gene set is shown in green. Overlaps (hits) are shown in black
lines. A positive ES indicates gene set enrichment at the top of the ranked list; a negative
ES indicates gene set enrichment at the bottom of the ranked list c) The bar plot shows
gene expression changes (by log2 fold changes) due to APOBEC2 knockdown at day 2 of
differentiation for all of the expressed genes of the MSigDB Reactome Cell Cycle gene
set (in gray). Genes that are bound in their promoters at 34hr after inducing
differentiation and that are upregulated (red) or downregulated (blue) in the absence of
APOBEC2.
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5.5 Bioinformatics analysis of APOBEC2’s consensus DNA binding motif
When I started my PhD very little was known about the enzymatic activity of APOBEC2
and its targets. APOBEC2’s binding activity, deaminase substrate, sequence specificity
and the physiological genetic element(s) it binds to were not known (and remain so in the
literature, to date). Over the course of my project, I have identified that APOBEC2 binds
to DNA and also established a list of genes that are highly likely to be substrates of
APOBEC2 (either direct or indirect through binding with other chromatin factors). This
opens up a new avenue for us to explore any potential APOBEC2 sequence specificity. I
next determined the presence of any sequence patterns (or motifs) in the APOBEC2
binding regions. The goal of doing this is to find the most enriched motifs that could be
best representing the potential enzymatic substrate of APOBEC2. This is important for
future work in the field in determining the mechanism of how APOBEC2’s binding to
these genomic regions could lead to gene expression changes.
I used MEME-ChIP (Bailey et al., 2009; Machanick and Bailey, 2011) to predict
de novo DNA binding motifs on the binding sites of the 14-hour and 34-hour time point.
The two of the most significant binding motifs are Motif 14: GCGSSVRDTTYRAAH
(identified by MEME scanning the binding regions at the 14-hour time point and Motif
34: YRGCCAATSRGMR (identified by MEME scanning the binding regions at the 34hour time point). Furthermore I used FIMO (Grant et al., 2011) to scan the APOBEC2
binding regions for the presence of the identified motifs. I determined that Motif 14 is
present in ~38 and 13% of the binding sites, for the 14-hour and 34-hour time point
respectively. While Motif 34 is present in 25% and 24% of the binding sites for the 14hour and 34-hour time point respectively (Figure 5.8a).
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Both of the motifs are distributed within 1kb of the TSS for both time points
(Figure 5.8b). Overall, about 79% of the genes that are bound by APOBEC2 in the 14hour time point continue to remain bound at the 34-hour time point. This is also evident
in the overlap in the occurrence of the motifs discovered from binding locations. Motif 14
that is enriched in the 14-time point binding regions is also present in the 34-hour time
point but at a lower overall percentage. Motif 34 that is enriched in the 34-hour time point
is found in both the 14-hour and 34-hour time point.
The data overall is suggestive of persistent APOBEC2 binding in at least a portion
of the occupied genes. This is an interesting result suggesting that APOBEC2 could be a
static inhibitor of transcription through differentiation.

Figure 5.8 Predictions and validations of APOBEC2’s consensus DNA binding motif
Top motifs –sequence patterns, that are the most enriched in APOBEC2 consensus peaks
(peaks from the majority of biological repeats) were identified using MEME-chip. Evalue represents the statistical significance of the de novo motif identification. Table
shows percent of motifs found in genes with peaks in their promoters using FIMO.
The bargraph shows the distribution of the motif location relative to the TSS for both
timepoints for each motif
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CHAPTER 6. Discussion
When this thesis project was starting many questions existed about APOBEC2. First,
there was no evidence as to whether or not APOBEC2 at physiological levels can act as
an RNA editor or as a DNA demethylator as has been previously hypothesized. Secondly,
neither the substrate of APOBEC2 (presumably nucleic acid) nor the physiological target
(in RNA or DNA) was known. Consequently, neither APOBEC2’s potential enzymatic
activity nor its mechanism of action was known. Through my thesis work, I was able to
tackle both of these questions. This work was mainly possible because of the advent of
high throughput sequencing technologies, impacting the process of searching for gene
targets in an exhaustive manner through transcriptome and genome wide analysis. The
results, which were presented during the previous chapters, will be discussed in more
depth here.

6.1 APOBEC2’s importance in muscle biology

6.1.1 Results using immortalized satellite cells
My experiments provide some genetic evidence that APOBEC2 is important in muscle
biology in a cell culture model and also in an animal model. Working with myoblasts
(C2C12s), I demonstrated that APOBEC2 is an important factor for timely progression to
cell cycle exit and proper muscle differentiation. Working with the APOBEC2-/- mouse
model I showed that even though there are no apparent changes in the rate of myogenesis
during de novo muscle formation, steady state muscle is qualitatively and quantitatively
different. APOBEC2-/- animals have more muscle fibers that are smaller in size, show a
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reduction in muscle strength and have muscle with mispositioned nuclei much earlier in
life than previously described (Sato et al., 2010). These results collectively link
APOBEC2 to postnatal muscle maturation and maintenance.
During the course of this work other research groups have provided additional
evidence that corroborate some of my findings. Carrió et al utilized embryonic stem cells
that can be transformed to take a muscle-specific cell fate through inducible
overexpression of Pax7 (iPax7 ES). In these cells, upon transformation with Pax7 and
induction of differentiation, the levels of APOBEC2 expression increase - similarly to my
findings using the C2C12 model. Conversely when APOBEC2 is knocked down in the
iPax7 ES cells, this dramatically impairs the expression of differentiation markers such as
Myog and, ultimately, muscle differentiation (Carrió et al., 2016). A similar result was
published by Vonica et al induced APOBEC2 knockdown (in C2C12s) using siRNAs and
also observed repression of Myog expression (Vonica et al., 2011). In contrast to these
studies, Ohtsubo et al. used knockdown experiments in primary myoblast cells but did
not observe the same delay in differentiation phenotype (Ohtsubo et al., 2017a). A
significant factor that could account for such differences in the cell culture systems is the
timing of differentiation induction through shift in low serum. In my experiments, as well
as those by Carrió et al. (where the same siRNA sequences were used for APOBEC2
knockdown as in my studies) and Vonica et al., APOBEC2 is knocked down at the
myoblast stage prior to the induction of differentiation. Therefore there is little
APOBEC2 either before or after the differentiation stimulus. This clearly results in an
inhibition in expression of Myog ((Carrió et al., 2016; Vonica et al., 2011) and this
thesis) supporting the notion that APOBEC2 is important for proper expression of Myog
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during myoblast differentiation. Conversely, in Ohtsuboa et al. initiation of the
APOBEC2 knock down is concurrent with the induction of differentiation (reducing
protein abundance probably within the first day of induction, a time at which cells are
exiting cell cycle) (Ohtsubo et al., 2017a). Surprisingly this resulted in the opposite
phenotype: upregulation of Myog and other differentiation markers and no delay in
differentiation. At face value, this discrepancy might simply suggest that APOBEC2 is
required earlier during myogenesis for proper cell cycle exit (something that will be
discussed more extensively below).

6.1.2 Results using the APOBEC2-/- mouse model
In contrast to these discrepancies in cell line derived data, my results of a role of
APOBEC2 in fiber size but absence of a delay in de novo myogenesis phenotype in
APOBEC2-/- are completely congruent with Ohtsubo et al. The latter study additionally
shows an increase in the number of smaller primary myotubes formed in APOBEC2-/mice during the early stages of regeneration and also during the initial days of
differentiation of APOBEC2-/- myoblasts in cell culture (Ohtsubo et al., 2017a).
During de novo myogenesis activated satellite cells (or proliferating myoblasts)
have a choice: either exit cell cycle and differentiate or exit cell cycle and return to
quiescence. Given this dual potential of the cells here and my results linking APOBEC2
to cell cycle regulation during C2C12 differentiation it would be interesting to look for
any APOBEC2 dependent changes in cell cycle regulation in the earlier stages of
regeneration in the mouse model. Indeed a recent report used single-myofiber cultures
from the APOBEC2-/- mice and demonstrated a reduction in the pool of quiescent satellite
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cells, suggesting that APOBEC2 could be regulating the withdrawal of activated cells
from cell cycle and their return to quiescence (G0) (Ohtsubo et al., 2017b). This also
agrees with the phenotype of increased fiber number that both Ohtsubo et al. and I
observe, potentially due to less cells returning to quiescence thus tipping the balance
towards more proliferating myoblasts and more fibers formed. It would also be
interesting to determine if the defects in cell cycle potentially resulting in hyper
proliferation could lead to satellite cell exhaustion in aging mice or following repeated
cycles of muscle degeneration- regeneration. This could explain the development of
myopathy and atrophy in the mice lacking APOBEC2 (Sato et al., 2017).

6.1.3 Overall role of APOBEC2 in muscle development and maintenance
At the organismal level, it is clear that APOBEC2 is important in muscle health.
APOBEC2-/- lose muscle strength as shown through the inverted grip test (Figure 2.4f)
and APOBEC2-/- mice display impaired exercise capacity and mitochondrial defects that
increase muscle mitophagy, ultimately leading to myopathy and muscle atrophy (Sato et
al., 2017).
At the cellular level, APOBEC2-/- mice have mispositioned nuclei in muscle cells,
which is considered a pathological marker of muscle disorders and their presence has
been associated with ongoing muscle repair. Nevertheless it remains to be determined if
this is the consequence or the cause of myopathy (Folker and Baylies, 2013). Recent
research has shown that muscle contraction is necessary and sufficient for peripheral
nuclear movement (Roman et al., 2017; Rosen and Baylies, 2017). It would be
informative to determine if APOBEC2 depletion is associated with defects in muscle
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contraction. Regardless, a likely hypothesis to explain mispositioned nuclei, based on my
data, would be satellite cell dysfunction: specifically, C2C12 (satellite) cells have a defect
in cell cycle exit, and if I extrapolate from that to the mouse, I can imagine a scenario
where lack of cell cycle exit correlates with a reduction in self renewal (a reduction of
cells that return to quiescence). This would then result in more proliferating cells that are
constantly fusing with the myotubes - resulting in the phenotype of haphazardly
nucleated fibers, observed in the mice.
Also at the cellular level, APOBEC2-/- animals are thought to have a higher
proportion of slow muscle fibers (as opposed to fast) suggesting that normally the protein
is important in muscle remodeling - allowing the muscle to adapt to specific conditions. It
might be interesting to check whether during de novo myogenesis there are any defects in
the proportion of fiber types (slow vs. fast), which would suggest that APOBEC2 might
be influencing cell fate (i.e. the differentiation towards a specific muscle fiber type).
The cellular and organismal data generated thus far speak to a role for APOBEC2
in muscle maintenance. It is possible that APOBEC2 is really not involved in the
development of muscle tissue. Conversely, it is also possible that the lack of a phenotype
in APOBEC2-/- during development is due to redundancy with another factor. For
example Myf5 and MyoD can functionally substitute for one another during myogenesis
and inhibition in muscle development is observed only when both genes are null
(Rudnicki et al., 1993). It would be interesting to look for upregulation of any of the
MRFs or AID/APOBECs during development in the APOBEC2-/- mice and also follow
this up with mouse genetics studies where multiple MRFs (or other AID/APOBEC) and
APOBEC2 are deleted. Interestingly in the C2C12 differentiation model, when
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APOBEC2 is knocked down, APOBEC3 (which is normally downregulated through
differentiation) is significantly upregulated (log2 fold change 1.03, adjusted p value 6.7e05). It is unclear whether APOBEC3 is compensating for the lack of APOBEC2 or if its
expression levels are influenced by the upregulation of the interferon response due to
APOBEC2 knockdown (Table 3.2). If inhibition of both APOBEC2 and APOBEC3
could lead to a more drastic phenotype then it could be supportive evidence for this
possibility.
In conclusion I would like to emphasize that the collective work presented here
and previous published work suggest that APOBEC2 is likely fulfilling multiple roles in
muscle at different stages of muscle development, for example in cell cycle regulation
during myogenesis (or possibly satellite cell renewal) or in muscle remodeling or growth
in fully formed muscle.

6.2 APOBEC2 does not fit in the traditional mold of AID/APOBEC family
AID/APOBEC family members (as discussed in the introduction chapter) have been
shown to be perform diverse biological roles through various mechanisms: RNA editing,
DNA editing and modifying DNA 5mC levels. My analysis using next generation
sequencing methods addressed some of these potential roles for APOBEC2.
A direct conclusion from my data is that APOBEC2 is not acting as an RNA
editor (in either C-to-U or A-to-I). In both proliferating myoblasts and differentiating
myotubes no such activity could be observed. Moreover previous work in the lab looking
at potential RNA editing in mature muscle tissue using APOBEC2-/- (Fritz, 2014)
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supports the same conclusion: no changes in RNA editing are observed, while using
pipelines fitted to detect RNA editing.
Furthermore, the methylation studies presented here rule out the possibility that
APOBEC2 acts as a DNA demethylase in myoblasts (C2C12s) since only sporadic
hypermethylated events (which do not correlate with expression changes in the
corresponding genes) were detected at any of the timepoints after differentiation when
APOBEC2 is absent. However, the caveat remains that the C2C12 model might not be
representative of what happens in vivo in mouse. I cannot completely rule out the
possibility that APOBEC2 could mediate some methylation changes during muscle
development. For example previous work on AID shows no affects in DNA methylation
in an ex vivo stimulated B cell model (Fritz et al., 2013) but another study showed that
AID is essential for demethylation and diversification of methylome in germinal center B
cells (GCBs) in vivo (Dominguez et al., 2015). As well, for my work I had to pick
timepoints - which I did based on expression levels of APOBEC2 (I hypothesized that
high expression levels would most optimally correlate with function). However I may
have missed timepoints where methylation change would transiently occur. I believe that
this is unlikely since recent reports looking at genome scale DNA methylation changes
during muscle- lineage determination and terminal differentiation (fully formed muscle)
demonstrate the presence of significant DMRs (majority hypermethylated) but no
methylation changes between primary myoblasts and myotubes when differentiated in
culture (Carrió et al., 2015; Tsumagari et al., 2013). This is in accordance with what I
observe in my cell culture system. It is also possible that eRRBS might not be capturing
regions in which methylation changes dependent on APOBEC2 do occur (RRBS tends to
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cover most deeply promoter and coding DNA sequence-CDS regions with very little
coverage of intergenic sites and potential enhancer sites). As well it is also possible that
very few APOBEC2 dependent changes occur but that those are crucial: for instance,
work with the iPax7 ES cell model (described above) suggested that APOBEC2 reduces
Moyg-associated DNA demethylation through differentiation (Carrió et al., 2016) which
would explain Myog’s repression. This site is not well covered in my eRRBS data and
there maybe others that behave similarly. Thus, there might be few key DNA
demethylation events that could be mediated by APOBEC2 and that can be undetectable
in our RRBS analysis because of low signal to noise ratio or lack of coverage in the
affected regions (low sequencing read representation). Moreover, in the future it would
be important to check whether there are any significant DNA methylation changes,
specifically in the promoters of genes that were shown through ChIP-Seq to be directly
bound by APOBEC2. In all, my work does not support the hypothesis of a role of
APOBEC2 in DNA deamination.
Lastly as discussed more extensively below, APOBEC2 seems to be a chromatinbinding factor. It is unclear whether APOBEC2 can bind to DNA directly or whether it
does so through binding to a cofactor/complex. Currently we are working on determining
whether there is physical direct binding and detectable DNA editing activity in regions of
the DNA where APOBEC2 is enriched. This would be an interesting avenue to follow up
on since deamination at TSS can induce DNA breaks (which in the satellite cell system
have been linked to differentiation -specifically, muscle differentiation is presumed to be
dependent on targeted DNA strand breaks through the action of nuclease caspaseactivated DNase (CAD) that lead to gene expression changes (Larsen et al., 2010). It is
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tempting to speculate that APOBEC2 could be implicated in this process. Beyond these
early findings, recent research has shown that transient DNA strand breakage exerts an
effect on cell fate, acting to limit stem cell self-renewal and stimulate differentiation,
which has been shown to be important in case of many tissues, including muscle (AlKhalaf et al., 2016; Behrens et al., 2014; Larsen and Megeney, 2010; Larsen et al., 2010;
Narciso et al., 2007). Overall, determining if APOBEC2 has a DNA editing role would be
an important next step and could bring us closer to understanding better APOBEC2’s
activity.
6.3 APOBEC2 adds a novel role to the AID/APOBEC family of enzymes
My data provide molecular evidence of the importance of APOBEC2 at the
transcriptional level.

I have demonstrated that APOBEC2 is a regulator of gene

expression, which is a novel role, previously undescribed for any of the AID/APOBEC
family members. APOBEC2 (directly or indirectly) affects gene networks important for
muscle differentiation and cell cycle regulation as demonstrated by the deregulation of
the myogenesis pathway genes and the E2F target genes. I showed that two central genes
important in myogenesis and cell cycle exit, Myog and Cdkn1a/p21 are downregulated
due to APOBEC2 knockdown, suggesting that normally APOBEC2 might be acting
upstream of these factors and affecting their proper induction during cell differentiation.
It is still unclear how APOBEC2 might be mediating this process. In the future it would
also be interesting to determine if expressing Myog or Cdkn1a/p21 would be sufficient to
rescue the phenotype observed.
But how does APOBEC2 mediate transcriptional regulation? Since it is unlikely
to be a demethylase or an RNA editor, this outcome can only be due to its direct or
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indirect binding to DNA, and some catalytic activity that remains unresolved but which
can mediate the transcriptional changes I observe. In that context, I have shown
APOBEC2 acting as direct chromatin binder. In differentiated myotubes (Figure 5.1) I
showed that even though the majority of the protein resides in the cytoplasm I could
detect some nuclear APOBEC2 tightly bound to the chromatin. The discovery that
APOBEC2 localizes in the nucleus and binds to chromatin is supported by recent studies
in zebrafish where it was shown that sumoylation regulates APOBEC2 nuclear exclusion
but once in the nucleus APOBEC2 can regulate the binding of POU6F2 (a homeodomain
transcription factor associated with retinal differentiation) to DNA (Powell et al., 2014).
For future work, it would be interesting to determine the dynamics and timing of
APOBEC2 nuclear localization during the differentiation process as this could provide
additional insights about the regulation of APOBEC2’s activity and functional
consequences of inducing its shuttling to the nucleus.
I have shown that APOBEC2 binds to genes (close to their TSS) consistently at
both time points assessed (14-hour and 34-hour post differentiation) suggesting
substantial duration of occupancy at the relevant promoters. It would be interesting to see
if this result would hold true if we assess APOBEC2 binding during the myoblast
proliferation stage or at later time points in the terminal differentiation or in the mature
muscle tissue. The number of true APOBEC2 binding sites might be even greater than
what we have reported here since our analysis showed that further optimization of the
ChIP-Seq or increase in sequencing depth could increase the signal detected. Moreover
the analysis shown here is used to detect narrow binding regions which are characteristic
of transcription factor binding (narrow peaks), it would be interesting to look for other
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types of binding such as broader binding regions characteristic of bigger complexes or
histones (broad peaks).
I have also shown that the top enriched pathways among the APOBEC2 bound
genes are cell cycle related pathways. This is in accordance with our phenotype of defects
in cell cycle exit during differentiation when APOBEC2 is depleted. I also show that
APOBEC2 occupied genes (including the cell cycle related genes) are overrepresented in
the list of genes that are normally inhibited through differentiation (and upregulated when
APOBEC2 is depleted) suggesting that APOBEC2 might have a role in transcription
inhibition (Figure 5.6; 5.7) The latter is also corroborated with the conclusion that higher
APOBEC2 binding correlates with gene repression through differentiation. Tying
together the transcriptome data to the APOBEC2 genome wide binding data turned out to
be fruitful here in generating hypothesis as to how APOBEC2 is operating. However, the
constrain in such comparison is that expression changes and occupancy might not be
exactly congruent. It is not known how much correlation we should expect between
APOBEC2 binding to a gene estimated by ChIP-Seq peaks and transcript abundance for
the gene estimated by RNA-Seq (Cheng et al., 2012). It would be interesting to see the
consequences of APOBEC2 binding at later time points through differentiation, which
could provide additional evidence for APOBEC2’s role in gene repression. Finally, I
have yet to perform validation experiments on the ChiP-Seq data, mostly because I am
waiting to generate a CRISPR-knockout of APOBEC2 in C2C12 cells. The reason I want
to compare the control to a knockout and not a knockdown is that the antibody I used is
efficient enough to pick up even small amounts of protein that might still be present in
the knockdown samples, resulting in DNA fragments that after amplification rounds are
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still highly represented (and very small differences between wildtype and knockdown
samples via ChIP-Seq data). Thus validation experiments are still ongoing in the lab.
Overall, more work is required to determine exactly how APOBEC2 inhibits
transcription. One possibility is that APOBEC2 is part of a repressive epigenetic
complex; unpublished Bio-ID data from a colleague (Javier Marcelo Di Noia, Poorani
Ganesh Subramani, McGill University) who used APOBEC2 as a control for a study in
AID in protein:protein interaction experiments in 293T and B cells demonstrates that
APOBEC2's neighbors include exactly such a complex, comprising HDAC1, PRMT7,
SMARCA5, MBD3, RIF1 and intriguingly, H2AF(data not shown). It would be worth to
do similar experiments in C2C12. Another possibility is that APOBEC2 is an inactive
deaminase, which recognizes and binds a specific nucleotide sequence or perhaps a
specific nucleotide modification, thus recruiting such a complex to specific promoters.
Whether the specific promoters are recognized by APOBEC2 and also by the repressor
complex, or independently by APOBEC2 remains to be determined.

6.4 Getting closer to understanding how APOBEC2 is mediating its biological role
The discovery of potential promising APOBEC2 binding targets presents an opportunity
to gain insights into APOBEC2’s activity. One way I attempted to do this is by
bioinformatically searching for overrepresented sequence patterns (motifs) that could best
represent the enzymatic substrates. Of all of the predicted motifs the top enriched ones
were shown (Figure 5.8) containing CCAAT and TTYRAA. Interestingly most of these
motifs are within 1kb of the transcription binding sites and some are very close to the
start (within 50bp). These motifs could be crucial tools in in vitro (biochemical) analyses

115

of function. Another interesting question regarding APOBEC2 is how does it determine
which promoter regions to bind to. Its binding to promoters could be determined by (1) a
specific DNA motif (2) other interacting proteins (3) a combination of the above. It
would be interesting to determine if the motifs that we have identified are significantly
enriched in the APOBEC2 bound genes as compared to all of the promoters. This could
give us more insights into APOBEC2’s mechanism of mediating gene repression.
There are some important questions that still remain to be answered and help
elucidate how APOBEC2 is mediating its function. Is the ZDD domain necessary for
APOBEC2’s function during myoblast differentiation? One way to answer this question
is to try to recapitulate the activity of APOBEC2 using a catalytic mutant version of the
protein. Does APOBEC2 directly bind to the DNA? An electrophoretic mobility shift
assay (EMSA) using the substrates or the motif sequence could provide some answers.
Additionally, utilizing the substrates in a mutation assay could provide evidence for
mutator activity. As mentioned, our sequencing datasets also provide an avenue, where
we can scan for possible mutations. Does APOBEC2 bind to other cofactors or epigenetic
remodelers? Immunoprecipitation of such complexes combined with mass spectrometry
could corroborate the BioID data. Is the function of APOBEC2 in cell cycle applicable to
other systems? There is increasing evidence that APOBEC2 is expressed in systems
beyond the cardiac and skeletal muscle and that in some of these it mediates functional
effects (Powell et al., 2014). APOBEC2 is also expressed in mouse neurons (Sharma et
al., 2016), in placenta (not published, personal communication), immune cells (Immgen
database). Moreover, changes in APOBEC2 expression (either upregulated or
downregulated) in humans also correlate with breast cancer, sarcoma, colorectal
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carcinoma, non-small cell lung carcinoma (Expression Atlas, EMBL-EBI) etc. Therefore
elucidating whether or not APOBEC2 has a mutator or epigenetic role would be
important for elucidating important gene regulatory mechanisms that additionally might
have a role in cancer.

6.5 Concluding remarks
The excitement around AID/APOBEC exists (at least partly) because of how they
mediate alterations (resulting in mutations or editing events) at the level of
polynucleotides to fulfill a biological role. Their discovery presented a novel, surprising
(and fascinating!) mechanism of expanding genome diversity. Further research through
the years has shown that AID/APOBEC(s) are important in diverse biological systems
with implications in health and disease. At the time I started working on this thesis
project, APOBEC2 was considered the most mysterious and obscure protein of the
APOBEC/AID family. Few things were already known about APOBEC2’s biological
role but nothing was known as to how it mediates its role and as to whether the
mechanism is similar to the other AID/APOBEC enzymes. The collective work in my
thesis disproves the hypothesis that APOBEC2 is mediating DNA demethylation or RNA
editing (on C or in A) similar to other members of AID/APOBEC. Instead, my work
demonstrates that APOBEC2 has a clear role (direct or indirect) as a transcriptional
repressor through binding (directly or possibly as part of a complex) to promoters of
genes relevant to muscle differentiation (and specifically to cell cycle exit). I am hopeful
that the specific binding targets I discovered will be utilized to elucidate the precise
mechanism of how APOBEC2 affects gene expression and thus to decipher its broader
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role (potentially beyond muscle) in gene expression regulatory mechanisms and/or in
driving genome biological diversity.
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CHAPTER 7. Materials and Methods
7.1 C2C12 cell culture
C2C12 cells (CRL-1772, ATCC) were maintained in DMEM (30-2002, ATCC)
with 10% fetal bovine serum (FBS) and feed every two days. To differentiate equal
number of cells (0.25 x 10^6) were seeded in 6-well plates followed by media change to
DMEM with 2% horse serum after 12 hours. For generating single cell clones for RNAseq and RRBS experiments C2C12s were sorted using fluorescence-activated cell sorting
(FACS) and seeded into a 96 well plate. Each clone was expanded and tested for
successful knockdown through immunoblotting.
7.2 Protein knockdown using lentivirus infection
C2C12s were infected with lentiviruses carrying shRNAs, targeting APOBEC2
(or GFP as a control), which allows for infection of both proliferating and nonproliferating cells and provides a stable repressive effect. All APOBEC2 shRNAs were
obtained from The Broad Institute’s Mission TRC-1 mouse library and present in
pLKO.1-puro construct, which carries the puromycin-resistance gene and drives shRNA
transcription from a human U6 promoter. Plasmids used: pLKO.1 - TRC cloning vector
(Addgene, # 10878) (Moffat et al., 2006); pLKO.1 puro GFP siRNA (Addgene, # 12273)
(Orimo et al., 2005). The design of shRNAs and cloning in pLKO.1-TRC, were done
according to the Addgene protocol (Protocol Version 1.0. December 2006). The
following siRNAs sequences were used for APOBEC2 knockdown:
shRNA#1
shRNA#2
shRNA#3
shRNA#4
GFPsiRNA,

CCTGGCTTCCTGATTCTACTT
GCCTCTCAGAATGGAGATGAT
CTTCCTATACTATGAGGAGAA
GCTACCAGTCAACTTCTTCAA
GCAAGCTGACCCTGAAGTTCAT
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Lentiviruses were produced by co-transfection of pLKO.1-puro short hairpins
containing construct, packaging plasmid psPAX2 (Addgene, #12260) and envelope
plasmid pMD2.g (Addgene, #12259) in HEK 293T cells. Transfections were done using
Lipofectamine 2000 Reagent (Lifetechnologies) as per manufacturer instructions.
Supernatants with lentiviral particles were collected at 24 and 48 hours after transfection,
passed through a 0.45 mm filter and applied to C2C12s. For APOBEC2 constitutive
knockdown 30% confluent cells were infected with pLKO.1 containing lentiviruses in
growth media containing 8ug/mL polybrene for 12 hours. Two days after lentiviral
infection cells were cultured with 4ug/ml virus-free puromycin containing media for two
more days to select cells stably expressing the shRNAs.
7.3 Cell cycle and cell proliferation analysis
Equal number of cells (0.125 x 10^6) were seeded in 6-well plates followed by
media change to DMEM with 2% horse serum after 12 hours. C2C12s were harvested by
trypsinization and stained with EdU (Thermofisher, Clik-iT EdU, C10337) as per
manufacturer instructions. Following washes of the Click-it solution cells were
resuspended with 0.05 mg/ml Propidium Iodide (PI) and 0.1 mg/ml RNAseA mix,
transfer into Eppendorf tubes and stained for 30 min at room temperature in the dark and
analyzed by flow cytometry. Data were gated to exclude apoptotic cells.
7.4 Immunoblotting
For immunoblotting experiments, the C2C12s were first washed with cold 1xPBS
and lysed in 100ul RIPA lysis buffer (santacruz, sc-24948) in 6-well plates. They were
incubated at 4°C for 15 min and then extracts were scrapped into an eppendorf tube.
Lysates were snap frozen in liquid nitrogen to improve efficiency of lysis. After thawing
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the lysates on ice and clearing out cell debris by centrifugation, same amount of total
protein (ranges between 10-30μg) was loaded onto each lane of a Polyacrylamide gel
(Criterion XT Bis-Tris Gel 12%, Bio-Rad). Following electrophoresis, the resolved
protein was transferred to a polyvinylidene difluoride (PVDF) (Bio-Rad) membrane and
subjected to western blot (WB) analysis. The source and dilution for each antibody used
were: polyclonal rabbit-APOBEC2 (gift from Alin Vonica MD, PhD) (1:1000),
monoclonal mouse-APOBEC2 (clone 15E11, homemade) 1:5000, TroponinT, clone JLT12 (T6277, Sigma-Aldrich) 1:500, alpha tubulin DM1A (Abcam, ab7291) 1:5000,
MyHC, MF-20 (DSHB) 1:20.
7.5 Immunofluorescence staining and fusion index of C2C12s
C2C12 cells (0.05^106) were seeded in collagen coated coverslips (BD
Biosciences, 356450) in 12- well plate the day before inducting of differentiation with
2% horse serum. They were washed with cold PBS and fixed with paraformaldehyde
(4%) in PBS for 10 min at 4°C. This was followed by 2 washes, 5 min each at room
temperature and blocking solution (0.5% BSA, 1% gelatin, 5% normal goat serum, 0.1%
Triton) in PBS for 1 hour at room temperature. This was followed by overnight stain with
antibodies in a humidified chamber at 4°C, three washes with cold PBS 5 min each at
room temperature. Coverslips were then incubated with secondary antibodies for 1 hour
at room temperature, followed by three washes with PBS 5min in at room temperature.
Immunofluorescence staining of C2C12 cells was carried out with antibodies specific for
MyHC (MyHC MF20, DSHB), DAPI (Vectoshield Antifade Mounting Medium with
DAPI, H-1200), Flag (Sigma-Aldrich, F1804). Images were taken using confocal Leica
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TCS SP5 II or widefield Zeiss Cell Observer and image analysis was done with Fiji
(ImageJ).
7.6 APOBEC2-/- mice
C57BL/6 wild-type and APOBEC2-/- (provided by Lawrence Chan and Benny
Hung-Junn Chan, Baylor College of Medicine) were used for the regeneration
experiments. All mice were bred and maintained under specific pathogen-free conditions
at the Rockefeller University Animal Care Facility and The Rockefeller University
Institutional Animal Care and Use Committee (IACUC) approved all procedures
involving mice.
7.7 BaCl2 induced muscle injury and regeneration
To induce muscle injury we performed intramuscular injection of BaCl2 in the
Tibialis Anterior (TA) muscle as previously described. BaCl2 induces muscle fiber
necrosis while completely preserving the basement membrane (Caldwell et al., 1990)
followed by regeneration. We used 8-10 week old female mice in all of the experiments.
According to approved IACUC protocols mice were anaesthetized by isoflurane
inhalation. BaCl2 (50 uL of 1.5% w/v in saline) or 0.9% sodium chloride solution (as a
control) was injected into the TA muscle of hind limb. For pain relief mice were given
acetaminophen in the drinking solution (4.48mg.ml, acetaminophen) as described
(Mickley et al., 2006). Injected animals were caged singly throughout the experiments.
On day 14 after injury, the mice were euthanized and the TA muscles were collected,
followed by cryosection and staining.
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7.8 Muscle tissue cryosection, staining and image analysis
TA muscles were frozen in liquid nitrogen cooled in 2-methylabutane and
embedded in optimal cutting temperature compound (OCT). 10 um-thick cross sections
were made using Microm HM505E cryostat at -20C, air dried and stained with Wheat
Germ Agglutinin, Alexa Fluor 488 Conjugate (1ug/mL) and DAPI (1ug/ml). Images were
acquired using an inverted fluorescent microscope (Eclipse Ti, Nikon) coupled to a Neo
sCMOS camera (Andor Technology), and multiple images of whole TA muscle cross
section were stitched with the software supplied by the manufacturer (NIS-Elements AR,
Nikon). Images were acquired using 10x objective with a scale of 0.65um/pixel. For
each TA muscle cross-section 3 non-overlapping sections (close to the muscle center)
were chosen. For quantification of the number of fibers with mispositioned nuclei ImageJ
macros were used.
7.9 Inverted grip-hanging test
Experiment was performed by Luendreo Barboza. Animals were places in grip
apparatus lifted 30cm from the ground. The time of hanging was measured for 5
successive trials. Experiment was done with one mouse cohort.
7.10 Salt-extraction profiling
C2C12 cells were seeded in equal numbers (2x10^6) and induced to differentiate
after 12 hours. 5 days after differentiation they were lysed in the plate with 100ul sucrose
lysis buffer (320mM sucrose, 0.5% NP-40, 10mM Tris pH8, 3mM CaCl2, 2mM Mg
acetate, 0.1mM EDTA). Extracts were incubated for 5 minutes on ice and spun at 500g
for 5 minutes to collect the nuclear pellet and supernatant as the cytosol fraction. Nuclear
pellets were washed with no-salt Nuclei Buffer (50mM Tris pH8, 1%NP-40, 10%
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glycerol). Following the washes the nuclear proteins were extracted at increasing
concentrations of NaCl from 250 mM up to 2 M in Nuclei Buffer during which they are
homogenized using dounce tissue grinders (Fisher, K8853000000), incubated on ice for
10min and spun at 4°C for 10 additional minutes. Eluted materials was collected,
resolved on polyacrylamide gel electrophoresis (Criterion XT Bis-Tris Gel 12%, BioRad) and immunoblotted with specific antibodies: H4 antibody (cat, company) 1:5000,
monoclonal mouse-APOBEC2 (clone 15E11, homemade) 1:5000, alpha tubulin DM1A
(Abcam, ab7291) (1:5000).
7.11 RNA analysis
7.11.1 RNA expression analysis
Library preparation and sequencing were done by Rockefeller University
Genomics Resource Center [https://www.rockefeller.edu/genomics/] using TruSeq
Stranded mRNA Sample Prep kit as per manufacturer’s instruction. The procedure
includes purification of poly-adenylated RNAs. Libraries were sequenced with 50bp
paired-read sequencing on the HiSeq2500 (Illumina).
Paired end read alignments and gene expression analysis were performed with the
Bioinformatics Resource Center at Rockefeller University. Paired-end reads were aligned
to mm10 genome using the subjunc function in the Bioconductor Rsubread (Liao et al.,
2013) package and bigWig files for visualization were generated from aligned reads
using the Bioconductor rtracklayer (Lawrence et al., 2009) and GenomicAlignments
packages (Lawrence et al., 2013). For analysis of differential expression, transcript
quantifications were performed using Salmon (Patro et al., 2017) in quasi-mapping mode.
Gene expression values were calculated from transcript quantifications using tximport
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(Soneson et al., 2016). Gene expression changes were identified at a cut off of 5% FDR
(benjamini-hockberg correction) using the Wald test implemented in DESeq2 (Love et
al., 2014). Annotation files used:
BSgenome.Mmusculus.UCSC.mm10(v1.4.0);org.Mm.db(v3.5.0);
TxDb.Mmusculus.UCSC.mm10.knownGene.gtf.gz(v3.4.0)
7.11.2 Gene Set Enrichment Analysis
GSEA (v3.0) (Subramanian et al., 2005) was ran on a list of genes that are preranked based on Wald statistic, which is the log2 fold change value divided by the
standard error according to GSEA recommendations. Molecular Signature Database
(MSigDB) Gene Sets were used (Liberzon et al., 2015), and converted from human to
mouse using the entrezID, using Mouse Genome Informatic (MGI) Vertebrate homology
(HOM_MouseHumanSequence) (Blake et al., 2017) and HGNC Comparison of
Orthology Predictions (HCOP) orthology (Eyre et al., 2007; Gray et al., 2015; Wright et
al., 2005). The following MSigDB gene sets were used: c2.cp.reactome.v5.0.entrez.gmt,
Reactome gene sets, Entrez IDs (Croft et al., 2014; Fabregat et al., 2018) and
H.v5.0.entrez.gmt, Hallmark gene sets Entrez IDs, (Liberzon et al., 2015).
GSEA’s parameters:
java -cp <path>/gsea-3.0.jar -Xmx512m xtools.gsea.GseaPreranked -gmx
<GenesetFile.gmt> -norm meandiv -nperm 1000 -rnk <Preranked_gene.rnk> scoring_scheme classic -rpt_label <Label> -create_svgs false -make_sets true plot_top_x 20 -rnd_seed timestamp -set_max 500 -set_min 15 -zip_report false -out
<outputFolder> -gui false
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For each of the MSigDB gene sets listed above we generated our own collection
by overlapping the MSigDB gene sets with the genes that are coordinately differentially
expressed during the C2C12 differentiation at the specific time points chosen. We ended
up with the following collection of gene sets of genes that are significantly unregulated,
downregulated or not significantly changed during differentiation from day 0 to day 2:
OriginalGeneSet_d2d0DEG_UP;OriginalGeneSet_d2d0DEG_DOWN;
OriginalGeneSet_d2d0DEG_NS.
The False Discovery Rate (FDR) is calculated by comparing the actual data with
1000 Monte-Carlo simulations. The NES (Normalized Enrichment Score) computes the
density of modified genes in the dataset with the random expectancies, normalized by the
number of genes found in a given gene cluster, to take into account the size of the cluster.
7.11.3 RNA editing analysis
RNA editing analysis was performed by Dewi Harjanto, PhD as previously
reported elsewhere (Harjanto et al., 2016). Editing detection was performed by
comparing C2C12 control samples (GFPsh) to APOBEC2 knockdown samples using
RNA-seq datasets in triplicates for each sample. Minimum filters include quality control
thresholds (minimum of five reads covering the putative site with at least two reads
supporting the editing event; filtering of reads that contain indels or support an edit in the
first or last two base pairs of a read). Stringent filters applied to the APOBEC1 dependent
C-to-U edited sites include all of the above and additionally the magnitude of the control
vector was at least 15 and the angle between the wild-type and knockout vectors was at
least 0.11 radians, as described in the paper referenced in this section.
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7.12 DNA methylation analysis
7.12.1 Enhanced Reduced representation bisulfite sequencing (eRRBS)
eRRBS library preparation, sequencing and read alignment was performed by the
Epigenomics Core Facility of Weill Cornell Medicine [epicore.med.cornell.edu/] as
previously described (Akalin et al., 2012a; Garrett-Bakelman et al., 2015). The procedure
includes bisulfite conversion of the DNA. Libraries were sequenced with 50bp single
reads (SR) in HiSeq2500 (Illumina). Reads were aligned to a bisulfite converted
reference mouse genome with Bismark (Krueger and Andrews, 2011). The methylation
context for each cytosine was determined with scripts from the core facility.
Here coverage of specific genomic regions by eRRBS dataset, refers to the percent of
features (eg percent of promoters, CpG islands) that contain at least one CpG that is well
covered (> 10x). For gene specific annotations the mm10 UCSC knownGene annotations
from the UCSC table browser were used and for CpG islands the mm10 cpgIslandExt
track of the UCSC table browser. Genomic features were defined as: CpG islands, CpG
island shores were defined as 2kb upstream and downstream of a CpG island; Gene
promoters (region 2kb upstream and 2kb downstream of the TSS), exons, introns and
intergenic regions.
7.12.2 Differential methylation analysis
MethylKit (v1.3.8) (Akalin et al., 2012b) was used to identify differentially
methylated cytosines (DMCs) with q-value less than 0.01 and methylation percentage
difference of at least 25% after filtering eRRBS dataset by coverage, normalizing by
median and including CpG sites that are covered >10x, in 3 out of 5 biological replicates
(lo.count

=

10,

lo.perc

=

NULL,

hi.count
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=

1000,

hi.perc

=

99.9),

(destrand=TRUE,min.per.group=3L). eDMRs (v0.6.4.1) (Li et al., 2013) was used to
empirically determine differentially methylated regions, using the DMCs identified with
methylKit. In order for a region to be defined as a DMR, default parameters
(num.DMCs=1, num.CpGs=3, DMR.methdiff=20) of eDMR were used, so that each
region has: (1) at least 1 DMC in the region, as determined using methylKit, (2) at least 3
CpGs included in the region and (3) absolute mean methylation difference greater than
20%. For a region to be defined as a significant DMR, default parameters were used
(DMR.qvalue = 0.001, mean.meth.diff = 20, num.CpGs = 5, num.DMCs = 3) so that each
significant DMRs has (1) 5 CpGs where at least 3 of them are significant DMCs as
determined by methylKit (2) have a minimum 20% methylation change for the region.
7.13 Chromatin binding analysis
7.13.1 Chromatin immunoprecipitation method
C2C12s were plated at ~70% confluence 12 hours prior to inducing
differentiation (seed ~2x10^6 cells) maintained in DMEM (ATCC, 30-2002) with
10%FBS. This was followed by media change to DMEM with 2% horse serum (Life
Biotechnologies, 26050-088) to induce differentiation. The cells (~5x10^6 /10cm plate)
were harvested at 24-hour or 34-hour after inducing differentiation. They were fixed on
plate with 1% PFA in PBS for 10 minutes at RT. Glycine was added to a final
concentration of 125mM. Cells were washed 2 times with 1x PBS with protease inhibitor
cocktail (PIC, Roche, 11836170001). They were lysed on the plate with cold Farnham
lysis buffer to ~10x10^6 cells /mL (5mM PIPES pH 8.0, 0.5% NP-40, 85mM KCl,1mM
EDTA, PIC) and incubated rotating for 15min at 4°C . Lysates were scraped off the
plates, pelleted and resuspended in LB2 (10 mM Tris pH 8.0, 200 mM NaCl, 1 mM
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EDTA, 0.5 mM EGTA, PIC) and incubated rotating for 15 minutes at 4°C and then
centrifuged. Pellets were resuspended to 5x10^7 cells/mL in LB3 (10 mM Tris pH 8.0,
100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium-deoxycholate, 0.5% sodium
lauroyl sarcosinate, PIC) until suspension was homogenized. Samples were then
sonicated using Covaris ultrasonicator model S220 for 15 minutes with the following
settings: 140W peak power, 5% duty, 200 cycles per burst. TritonX-100 to a final
concentration of 1% was added to the samples. Samples were clarified by centrifugation
at 20,000 g for 10 minutes at 4°C. The supernatant is the soluble chromatin extract. The
soluble fragmented chromatin from ~2.5x10^7 was used for each IP. For each IP 100ul
Dynabeads (Thermofisher anti-rabbit M280, 11203D) were mixed with 10ul polyclonal
rabbit-APOBEC2 antibodies (gift from Alin Vonica MD, PhD) incubating overnight (~16
hours). A magnetic stand was used to separate beads from the lysate and beads were
washed one time each with for 5min in: low salt wash (0.1%SDS, 1%Triton X-100, 2mM
EDTA, 20mM Tris pH8, 150mM NaCl, PIC), high salt wash (0.1%SDS, 1% Triton X100, 2mM EDTA, 20mM Tris pH8, 500mM NaCl, PIC), lithium chloride wash (150mM
LiCl, 1% NP-40, 1% NaDOC, 1mM EDTA, 10mM TrispH8, PIC), TE wash (10mM
Tris-HCl pH8, 1mM EDTA, 50mM NaCl, PIC). Beads were resuspended in 52 ul of
elution buffer (50mM Tris-HCl pH8, 10mM EDTA, 1%SDS) and incubated at 30min at
65°C while shaking to prevent beads from settling. The eluate was transferred to a new
tube, inputs of the same volume were incubated for 8 hours at 65°C to reverse the
crosslink. The samples were treated with RNAse (Roche, Cat. No. 11 119 915 001) for 1
hour at 37°C, and with Proteinase K for 2 hours at 55°C. Fragmented DNA was purified
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with Ampure beads (Agencourt AMPure XP beads A63881) as per the manufacter’s
instructions.
7.13.2 Chromatin immunoprecipitation sequencing and analysis
The ChiP-Seq included biological triplicates for each group. ChIP-Seq libraries
were prepared using NEBNext Ultra DNA Library Prep Kit as per manufacturer’s
instructions. Libraries were sequenced with 75 base pair single read sequencing on the
NextSeq 500 (Illumina). Read alignments and initial analysis were performed with the
Bioinformatics Resource Center at Rockefeller University. Single-end reads were aligned
to mm10 genome using the subread function in the Bioconductor Rsubread (Liao et al.,
2013) package and bigWig files for visualization were generated from aligned reads
using the Bioconductor rtracklayer (Lawrence et al., 2009) and GenomicAlignments
packages (Lawrence et al., 2013). Quality metrics for the ChIP-Seq data were assessed
using ChIPQC bioconductor package (Carroll et al., 2014), according to Encyclopedia of
DNA Elements (ENCODE) working standards and guidelines for ChIP experiments
(Landt et al., 2012). Reads mapping to more than one genomic location were filtered
prior to peak calling using Model-based Analysis of ChIP-Seq (MACS2) (Feng et al.,
2011; Zhang et al., 2008) with duplicate filtering applied and input DNA sample as a
control. Peaks that are reproducible in the majority of the replicates (present in 2 out of 3)
were filtered for known artifact or blacklisted regions (The ENCODE Project
Consortium, 2012). For each of the peaks a weighted mean location of peak summits
across biological replicates is calculated (Yang et al., 2014). The list of binding regions
100 base pairs around the mean peak summits was used for downstream analysis.
Ngs.plot (v2.61) was used with specific parameters (-G mm10 -D refseq -C -L 1000 -FL
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150 -P 4 -SC 0,1 -GO none -RB 0.05) to generate average profiles of ChIP-Seq reads
(Shen et al., 2014). ChIPSeeker (v1.14.2) (Yu et al., 2015) and ChIPpeakAnno (3.12.7)
(Zhu, 2013; Zhu et al., 2010) were used for downstream analysis after peak calling for
annotation of the binding regions to the nearest gene. clusterProfiler (3.6.0) (Yu et al.,
2012) was used for the pathway enrichment analysis of the genes with peaks using
MSigDB database. The MSigDB gene sets are first converted from human to mouse
entrezID,

using

Mouse

Genome

Informatics

(MGI)

Vertebrate

homology

(HOM_MouseHumanSequence) (Blake et al., 2017) and HGNC Comparison of
Orthology Predictions (HCOP) orthology (Eyre et al., 2007; Gray et al., 2015; Wright et
al., 2005). The following MSigDB gene sets were used: c2.cp.reactome.v5.0.entrez.gmt,
Reactome gene sets Entrez IDs (Croft et al., 2014; Fabregat et al., 2018) and
H.v5.0.entrez.gmt, Hallmark gene sets Entrez IDs (Liberzon et al., 2015). GSEA
(Subramanian et al., 2005) (v3.0) was used for testing the enrichment of the APOBEC2
occupied geneset in the list of genes that are differentially expressed. Annotation files
used:

BSgenome.Mmusculus.UCSC.mm10

(v1.4.0)

org.Mm.db

(v3.5.0),

TxDb.Mmusculus.UCSC.mm10.knownGene.gtf.gz(v3.4.0);
7.13.3 Prediction of binding motifs
The MEME-ChIP pipeline within the MEME suite of motif tools (v4.12.0) was
used for motif based analysis (Ma et al., 2014; Machanick and Bailey, 2011). Peaks that
are reproducible in the majority of the replicates (present in 2 out of 3) (Yang et al.,
2014) were used for motif discovery after being filtered for blacklisted regions (The
ENCODE Project Consortium, 2012). For each of the peaks a weighted mean location of
peak summits across biological replicates is calculated (Yang et al., 2014). The list of
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binding regions 100 base pairs around the mean peak summits was used for motif
analysis. The MEME-ChIP pipeline was run with parameter --parse-genomic-coord to
allow for the retrieval of discovered motif genomic locations. Within the MEME-ChIP
pipeline, a background file is initially created by shuffling input Fasta sequences. MEME
and DREME were used to predict de novo DNA binding motifs.

De novo motif

assignment to known motifs within the Jaspar 2014 database was performed using
TomTom (Gupta et al., 2007). FIMO (Grant et al., 2011) was used for scanning for the
occurrences of a given motif. The distribution of the motif location relative to the nearest
TSS was done using ChipSeeker (v1.14.2)(Yu et al., 2015).

132

REFERENCES
Akalin, A., Garrett-Bakelman, F.E., Kormaksson, M., Busuttil, J., Zhang, L.,
Khrebtukova, I., Milne, T.A., Huang, Y., Biswas, D., Hess, J.L., et al. (2012a). Base-Pair
Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic
Landscapes in Acute Myeloid Leukemia. PLOS Genetics 8, e1002781.
Akalin, A., Kormaksson, M., Li, S., Garrett-Bakelman, F.E., Figueroa, M.E., Melnick,
A., and Mason, C.E. (2012b). methylKit: a comprehensive R package for the analysis of
genome-wide DNA methylation profiles. Genome Biology 13, R87.
Al-Khalaf, M.H., Blake, L.E., Larsen, B.D., Bell, R.A., Brunette, S., Parks, R.J.,
Rudnicki, M.A., McKinnon, P.J., Dilworth, F.J., and Megeney, L.A. (2016). Temporal
activation of XRCC1-mediated DNA repair is essential for muscle differentiation. Cell
Discovery 2, 15041.
Anant, S., Mukhopadhyay, D., Sankaranand, V., Kennedy, S., Henderson, J.O., and
Davidson, N.O. (2001). ARCD-1, an apobec-1-related cytidine deaminase, exerts a
dominant negative effect on C to U RNA editing. Am J Physiol Cell Physiol 281, C1904–
C1916.
Anders, S., Reyes, A., and Huber, W. (2012). Detecting differential usage of exons from
RNA-seq data. Genome Res. 22, 2008–2017.
Andrés, V., and Walsh, K. (1996). Myogenin expression, cell cycle withdrawal, and
phenotypic differentiation are temporally separable events that precede cell fusion upon
myogenesis. J Cell Biol 132, 657–666.
Atlasi, Y., and Stunnenberg, H.G. (2017). The interplay of epigenetic marks during stem
cell differentiation and development. Nature Reviews Genetics 18, 643–658.
Avery, O.T., MacLeod, C.M., and McCarty, M. (1944). Studies on the Chemical Nature
of the Substance Inducing Transformation of Pneumococcal Types. Journal of
Experimental Medicine 79, 137–158.
Bailey, T.L., Boden, M., Buske, F.A., Frith, M., Grant, C.E., Clementi, L., Ren, J., Li,
W.W., and Noble, W.S. (2009). MEME Suite: tools for motif discovery and searching.
Nucleic Acids Res 37, W202–W208.
Behrens, A., Deursen, J.M. van, Rudolph, K.L., and Schumacher, B. (2014). Impact of
genomic damage and ageing on stem cell function. Nature Cell Biology 16, 201–207.
Bentzinger, C.F., Wang, Y.X., and Rudnicki, M.A. (2012). Building Muscle: Molecular
Regulation of Myogenesis. Cold Spring Harb Perspect Biol 4, a008342.
Berkes, C.A., and Tapscott, S.J. (2005). MyoD and the transcriptional control of
myogenesis. Seminars in Cell & Developmental Biology 16, 585–595.
133

Betts, L., Xiang, S., Short, S.A., Wolfenden, R., and Carter, C.W. (1994). Cytidine
Deaminase. The 2·3 Å Crystal Structure of an Enzyme: Transition-state Analog
Complex. Journal of Molecular Biology 235, 635–656.
Bhutani, N., Brady, J.J., Damian, M., Sacco, A., Corbel, S.Y., and Blau, H.M. (2010).
Reprogramming towards pluripotency requires AID-dependent DNA demethylation.
Nature 463, 1042–1047.
Bierkens, M., Krijgsman, O., Wilting, S.M., Bosch, L., Jaspers, A., Meijer, G.A., Meijer,
C.J.L.M., Snijders, P.J.F., Ylstra, B., and Steenbergen, R.D.M. (2013). Focal aberrations
indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical
carcinogenesis. Genes Chromosomes Cancer 52, 56–68.
Blais, A., Tsikitis, M., Acosta-Alvear, D., Sharan, R., Kluger, Y., and Dynlacht, B.D.
(2005). An initial blueprint for myogenic differentiation. Genes Dev. 19, 553–569.
Blais, A., van Oevelen, C.J.C., Margueron, R., Acosta-Alvear, D., and Dynlacht, B.D.
(2007). Retinoblastoma tumor suppressor protein-dependent methylation of histone H3
lysine 27 is associated with irreversible cell cycle exit. J. Cell Biol. 179, 1399–1412.
Blake, J.A., Eppig, J.T., Kadin, J.A., Richardson, J.E., Smith, C.L., and Bult, C.J. (2017).
Mouse Genome Database (MGD)-2017: community knowledge resource for the
laboratory mouse. Nucleic Acids Res 45, D723–D729.
Blanc, V., Henderson, J.O., Newberry, R.D., Xie, Y., Cho, S.-J., Newberry, E.P.,
Kennedy, S., Rubin, D.C., Wang, H.L., Luo, J., et al. (2007). Deletion of the AU-Rich
RNA Binding Protein Apobec-1 Reduces Intestinal Tumor Burden in Apcmin Mice.
Cancer Res 67, 8565–8573.
Blanc, V., Park, E., Schaefer, S., Miller, M., Lin, Y., Kennedy, S., Billing, A.M.,
Hamidane, H.B., Graumann, J., Mortazavi, A., et al. (2014). Genome-wide identification
and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small
intestine and liver. Genome Biology 15, R79.
Blau, H.M., Pavlath, G.K., Hardeman, E.C., Chiu, C.P., Silberstein, L., Webster, S.G.,
Miller, S.C., and Webster, C. (1985). Plasticity of the differentiated state. Science 230,
758–766.
Bochtler, M., Kolano, A., and Xu, G.-L. (2017). DNA demethylation pathways:
Additional players and regulators. BioEssays 39, 1–13.
Bone, C.R., and Starr, D.A. (2016). Nuclear migration events throughout development. J
Cell Sci 129, 1951–1961.
Bracken, A.P., Ciro, M., Cocito, A., and Helin, K. (2004). E2F target genes: unraveling
the biology. Trends in Biochemical Sciences 29, 409–417.

134

Branco, M.R., Ficz, G., and Reik, W. (2012). Uncovering the role of 5hydroxymethylcytosine in the epigenome. Nature Reviews Genetics 13, 7–13.
Braun, T., and Gautel, M. (2011). Transcriptional mechanisms regulating skeletal muscle
differentiation, growth and homeostasis. Nat Rev Mol Cell Biol 12, 349–361.
Breslow, J.L. (1988). Apolipoprotein genetic variation and human disease. Physiol. Rev.
68, 85–132.
Caldwell, C. j., Mattey, D.L., and Weller, R.O. (1990). Role of the basement membrane
in the regeneration of skeletal muscle. Neuropathology and Applied Neurobiology 16,
225–238.
Cao, Y., Kumar, R.M., Penn, B.H., Berkes, C.A., Kooperberg, C., Boyer, L.A., Young,
R.A., and Tapscott, S.J. (2006). Global and gene-specific analyses show distinct roles for
Myod and Myog at a common set of promoters. EMBO J. 25, 502–511.
Cao, Y., Yao, Z., Sarkar, D., Lawrence, M., Sanchez, G.J., Parker, M.H., MacQuarrie,
K.L., Davison, J., Morgan, M.T., Ruzzo, W.L., et al. (2010). Genome-wide MyoD
Binding in Skeletal Muscle Cells: A Potential for Broad Cellular Reprogramming.
Developmental Cell 18, 662–674.
Carrió, Díez‐Villanueva Anna, Lois Sergi, Mallona Izaskun, Cases Ildefonso, Forn
Marta, Peinado Miguel A., and Suelves Mònica (2015). Deconstruction of DNA
Methylation Patterns During Myogenesis Reveals Specific Epigenetic Events in the
Establishment of the Skeletal Muscle Lineage. STEM CELLS 33, 2025–2036.
Carrió, E., Magli, A., Muñoz, M., Peinado, M.A., Perlingeiro, R., and Suelves, M.
(2016). Muscle cell identity requires Pax7-mediated lineage-specific DNA
demethylation. BMC Biology 14, 30.
Carroll, T.S., Liang, Z., Salama, R., Stark, R., and de Santiago, I. (2014). Impact of
artifact removal on ChIP quality metrics in ChIP-seq and ChIP-exo data. Front. Genet. 5.
Chargaff, E., Lipshitz, R., Green, C., and Hodes, M.E. (1951). The Composition of the
Desoxyribonucleic Acid of Salmon Sperm. J. Biol. Chem. 192, 223–230.
Chen, S.H., Habib, G., Yang, C.Y., Gu, Z.W., Lee, B.R., Weng, S.A., Silberman, S.R.,
Cai, S.J., Deslypere, J.P., and Rosseneu, M. (1987). Apolipoprotein B-48 is the product
of a messenger RNA with an organ-specific in-frame stop codon. Science 238, 363–366.
Cheng, C., Alexander, R., Min, R., Leng, J., Yip, K.Y., Rozowsky, J., Yan, K.-K., Dong,
X., Djebali, S., Ruan, Y., et al. (2012). Understanding transcriptional regulation by
integrative analysis of transcription factor binding data. Genome Res. 22, 1658–1667.
Coker, H.A., Morgan, H.D., and Petersen‐Mahrt, S.K. (2006). Genetic and In Vitro
Assays of DNA Deamination. In Methods in Enzymology, (Academic Press), pp. 156–
170.
135

Cole, D.C., Chung, Y., Gagnidze, K., Hajdarovic, K.H., Rayon-Estrada, V., Harjanto, D.,
Bigio, B., Gal-Toth, J., Milner, T.A., McEwen, B.S., et al. (2017). Loss of APOBEC1
RNA-editing function in microglia exacerbates age-related CNS pathophysiology. PNAS
114, 13272–13277.
Conerly, M.L., Yao, Z., Zhong, J.W., Groudine, M., and Tapscott, S.J. (2016). Distinct
Activities of Myf5 and MyoD Indicate Separate Roles in Skeletal Muscle Lineage
Specification and Differentiation. Developmental Cell 36, 375–385.
Conticello, S.G. (2008). The AID/APOBEC family of nucleic acid mutators. Genome
Biol 9, 229.
Conticello, S.G. (2012). Creative deaminases, self-inflicted damage, and genome
evolution. Annals of the New York Academy of Sciences 1267, 79–85.
Conticello, S.G., Thomas, C.J.F., Petersen-Mahrt, S.K., and Neuberger, M.S. (2005).
Evolution of the AID/APOBEC Family of Polynucleotide (Deoxy)cytidine Deaminases.
Mol Biol Evol 22, 367–377.
Conticello, S.G., Langlois, M.-A., and Neuberger, M.S. (2007a). Insights into DNA
deaminases. Nat Struct Mol Biol 14, 7–9.
Conticello, S.G., Langlois, M., Yang, Z., and Neuberger, M.S. (2007b). DNA
Deamination in Immunity: AID in the Context of Its APOBEC Relatives. In Advances in
Immunology, Frederick W. Alt and Tasuku Honjo, ed. (Academic Press), pp. 37–73.
Crick, F. (1958). On Protein Synthesis. The Symposia of the Society for Experimental
Biology 12 138–163.
Crick, F. (1970). Central Dogma of Molecular Biology. Nature 227, 561–563.
Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati,
P., Gillespie, M., Kamdar, M.R., et al. (2014). The Reactome pathway knowledgebase.
Nucleic Acids Res. 42, D472-477.
Datler, C., and Grimm, S. (2013). Reconstitution of CKMT1 expression fails to rescue
cells from mitochondrial membrane potential dissipation: Implications for controlling
RNAi experiments. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
1833, 2844–2855.
Davidson, N.O., Innerarity, T.L., Scott, J., Smith, H., Driscoll, D.M., Teng, B., and Chan,
L. (1995). Proposed nomenclature for the catalytic subunit of the mammalian
apolipoprotein B mRNA editing enzyme: APOBEC-1. RNA 1, 3–3.
Delker, R.K., Fugmann, S.D., and Papavasiliou, F.N. (2009). A coming-of-age story:
activation-induced cytidine deaminase turns 10. Nat Immunol 10, 1147–1153.

136

Di Noia, J.M., and Neuberger, M.S. (2007). Molecular Mechanisms of Antibody Somatic
Hypermutation. Annual Review of Biochemistry 76, 1–22.
Dominguez, P.M., and Shaknovich, R. (2014). Epigenetic function of activation-induced
cytidine deaminase and its link to lymphomagenesis. Front. Immunol. 5, 642.
Dominguez, P.M., Teater, M., Chambwe, N., Kormaksson, M., Redmond, D., Ishii, J.,
Vuong, B., Chaudhuri, J., Melnick, A., Vasanthakumar, A., et al. (2015). DNA
Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports
12, 2086–2098.
Dumont, N.A., Wang, Y.X., and Rudnicki, M.A. (2015). Intrinsic and extrinsic
mechanisms regulating satellite cell function. Development 142, 1572–1581.
ENCODE, and modENCODE (2011). ENCODE and modENCODE Guidelines For
Experiments Generating ChIP, DNase, FAIRE, and DNA Methylation Genome Wide
Location Data.
Etard, C., Roostalu, U., and Strähle, U. (2010). Lack of Apobec2-related proteins causes
a dystrophic muscle phenotype in zebrafish embryos. J Cell Biol 189, 527–539.
Eyre, T.A., Wright, M.W., Lush, M.J., and Bruford, E.A. (2007). HCOP: a searchable
database of human orthology predictions. Brief Bioinform 8, 2–5.
Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P., Haw,
R., Jassal, B., Korninger, F., May, B., et al. (2018). The Reactome Pathway
Knowledgebase. Nucleic Acids Res. 46, D649–D655.
Falco, G.D., Comes, F., and Simone, C. (2006). pRb: master of differentiation. Coupling
irreversible cell cycle withdrawal with induction of muscle-specific transcription.
Oncogene 25, 5244.
Feng, J., Liu, T., and Zhang, Y. (2011). Using MACS to Identify Peaks from ChIP-Seq
Data. Curr Protoc Bioinformatics CHAPTER, Unit2.14.
Figliola, R., and Maione, R. (2004). MyoD induces the expression of p57Kip2 in cells
lacking p21Cip1/Waf1: overlapping and distinct functions of the two cdk inhibitors. J.
Cell. Physiol. 200, 468–475.
Folker, E.S., and Baylies, M.K. (2013). Nuclear positioning in muscle development and
disease. Front Physiol 4.
Fossat, N., Tourle, K., Radziewic, T., Barratt, K., Liebhold, D., Studdert, J.B., Power, M.,
Jones, V., Loebel, D.A.F., and Tam, P.P.L. (2014). C to U RNA editing mediated by
APOBEC1 requires RNA‐binding protein RBM47. EMBO Reports 15, 903–910.
Franklin, R.E., and Gosling, R.G. (1953). Molecular Configuration in Sodium
Thymonucleate. Nature 171, 740–741.
137

Fritz, E. (2014). Genome-Wide Characterization of the Effects of Nucleic Acid
Modifying Enzymes: Cytidine Deaminases and DNA Methylation. Student Theses and
Dissertations.
Fritz, E.L., Rosenberg, B.R., Lay, K., Mihailović, A., Tuschl, T., and Papavasiliou, F.N.
(2013). A comprehensive analysis of the effects of the deaminase AID on the
transcriptome and methylome of activated B cells. Nat. Immunol. 14, 749–755.
Garrett-Bakelman, F.E., Sheridan, C.K., Kacmarczyk, T.J., Ishii, J., Betel, D., Alonso, A.,
Mason, C.E., Figueroa, M.E., and Melnick, A.M. (2015). Enhanced Reduced
Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair
Resolution. J Vis Exp.
Grant, C.E., Bailey, T.L., and Noble, W.S. (2011). FIMO: scanning for occurrences of a
given motif. Bioinformatics 27, 1017–1018.
Gray, K.A., Yates, B., Seal, R.L., Wright, M.W., and Bruford, E.A. (2015).
Genenames.org: the HGNC resources in 2015. Nucleic Acids Res 43, D1079–D1085.
Gu, H., Smith, Z.D., Bock, C., Boyle, P., Gnirke, A., and Meissner, A. (2011).
Preparation of reduced representation bisulfite sequencing libraries for genome-scale
DNA methylation profiling. Nat. Protocols 6, 468–481.
Guo, J.U., Su, Y., Zhong, C., Ming, G., and Song, H. (2011). Hydroxylation of 5Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain. Cell
145, 423–434.
Guo, K., Wang, J., Andrés, V., Smith, R.C., and Walsh, K. (1995). MyoD-induced
expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal
differentiation. Mol Cell Biol 15, 3823–3829.
Gupta, S., Stamatoyannopoulos, J.A., Bailey, T.L., and Noble, W.S. (2007). Quantifying
similarity between motifs. Genome Biology 8, R24.
Haldar, M., Karan, G., Tvrdik, P., and Capecchi, M.R. (2008). Two Cell Lineages, myf5
and myf5-Independent, Participate in Mouse Skeletal Myogenesis. Developmental Cell
14, 437–445.
Hardy, D., Besnard, A., Latil, M., Jouvion, G., Briand, D., Thépenier, C., Pascal, Q.,
Guguin, A., Gayraud-Morel, B., Cavaillon, J.-M., et al. (2016). Comparative Study of
Injury Models for Studying Muscle Regeneration in Mice. PLOS ONE 11, e0147198.
Harjanto, D., Papamarkou, T., Oates, C.J., Rayon-Estrada, V., Papavasiliou, F.N., and
Papavasiliou, A. (2016). RNA editing generates cellular subsets with diverse sequence
within populations. Nature Communications 7, 12145.
Harris, R.S., and Dudley, J.P. (2015). APOBECs and virus restriction. Virology 479–480,
131–145.
138

Harris, R.S., and Liddament, M.T. (2004). Retroviral restriction by APOBEC proteins.
Nat Rev Immunol 4, 868–877.
Harris, R.S., Petersen-Mahrt, S.K., and Neuberger, M.S. (2002). RNA Editing Enzyme
APOBEC1 and Some of Its Homologs Can Act as DNA Mutators. Molecular Cell 10,
1247–1253.
Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-Mahrt, S.K., Watt, I.N.,
Neuberger, M.S., and Malim, M.H. (2003). DNA deamination mediates innate immunity
to retroviral infection. Cell 113, 803–809.
Hasty, P., Bradley, A., Morris, J.H., Edmondson, D.G., Venuti, J.M., Olson, E.N., and
Klein, W.H. (1993). Muscle deficiency and neonatal death in mice with a targeted
mutation in the myogenin gene. Nature 364, 501–506.
Henderson, S., and Fenton, T. (2015). APOBEC3 genes: retroviral restriction factors to
cancer drivers. Trends Mol Med 21, 274–284.
Hernández-Hernández, J.M., García-González, E.G., Brun, C.E., and Rudnicki, M.A.
(2017). The myogenic regulatory factors, determinants of muscle development, cell
identity and regeneration. Seminars in Cell & Developmental Biology 72, 10–18.
Hersberger, M., Patarroyo-White, S., Qian, X., Arnold, K.S., Rohrer, L., Balestra, M.E.,
and Innerarity, T.L. (2003). Regulatable liver expression of the rabbit apolipoprotein B
mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous
APOBEC-1 leads to aberrant hyperediting. Biochemical Journal 369, 255–262.
Hershey, A.D., and Chase, M. (1952). Independent functions of viral protein and nucleic
acid in growth of bacteriophage. J Gen Physiol 36, 39–56.
Ikeda, T., Galil, K.H.A.E., Tokunaga, K., Maeda, K., Sata, T., Sakaguchi, N., Heidmann,
T., and Koito, A. (2011). Intrinsic restriction activity by apolipoprotein B mRNA editing
enzyme APOBEC1 against the mobility of autonomous retrotransposons. Nucleic Acids
Research 39, 5538.
Iyer, L.M., Zhang, D., Rogozin, I.B., and Aravind, L. (2011). Evolution of the deaminase
fold and multiple origins of eukaryotic editing and mutagenic nucleic acid deaminases
from bacterial toxin systems. Nucleic Acids Res 39, 9473–9497.
Judson, H.F. (1996). The Eighth Day of Creation: Makers of the Revolution in Biology,
Commemorative Edition (Plainview, N.Y: Cold Spring Harbor Laboratory Press).
Kafri, R., Springer, M., and Pilpel, Y. (2009). Genetic Redundancy: New Tricks for Old
Genes. Cell 136, 389–392.
Kitzmann, M., Carnac, G., Vandromme, M., Primig, M., Lamb, N.J., and Fernandez, A.
(1998). The muscle regulatory factors MyoD and myf-5 undergo distinct cell cyclespecific expression in muscle cells. J. Cell Biol. 142, 1447–1459.
139

Knisbacher, B.A., Gerber, D., and Levanon, E.Y. (2016). DNA Editing by APOBECs: A
Genomic Preserver and Transformer. Trends in Genetics 32, 16–28.
Kosugi, S., Hasebe, M., Tomita, M., and Yanagawa, H. (2009). Systematic identification
of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of
composite motifs. PNAS 106, 10171–10176.
Krueger, F., and Andrews, S.R. (2011). Bismark: a flexible aligner and methylation caller
for Bisulfite-Seq applications. Bioinformatics 27, 1571–1572.
Krzysiak, T.C., Jung, J., Thompson, J., Baker, D., and Gronenborn, A.M. (2012).
APOBEC2 Is a Monomer in Solution: Implications for APOBEC3G Models.
Biochemistry 51, 2008–2017.
Lada, A.G., Krick, C.F., Kozmin, S.G., Mayorov, V.I., Karpova, T.S., Rogozin, I.B., and
Pavlov, Y.I. (2011). Mutator effects and mutation signatures of editing deaminases
produced in bacteria and yeast. Biochemistry Moscow 76, 131–146.
Landt, S.G., Marinov, G.K., Kundaje, A., Kheradpour, P., Pauli, F., Batzoglou, S.,
Bernstein, B.E., Bickel, P., Brown, J.B., Cayting, P., et al. (2012). ChIP-seq guidelines
and practices of the ENCODE and modENCODE consortia. Genome Res. 22, 1813–
1831.
Larsen, B.D., and Megeney, L.A. (2010). Parole terms for a killer. Cell Cycle 9, 2940–
2945.
Larsen, B.D., Rampalli, S., Burns, L.E., Brunette, S., Dilworth, F.J., and Megeney, L.A.
(2010). Caspase 3/caspase-activated DNase promote cell differentiation by inducing
DNA strand breaks. Proc. Natl. Acad. Sci. U.S.A. 107, 4230–4235.
Lawrence, M., Gentleman, R., and Carey, V. (2009). rtracklayer: an R package for
interfacing with genome browsers. Bioinformatics 25, 1841–1842.
Lawrence, M., Huber, W., Pagès, H., Aboyoun, P., Carlson, M., Gentleman, R., Morgan,
M.T., and Carey, V.J. (2013). Software for Computing and Annotating Genomic Ranges.
PLOS Computational Biology 9, e1003118.
Lecossier, D., Bouchonnet, F., Clavel, F., and Hance, A.J. (2003). Hypermutation of
HIV-1 DNA in the absence of the Vif protein. Science 300, 1112.
Li, S., Garrett-Bakelman, F.E., Akalin, A., Zumbo, P., Levine, R., To, B.L., Lewis, I.D.,
Brown, A.L., D’Andrea, R.J., Melnick, A., et al. (2013). An optimized algorithm for
detecting and annotating regional differential methylation. BMC Bioinformatics 14, S10.
Liang, G., Kitamura, K., Wang, Z., Liu, G., Chowdhury, S., Fu, W., Koura, M., Wakae,
K., Honjo, T., and Muramatsu, M. (2013). RNA editing of hepatitis B virus transcripts by
activation-induced cytidine deaminase. PNAS 110, 2246–2251.

140

Liao, W., Hong, S.-H., Chan, B.H.-J., Rudolph, F.B., Clark, S.C., and Chan, L. (1999).
APOBEC-2, a Cardiac- and Skeletal Muscle-Specific Member of the Cytidine Deaminase
Supergene Family. Biochemical and Biophysical Research Communications 260, 398–
404.
Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and
scalable read mapping by seed-and-vote. Nucleic Acids Res 41, e108–e108.
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., and
Mesirov, J.P. (2011). Molecular signatures database (MSigDB) 3.0. Bioinformatics 27,
1739–1740.
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J.P., and Tamayo, P.
(2015). The Molecular Signatures Database Hallmark Gene Set Collection. Cell Systems
1, 417–425.
Liu, Q.-C., Zha, X.-H., Faralli, H., Yin, H., Louis-Jeune, C., Perdiguero, E.,
Pranckeviciene, E., Muñoz-Cànoves, P., Rudnicki, M.A., Brand, M., et al. (2012).
Comparative expression profiling identifies differential roles for Myogenin and p38α
MAPK signaling in myogenesis. J Mol Cell Biol 4, 386–397.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biology 15, 550.
Ma, W., Noble, W.S., and Bailey, T.L. (2014). Motif-based analysis of large nucleotide
data sets using MEME-ChIP. Nature Protocols 9, 1428–1450.
MacDuff, D.A., Demorest, Z.L., and Harris, R.S. (2009). AID can restrict L1
retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids
Res. 37, 1854–1867.
Machanick, P., and Bailey, T.L. (2011). MEME-ChIP: motif analysis of large DNA
datasets. Bioinformatics 27, 1696–1697.
Maddox, B. (2003). Rosalind Franklin: The Dark Lady of DNA (New York: Harper
Perennial).
Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003). Broad
antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse
transcripts. Nature 424, 99–103.
Marino, D., Perković, M., Hain, A., Jaguva Vasudevan, A.A., Hofmann, H.,
Hanschmann, K.-M., Mühlebach, M.D., Schumann, G.G., König, R., Cichutek, K., et al.
(2016). APOBEC4 Enhances the Replication of HIV-1. PLoS ONE 11, e0155422.
Megeney, L.A., Kablar, B., Garrett, K., Anderson, J.E., and Rudnicki, M.A. (1996).
MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev.
10, 1173–1183.
141

Mehta, A., Kinter, M.T., Sherman, N.E., and Driscoll, D.M. (2000). Molecular Cloning
of Apobec-1 Complementation Factor, a Novel RNA-Binding Protein Involved in the
Editing of Apolipoprotein B mRNA. Mol. Cell. Biol. 20, 1846–1854.
Meissner, A., Gnirke, A., Bell, G.W., Ramsahoye, B., Lander, E.S., and Jaenisch, R.
(2005). Reduced representation bisulfite sequencing for comparative high-resolution
DNA methylation analysis. Nucleic Acids Res 33, 5868–5877.
Mickley, A.G., Hoxha, Z., Biada, J.M., Kenmuir, C.L., and Bacik, S.E. (2006).
Acetaminophen Self-administered in the Drinking Water Increases the Pain Threshold of
Rats (Rattus norvegicus). Journal of the American Association for Laboratory Animal
Science 45, 48–54.
Miescher, F. (1871). Medicinisch-chemische Untersuchungen: 4. Med-Chem Unters 4:
441-460.
Mikl, M.C., Watt, I.N., Lu, M., Reik, W., Davies, S.L., Neuberger, M.S., and Rada, C.
(2005). Mice Deficient in APOBEC2 and APOBEC3. Mol Cell Biol 25, 7270–7277.
Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepfer, A.M., Hinkle, G., Piqani,
B., Eisenhaure, T.M., Luo, B., Grenier, J.K., et al. (2006). A Lentiviral RNAi Library for
Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen. Cell 124,
1283–1298.
Mootha, V.K., Lindgren, C.M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J.,
Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003). PGC-1αresponsive genes involved in oxidative phosphorylation are coordinately downregulated
in human diabetes. Nat Genet 34, 267–273.
Mousavi, K., Zare, H., Dell’Orso, S., Grontved, L., Gutierrez-Cruz, G., Derfoul, A.,
Hager, G.L., and Sartorelli, V. (2013). eRNAs Promote Transcription by Establishing
Chromatin Accessibility at Defined Genomic Loci. Molecular Cell 51, 606–617.
Mukhopadhyay, D., Anant, S., Lee, R.M., Kennedy, S., Viskochil, D., and Davidson,
N.O. (2002). C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express
both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B
mRNA-editing enzyme. Am. J. Hum. Genet. 70, 38–50.
Muramatsu, M., Sankaranand, V.S., Anant, S., Sugai, M., Kinoshita, K., Davidson, N.O.,
and Honjo, T. (1999). Specific Expression of Activation-induced Cytidine Deaminase
(AID), a Novel Member of the RNA-editing Deaminase Family in Germinal Center B
Cells. J. Biol. Chem. 274, 18470–18476.
Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., and Honjo, T.
(2000). Class Switch Recombination and Hypermutation Require Activation-Induced
Cytidine Deaminase (AID), a Potential RNA Editing Enzyme. Cell 102, 553–563.

142

Nabel, C.S., Jia, H., Ye, Y., Shen, L., Goldschmidt, H.L., Stivers, J.T., Zhang, Y., and
Kohli, R.M. (2012). AID/APOBEC deaminases disfavor modified cytosines implicated in
DNA demethylation. Nat Chem Biol 8, 751–758.
Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S., Nonaka, I., and
Nabeshima, Y. (1993). Myogenin gene disruption results in perinatal lethality because of
severe muscle defect. Nature 364, 532–535.
Narciso, L., Fortini, P., Pajalunga, D., Franchitto, A., Liu, P., Degan, P., Frechet, M.,
Demple, B., Crescenzi, M., and Dogliotti, E. (2007). Terminally differentiated muscle
cells are defective in base excision DNA repair and hypersensitive to oxygen injury.
Proc. Natl. Acad. Sci. U.S.A. 104, 17010–17015.
Ohtsubo, H., Sato, Y., Suzuki, T., Mizunoya, W., Nakamura, M., Tatsumi, R., and
Ikeuchi, Y. (2017a). APOBEC2 negatively regulates myoblast differentiation in muscle
regeneration. The International Journal of Biochemistry & Cell Biology 85, 91–101.
Ohtsubo, H., Sato, Y., Suzuki, T., Mizunoya, W., Nakamura, M., Tatsumi, R., and
Ikeuchi, Y. (2017b). Data supporting possible implication of APOBEC2 in self-renewal
functions of myogenic stem satellite cells: Toward understanding the negative regulation
of myoblast differentiation. Data in Brief 12, 269–273.
Okuyama, S., Marusawa, H., Matsumoto, T., Ueda, Y., Matsumoto, Y., Endo, Y., Takai,
A., and Chiba, T. (2012). Excessive activity of apolipoprotein B mRNA editing enzyme
catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. Int. J.
Cancer 130, 1294–1301.
Orimo, A., Gupta, P.B., Sgroi, D.C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R.,
Carey, V.J., Richardson, A.L., and Weinberg, R.A. (2005). Stromal Fibroblasts Present in
Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through
Elevated SDF-1/CXCL12 Secretion. Cell 121, 335–348.
Patro, R., Duggal, G., Love, M.I., Irizarry, R.A., and Kingsford, C. (2017). Salmon
provides fast and bias-aware quantification of transcript expression. Nature Methods 14,
417–419.
Piec, I., Listrat, A., Alliot, J., Chambon, C., Taylor, R.G., and Bechet, D. (2005).
Differential proteome analysis of aging in rat skeletal muscle. FASEB J.
Plongthongkum, N., Diep, D.H., and Zhang, K. (2014). Advances in the profiling of
DNA modifications: cytosine methylation and beyond. Nat Rev Genet 15, 647–661.
Porter, E.G., Connelly, K.E., and Dykhuizen, E.C. (2017). Sequential Salt Extractions for
the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes.
JoVE (Journal of Visualized Experiments) e55369–e55369.

143

Powell, C., Elsaeidi, F., and Goldman, D. (2012). Injury-Dependent Müller Glia and
Ganglion Cell Reprogramming during Tissue Regeneration Requires Apobec2a and
Apobec2b. J. Neurosci. 32, 1096–1109.
Powell, C., Grant, A.R., Cornblath, E., and Goldman, D. (2013). Analysis of DNA
methylation reveals a partial reprogramming of the Müller glia genome during retina
regeneration. PNAS 110, 19814–19819.
Powell, C., Cornblath, E., and Goldman, D. (2014). Zinc-binding Domain-dependent,
Deaminase-independent Actions of Apolipoprotein B mRNA-editing Enzyme, Catalytic
Polypeptide 2 (Apobec2), Mediate Its Effect on Zebrafish Retina Regeneration. J. Biol.
Chem. 289, 28924–28941.
Powell, L.M., Wallis, S.C., Pease, R.J., Edwards, Y.H., Knott, T.J., and Scott, J. (1987).
A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in
intestine. Cell 50, 831–840.
Prochnow, C., Bransteitter, R., Klein, M.G., Goodman, M.F., and Chen, X.S. (2007). The
APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature
445, 447–451.
Rai, K., Huggins, I.J., James, S.R., Karpf, A.R., Jones, D.A., and Cairns, B.R. (2008).
DNA Demethylation in Zebrafish Involves the Coupling of a Deaminase, a Glycosylase,
and Gadd45. Cell 135, 1201–1212.
Ramiro, A.R., and Barreto, V.M. (2015). Activation-induced cytidine deaminase and
active cytidine demethylation. Trends Biochem. Sci. 40, 172–181.
Rawls, A., Valdez, M.R., Zhang, W., Richardson, J., Klein, W.H., and Olson, E.N.
(1998). Overlapping functions of the myogenic bHLH genes MRF4 and MyoD revealed
in double mutant mice. Development 125, 2349–2358.
Rayon-Estrada, V., Harjanto, D., Hamilton, C.E., Berchiche, Y.A., Gantman, E.C.,
Sakmar, T.P., Bulloch, K., Gagnidze, K., Harroch, S., McEwen, B.S., et al. (2017).
Epitranscriptomic profiling across cell types reveals associations between APOBEC1mediated RNA editing, gene expression outcomes, and cellular function. PNAS 114,
13296–13301.
Relaix, F., and Zammit, P.S. (2012). Satellite cells are essential for skeletal muscle
regeneration: the cell on the edge returns centre stage. Development 139, 2845–2856.
Robbiani, D.F., Bothmer, A., Callen, E., Reina-San-Martin, B., Dorsett, Y.,
Difilippantonio, S., Bolland, D.J., Chen, H.T., Corcoran, A.E., Nussenzweig, A., et al.
(2008). AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH
translocations. Cell 135, 1028–1038.
Roberts, S.A., Lawrence, M.S., Klimczak, L.J., Grimm, S.A., Fargo, D., Stojanov, P.,
Kiezun, A., Kryukov, G.V., Carter, S.L., Saksena, G., et al. (2013). An APOBEC
144

cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45,
970–976.
Rogozin, I.B., Basu, M.K., Jordan, I.K., Pavlov, Y.I., and Koonin, E.V. (2005).
APOBEC4, a New Member of the AID/APOBEC Family of Polynucleotide
(Deoxy)Cytidine Deaminases Predicted by Computational Analysis. Cell Cycle 4, 1281–
1285.
Roman, W., Martins, J.P., Carvalho, F.A., Voituriez, R., Abella, J.V.G., Santos, N.C.,
Cadot, B., Way, M., and Gomes, E.R. (2017). Myofibril contraction and crosslinking
drive nuclear movement to the periphery of skeletal muscle. Nature Cell Biology 19,
1189–1201.
Rosen, J.N., and Baylies, M.K. (2017). Myofibrils put the squeeze on nuclei. Nature Cell
Biology 19, 1148–1150.
Rosenberg, B.R., Hamilton, C.E., Mwangi, M.M., Dewell, S., and Papavasiliou, F.N.
(2011). Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing
targets in transcript 3′ UTRs. Nat Struct Mol Biol 18, 230–236.
Rubio, M.A.T., Pastar, I., Gaston, K.W., Ragone, F.L., Janzen, C.J., Cross, G.A.M.,
Papavasiliou, F.N., and Alfonzo, J.D. (2007). An adenosine-to-inosine tRNA-editing
enzyme that can perform C-to-U deamination of DNA. PNAS 104, 7821–7826.
Rudnicki, M.A., Schnegelsberg, P.N.J., Stead, R.H., Braun, T., Arnold, H.-H., and
Jaenisch, R. (1993). MyoD or Myf-5 is required for the formation of skeletal muscle. Cell
75, 1351–1359.
Salter, J.D., Bennett, R.P., and Smith, H.C. (2016). The APOBEC Protein Family: United
by Structure, Divergent in Function. Trends in Biochemical Sciences 41, 578–594.
Sato, Y., Probst, H.C., Tatsumi, R., Ikeuchi, Y., Neuberger, M.S., and Rada, C. (2010).
Deficiency in APOBEC2 Leads to a Shift in Muscle Fiber Type, Diminished Body Mass,
and Myopathy. J. Biol. Chem. 285, 7111–7118.
Sato, Y., Ohtsubo, H., Nihei, N., Kaneko, T., Sato, Y., Adachi, S., Kondo, S., Nakamura,
M., Mizunoya, W., Iida, H., et al. (2017). Apobec2 deficiency causes mitochondrial
defects and mitophagy in skeletal muscle. FASEB J fj.201700493R.
Severi, F., Chicca, A., and Conticello, S.G. (2011). Analysis of Reptilian APOBEC1
Suggests that RNA Editing May Not Be Its Ancestral Function. Mol Biol Evol 28, 1125–
1129.
Sharma, A., Klein, S.L., Barboza, L., Lodhi, N., and Toth, M. (2016). Principles
Governing DNA Methylation during Neuronal Lineage and Subtype Specification. J.
Neurosci. 36, 1711–1722.

145

Sheehy, A.M., Gaddis, N.C., Choi, J.D., and Malim, M.H. (2002). Isolation of a human
gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418,
646–650.
Shen, L., Shao, N., Liu, X., and Nestler, E. (2014). ngs.plot: Quick mining and
visualization of next-generation sequencing data by integrating genomic databases. BMC
Genomics 15, 284.
Singh Kulwant, and Dilworth F. Jeffrey (2013). Differential modulation of cell cycle
progression distinguishes members of the myogenic regulatory factor family of
transcription factors. The FEBS Journal 280, 3991–4003.
Smith, Z.D., and Meissner, A. (2013). DNA methylation: roles in mammalian
development. Nature Reviews Genetics 14, 204.
Soleimani, V.D., Punch, V.G., Kawabe, Y., Jones, A.E., Palidwor, G.A., Porter, C.J.,
Cross, J.W., Carvajal, J.J., Kockx, C.E.M., van IJcken, W.F.J., et al. (2012).
Transcriptional dominance of Pax7 in adult myogenesis is due to high-affinity
recognition of homeodomain motifs. Dev. Cell 22, 1208–1220.
Soneson, C., Love, M.I., and Robinson, M.D. (2016). Differential analyses for RNA-seq:
transcript-level estimates improve gene-level inferences. F1000Research 4, 1521.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A.,
Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set
enrichment analysis: A knowledge-based approach for interpreting genome-wide
expression profiles. PNAS 102, 15545–15550.
Swanton, C., McGranahan, N., Starrett, G.J., and Harris, R.S. (2015). APOBEC
Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov 5,
704–712.
Sylvestre, Y., De Guire, V., Querido, E., Mukhopadhyay, U.K., Bourdeau, V., Major, F.,
Ferbeyre, G., and Chartrand, P. (2007). An E2F/miR-20a autoregulatory feedback loop. J.
Biol. Chem. 282, 2135–2143.
Takizawa, M., Tolarová, H., Li, Z., Dubois, W., Lim, S., Callen, E., Franco, S., Mosaico,
M., Feigenbaum, L., Alt, F.W., et al. (2008). AID expression levels determine the extent
of cMyc oncogenic translocations and the incidence of B cell tumor development. J. Exp.
Med. 205, 1949–1957.
Tan, M.H., Li, Q., Shanmugam, R., Piskol, R., Kohler, J., Young, A.N., Liu, K.I., Zhang,
R., Ramaswami, G., Ariyoshi, K., et al. (2017). Dynamic landscape and regulation of
RNA editing in mammals. Nature 550, 249.
Teater, M., Dominguez, P.M., Redmond, D., Chen, Z., Ennishi, D., Scott, D.W.,
Cimmino, L., Ghione, P., Chaudhuri, J., Gascoyne, R.D., et al. (2018). AICDA drives
146

epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nat
Commun 9, 222.
Teng, B., Burant, C.F., and Davidson, N.O. (1993). Molecular cloning of an
apolipoprotein B messenger RNA editing protein. Science 260, 1816–1819.
The ENCODE Project Consortium (2012). An integrated encyclopedia of DNA elements
in the human genome. Nature 489, 57–74.
Tschöp, K., Conery, A.R., Litovchick, L., Decaprio, J.A., Settleman, J., Harlow, E., and
Dyson, N. (2011). A kinase shRNA screen links LATS2 and the pRB tumor suppressor.
Genes Dev. 25, 814–830.
Tsumagari, K., Baribault, C., Terragni, J., Varley, K.E., Gertz, J., Pradhan, S., Badoo, M.,
Crain, C.M., Song, L., Crawford, G.E., et al. (2013). Early de novo DNA methylation and
prolonged demethylation in the muscle lineage. Epigenetics 8, 317–332.
Ustanina, S., Carvajal, J., Rigby, P., and Braun, T. (2007). The myogenic factor Myf5
supports efficient skeletal muscle regeneration by enabling transient myoblast
amplification. Stem Cells 25, 2006–2016.
Vonica, A., Rosa, A., Arduini, B.L., and Brivanlou, A.H. (2011). APOBEC2, a selective
inhibitor of TGFβ signaling, regulates left–right axis specification during early
embryogenesis. Developmental Biology 350, 13–23.
Walsh, K., and Perlman, H. (1997). Cell cycle exit upon myogenic differentiation.
Current Opinion in Genetics & Development 7, 597–602.
Wang, I.X., So, E., Devlin, J.L., Zhao, Y., Wu, M., and Cheung, V.G. (2013). ADAR
Regulates RNA Editing, Transcript Stability, and Gene Expression. Cell Reports 5, 849–
860.
Watson, J.D., and Crick, F.H.C. (1953). Molecular Structure of Nucleic Acids: A
Structure for Deoxyribose Nucleic Acid. Nature 171, 737–738.
Wedekind, J.E., Dance, G.S.C., Sowden, M.P., and Smith, H.C. (2003). Messenger RNA
editing in mammals: new members of the APOBEC family seeking roles in the family
business. Trends in Genetics 19, 207–216.
Wilkins, M.H.F., Stokes, A.R., and Wilson, H.R. (1953). Molecular structure of
deoxypentose nucleic acids. Nature 171, 738–740.
Wright, M.W., Eyre, T.A., Lush, M.J., Povey, S., and Bruford, E.A. (2005). HCOP: The
HGNC comparison of orthology predictions search tool. Mamm Genome 16, 827–828.
Yaffe, D., and Saxel, O. (1977). Serial passaging and differentiation of myogenic cells
isolated from dystrophic mouse muscle. Nature 270, 725–727.

147

Yamanaka, S., Poksay, K.S., Arnold, K.S., and Innerarity, T.L. (1997). A novel
translational repressor mRNA is edited extensively in livers containing tumors caused by
the transgene expression of the apoB mRNA-editing enzyme. Genes Dev. 11, 321–333.
Yang, X., Koltes, J.E., Park, C.A., Chen, D., and Reecy, J.M. (2015). Gene CoExpression Network Analysis Provides Novel Insights into Myostatin Regulation at
Three Different Mouse Developmental Timepoints. PLOS ONE 10, e0117607.
Yang, Y., Fear, J., Hu, J., Haecker, I., Zhou, L., Renne, R., Bloom, D., and McIntyre,
L.M. (2014). Leveraging biological replicates to improve analysis in ChIP-seq
experiments. Comput Struct Biotechnol J 9.
Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). clusterProfiler: an R Package for
Comparing Biological Themes Among Gene Clusters. OMICS 16, 284–287.
Yu, G., Wang, L.-G., and He, Q.-Y. (2015). ChIPseeker: an R/Bioconductor package for
ChIP peak annotation, comparison and visualization. Bioinformatics 31, 2382–2383.
Zhang, H., Yang, B., Pomerantz, R.J., Zhang, C., Arunachalam, S.C., and Gao, L. (2003).
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1
DNA. Nature 424, 94–98.
Zhang, K., Sha, J., and Harter, M.L. (2010). Activation of Cdc6 by MyoD is associated
with the expansion of quiescent myogenic satellite cells. J. Cell Biol. 188, 39–48.
Zhang, P., Wong, C., DePinho, R.A., Harper, J.W., and Elledge, S.J. (1998). Cooperation
between the Cdk inhibitors p27KIP1 and p57KIP2 in the control of tissue growth and
development. Genes & Development 12, 3162–3167.
Zhang, P., Wong, C., Liu, D., Finegold, M., Harper, J.W., and Elledge, S.J. (1999).
p21(CIP1) and p57(KIP2) control muscle differentiation at the myogenin step. Genes
Dev. 13, 213–224.
Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum,
C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based Analysis of ChIP-Seq
(MACS). Genome Biology 9, R137.
Zhu, L.J. (2013). Integrative Analysis of ChIP-Chip and ChIP-Seq Dataset. In Tiling
Arrays, (Humana Press, Totowa, NJ), pp. 105–124.
Zhu, L.J., Gazin, C., Lawson, N.D., Pagès, H., Lin, S.M., Lapointe, D.S., and Green,
M.R. (2010). ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIPchip data. BMC Bioinformatics 11, 237.

148

